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Abstract (363 words)  
 
Objective 
There is substantial interest in how glucagon-like peptide-1 receptor agonists (GLP-
1RA) and sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce cardiovascular 
and renal events, yet robust mechanistic data in humans remain sparse.  We 
conducted a narrative review of published and ongoing mechanistic clinical trials 
investigating the actions of SGLT2 inhibitors and GLP-1RAs, to help the community 
appreciate the extent of ongoing work and the variety and design of such trials.  
 
Approach and Results 
To date, trials investigating the mechanisms of action of SGLT2 inhibitors have 
focused on pathways linked to glucose metabolism and toxicity, 
hemodynamic/volume, vascular and renal actions, and cardiac effects, including 
those on myocardial energetics.  The participants studied have included those with 
established cardiovascular disease (including coronary artery disease and heart 
failure), liver disease, renal impairment, obesity and hypertension; some of these 
trials have enrolled patients both with and without type 2 diabetes.  GLP-1RA 
mechanistic trials have focused on glucose-lowering, insulin-sparing, weight 
reduction and blood pressure lowering effects, as well as possible direct vascular, 
cardiac and renal effects of these agents.  
 
Very few mechanisms of action of SGLT2 inhibitors or GLP-1RAs have so far been 
convincingly demonstrated.  One small trial (n=97) of SGLT2 inhibitors has 
investigated the cardiac effects of these drugs, where a small reduction in left 
ventricular mass was found.  Data on vascular effects are limited to one trial in type 1 
diabetes which suggests some beneficial actions.  SGLT2 inhibitors have been 
shown to reduce liver fat.  We highlight the near absence of mechanistic data to 
explain the beneficial effects of SGLT2 inhibitors in patients without diabetes.  GLP-
1RAs have not been found to have major cardiovascular mechanisms of action in the 
limited, completed trials.  Conflicting data around the impact on infarct size have 
been reported.  No effect on left ventricular ejection fraction has been demonstrated.  
 
Conclusions 
We have tabulated the extensive ongoing mechanistic trials that will report over the 
coming years.  We report two exemplar ongoing mechanistic trials in detail to give 
examples of the designs and techniques employed.  The results of these many 
ongoing trials should help us understand how SGLT2 inhibitors and GLP-1RAs 
improve cardiovascular and renal outcomes and may also identify unexpected 
mechanisms suggesting novel therapeutic applications.  
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Abbreviations  
 
EF   ejection fraction 
GLP-1RA  glucagon-like peptide-1 receptor agonists 
HF   heart failure 
LV   left ventricular 
MRI   magnetic resonance imaging 
MRS   magnetic resonance spectroscopy 
NAFLD  non-alcoholic fatty liver disease 
PCOS   polycystic ovarian syndrome 
SGLT2  sodium-glucose co-transporter 2 
T2D   type 2 diabetes 
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Introduction  
 
Both sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 
receptor agonists (GLP-1RA) reduce cardiovascular and renal events in patients with 
type 2 diabetes (T2D).  
 
Several large international cardiovascular outcome trials demonstrated the 
cardiovascular (and renal) benefits of canagliflozin, dapagliflozin and empagliflozin.1–
4  A recent meta-analysis showed that drugs in this class reduced major adverse 
cardiac events (a composite of acute myocardial infarction, stroke or cardiovascular 
death), as well as heart failure (HF) hospitalization and renal endpoints.5  Of note, 
there was no obvious effect on stroke, and an unconvincing effect on myocardial 
infarction.6  Whilst there was some variability in the effect of specific agents on 
individual endpoints, it remains unclear to what extent these are true differences 
between drugs, the participants studied or both, or are simply a chance finding.  In 
2019, two further SGLT2 inhibitor trials demonstrated the benefit of these drugs to 
patients with chronic kidney disease,4 and patients with HF with reduced ejection 
fraction (EF), including HF with reduced EF without T2D.7  
 
Seven GLP-1RA mortality/morbidity trials have been published.  A recent meta-
analysis reported that GLP-1RAs reduce major adverse cardiac events, 
cardiovascular death and all-cause mortality by around 12%, with evidence for 
around a 9% reduction in myocardial infarction and 16% reduction in stroke.8  
Furthermore, HF was lowered by 9% and a composite renal outcome that includes 
macroalbuminuria lowered by 17%.  There was modest heterogeneity in results for 
major adverse cardiac events with Evaluation of Cardiovascular Outcomes in 
Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment 
With AVE0010 (Lixisenatide) (ELIXA) being the main outlier.  There is much more 
evidence of differences between drugs and also between the patients studied in the 
GLP-1RA trials, compared with the SGLT2 inhibitor trials.6  
 
SGLT2 inhibitors and GLP-1RAs have been recommended in patients with diabetes 
and existing cardiovascular disease in all major international guidelines.9,10  The 
recent European Society of Cardiology guidelines have gone a step further and 
recommended that these agents should be first-line therapy (replacing metformin) in 
drug-naive patients with cardiovascular disease and diabetes.11  
 
Mechanisms of action and need for further study  
 
The clinical benefits for both classes of drugs cannot be explained only by effects on 
glucose-lowering or other established risk factors, leading many to consider novel 
mechanisms of action.  Some clinicians may not be overly interested in 
understanding mechanisms provided large trials show meaningful benefits alongside 
evidence of safety.  However, others would strongly argue that understanding 
mechanisms has several potential benefits such as i) help the development of new 
classes of drugs in the future, ii) improved understanding of possible new 
applications for these drugs; and, iii) lead to a better understanding of the adverse 
effects of drugs and how to potentially mitigate these.  There is no consensus about 
the mechanisms explaining the action of these drugs and more work is therefore 
needed to elucidate these.  
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Methods  
 
We have summarized the wide range of completed and ongoing mechanistic studies 
in relation to the pathways under investigation, the different investigative approaches 
utilized, and the variety of populations targeted (Figures 1 and 2).  We have 
organized trials by design (placebo-controlled vs non-placebo-controlled or active 
comparator), population (with diabetes vs without diabetes) and sample size.  We 
have not included trials primarily investigating pharmacodynamics, pharmacokinetics, 
dosing, efficacy, safety and cardiovascular outcomes.  We have only included 
randomized larger (n≥40) trials of longer duration (≥3 months).  We have not included 
trials which primarily investigate effects on glucose-lowering/metabolism or other 
established risk factors (blood pressure-lowering, weight-lowering, lipid profile).  
 
Completed mechanistic randomized placebo-controlled trials of SGLT2 
inhibitors (Table 1a)  
 
Cardiac effects of SGLT2 inhibitors in patients with diabetes  
Of the multiple trials investigating cardiac remodeling, only one such trial has 
reported - EMPA-HEART (n=97), a randomized placebo-controlled parallel group 
trial, demonstrated a modest effect of empagliflozin on LV mass on magnetic 
resonance imaging (MRI) in patients with T2D, stable coronary artery disease but 
normal EF (NCT02998970).12   
 
Cardiac, biomarker, symptom and fitness effects of SGLT2 inhibitors in 
patients with and without diabetes  
DEFINE-HF (n=263) was a randomized placebo-controlled parallel group trial in HF 
(LV EF ≤40%) patients with and without T2D, showing that 12 weeks of treatment 
with dapagliflozin did not affect mean N-terminal pro-B-type natriuretic peptide but 
increased the proportion of patients experiencing clinically meaningful improvements 
in HF-related health status (Kansas City Cardiomyopathy Questionnaire) 
(NCT02653482).13  EMPERIAL-preserved (NCT03448406) (n=315) and EMPERIAL-
reduced (NCT03448419) (n=312) were randomized placebo-controlled parallel group 
trials in patients with HF (left ventricular (LV) EF >40% and ≤40% respectively) with 
and without T2D, which both did not show any change from baseline to week 12 in 
exercise ability with empagliflozin, as measured by the six minute walk test.14  
 
Vascular effects of SGLT2 inhibitors in patients with diabetes  
EMPA-RenalTx, a randomized placebo-controlled parallel group trial, demonstrated 
that post-transplantation diabetes (renal transplant) (n=49) patients on empagliflozin 
(vs placebo) over 24 weeks showed no between-group difference with pulse wave 
velocity (NCT03157414).15  In a randomized placebo-controlled parallel group trial of 
40 patients with type 1 diabetes, empagliflozin on top of metformin over 12 weeks 
improved flow-mediated dilatation, reactive hyperemia index, pulse wave velocity and 
carotid artery stiffness (NCT03639545).16  
 
Liver effects of SGLT2 inhibitors in patients with diabetes  
The randomized placebo-controlled parallel group EFFECT II trial of 84 T2D patients 
with non-alcoholic fatty liver disease showed that, over 12 weeks, dapagliflozin and 
omega-3 carboxylic acids significantly reduced liver fat content measured on MRI, 
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whilst dapagliflozin monotherapy reduced all measured hepatocyte injury biomarkers 
and fibroblast growth factor 21 (NCT02279407).17  In 56 T2D patients, a randomized 
placebo-controlled parallel group trial showed that canagliflozin (vs placebo) did not 
change intrahepatic triglyceride measured on magnetic resonance spectroscopy 
(MRS) (NCT02009488).18  
 
Liver effects of SGLT2 inhibitors in patients without diabetes  
The randomized placebo-controlled parallel group Dapalost trial of 50 non-diabetic or 
prediabetic patients, showed that although the combination of dapagliflozin and 
exenatide reduced liver fat (as measured on MRI) from baseline at 24 weeks, this 
was not significantly different compared to placebo (NCT02313220).19  
 
Completed mechanistic randomized non-placebo-controlled trials of SGLT2 
inhibitors (Table 1b)  
 
Vascular effects of SGLT2 inhibitors in patients without diabetes  
In a randomized controlled parallel group comparison of 3 months treatment with 
empagliflozin or metformin in 40 women with polycystic ovarian syndrome (PCOS), 
without T2D and without prediabetes, SGLT2 inhibitor therapy had no effect on 
reactive hyperemia index or augmentation index assessed with EndoPAT 
(NCT03008551).20  
 
Renal effects of SGLT2 inhibitors in patients with diabetes  
In the randomized controlled parallel group RED study of T2D patients (n=44) 
comparing dapagliflozin or gliclazide over 12 weeks, dapagliflozin reduced measured 
glomerular filtration rate and reduced filtration fraction without increased renal 
vascular resistance as measured by inulin- and para-aminohippurate clearance 
(NCT02682563).21  
 
Liver effects of SGLT2 inhibitors in patients with diabetes  
The randomized parallel group E-LIFT study of empagliflozin versus standard care 
showed that 50 non-alcoholic fatty liver disease (NAFLD) patients with T2D on 
empagliflozin over 3 months had reduced liver fat and improved alanine transferase 
levels on MRI (NCT02686476).22  
 
Completed mechanistic randomized placebo-controlled trials of GLP-1RAs 
(Table 2a)  
 
Cardiovascular effects of GLP-1RAs in patients with diabetes  
The randomized placebo-controlled parallel group MAGNA VICTORIA trial of 50 T2D 
patients showed that liraglutide over 26 weeks reduced early LV diastolic filling and 
LV filling pressure, and reduced LV systolic function on cardiac MRI 
(NCT01761318).23  In 47 T2D patients of South Asian descent, with or without 
ischemic heart disease, randomly assigned to 26-week treatment with liraglutide or 
placebo, liraglutide did not affect LV diastolic and systolic function, aortic stiffness, 
myocardial triglyceride content, or extracellular volume, measured by MRI 
(NCT02660047).24  In a 12-week placebo-controlled parallel group trial in 49 T2D 
patients, liraglutide did not impact endothelium-dependent vasodilation 
(NCT00620282).25  AddHope2 was a randomized placebo-controlled cross-over 
study over 12 weeks (with a 2 week washout period) in 41 T2D patients with stable 
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coronary disease, which showed that liraglutide did not change LV EF at rest, at low 
stress, at peak stress, or at recovery, measured by dobutamine stress 
echocardiography (NCT01595789).26  This trial also showed no change in wall 
motion score index at any stress levels and no change in global longitudinal strain or 
global longitudinal strain rate at rest.  
 
Cardiovascular effects of GLP-1RAs in patients with and without diabetes  
Both the randomized placebo-controlled parallel group FIGHT study of 300 patients 
recently hospitalized with HF (with reduced LV EF) (NCT01800968), with or without 
T2D, and the randomized placebo-controlled parallel group LIVE study 
(NCT01472640) of 241 HF patients (EF ≤45%), with or without T2D, found that 
liraglutide (vs placebo), over 180 days and 24 weeks respectively, did not change LV 
EF on echocardiogram.27,28  Furthermore, in LIVE, liraglutide was associated with 
increased heart rate and more serious cardiac adverse events.28  In the randomized 
placebo-controlled parallel group POSTCON II trial of ST-segment elevation 
myocardial infarction patients (n=148 with MRI data), exenatide over 3 months 
reduced MRI-measured final infarct size in patients with a short system delay (≤132 
minutes) but not in those with a long system delay (>132 minutes) (NCT00835848).29  
A randomized placebo-controlled parallel group trial of 96 ST-segment elevation 
myocardial infarction patients showed that liraglutide improved myocardial salvage 
and infarct size on MRI after 3 months (NCT02001363).30  EMPIRE randomized 116 
ST-segment elevation myocardial infarction patients to exenatide or placebo in 
parallel groups, and showed that at 6 months (n=58), exenatide reduced E/e’ with 
improved strain parameters, measured by conventional and speckle tracking 
echocardiography (NCT01580514).31  
 
Cardiovascular effects of GLP-1RAs in patients without diabetes  
EXAMI was a randomized placebo-controlled parallel group trial of 191 non-diabetic 
patients with ST-segment elevation myocardial infarction, and showed that exenatide 
over 4 months did not change myocardial infarct size on MRI (NCT01254123).32  45 
non-diabetic patients with schizophrenia were randomized to exenatide or placebo in 
parallel groups in the TAO trial, which showed that exenatide reduced pulse wave 
velocity at 3 months (NCT01794429).33  
 
Renal effects of GLP-1RAs in patients with diabetes  
SAFEGUARD was a randomized placebo-controlled parallel group trial of 56 T2D 
patients on exenatide, showing no change in effective renal plasma flow, measured 
by para-aminohippurate clearance, over 12 weeks (NCT01744236).34  
 
Liver and gallbladder effects of GLP-1RAs in patients with diabetes  
SAFEGUARD randomized 56 T2D patients to liraglutide vs sitagliptin vs placebo in 
parallel groups, and did not find any change in gallbladder volume, hepatic steatosis 
or fibrosis, after 12 weeks of treatment (NCT01744236).35,36  The randomized 
placebo-controlled parallel group LEAN study of 52 T2D patients with non-alcoholic 
steatohepatitis showed that liraglutide over 48 weeks led to histological resolution of 
non-alcoholic steatohepatitis (NCT01237119).37  
 
Liver and gallbladder effects of GLP-1RAs in patients with or without diabetes  
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A randomized placebo-controlled study of 40 patients with or without T2D showed 
that liraglutide delayed gastric emptying on scintigraphy, at 5 and 16 weeks of 
treatment (NCT02647944).38  
 
Liver, gallbladder, metabolic and biomarker effects of GLP-1RAs in patients 
without diabetes  
The LIPT randomized placebo-controlled trial of 72 PCOS patients without diabetes, 
showed that liraglutide for 26 weeks reduced liver fat content, reduced visceral 
adipose tissue, reduced the prevalence of NAFLD (NCT02073929).39  Furthermore, 
LIPT showed improved bleeding regularity, improved markers of ovarian function and 
reduced midregional-pro-atrial natriuretic peptide.40,41  A randomized placebo-
controlled trial of 52 non-diabetic overweight/obese patients showed that liraglutide 
over 12 weeks was not associated with any change in gallbladder EF measured on 
ultrasonography (NCT02717858).42  Dapalost randomized 50 non-diabetic or 
prediabetic patients to exenatide/dapagliflozin vs placebo over 24 weeks, showing no 
between-group difference on liver fat on MRI (NCT02313220).19  
 
Lung effects of GLP-1RAs in patients without diabetes  
The randomized placebo-controlled SCALE trial of 359 non-diabetic patients with 
moderate-severe obstructive sleep apnea showed that liraglutide over 32 weeks 
reduced apnea-hypopnea index (NCT01557166).43  
 
Neurological and anti-inflammatory effects of GLP-1RAs in patients with and 
without diabetes  
GLIP1 randomized 120 patients with out of hospital cardiac arrest, with or without 
diabetes, to exenatide or placebo, and found that there was no change to 
neurological function at 30, 90 and 180 days (NCT02442791).44  TODINELI was a 
randomized placebo-controlled trial of 48 type 1 diabetes patients, showing that 
liraglutide over 26 weeks reduced interleukin-6, whilst neuronal function was 
unaltered (NCT02138045).45  
 
Neurological effects of GLP-1RAs in patients without diabetes  
GREAT randomized 103 prediabetic patients with schizophrenia, schizotypal disorder 
or paranoid psychosis to liraglutide or placebo, and showed that there was no 
change in measures of psychopathology at 1 year (NCT01845259).46  62 non-
diabetic patients with Parkinson’s disease were randomized to exenatide or placebo 
in EXENATIDE-PD, and over 60 weeks, exenatide had positive effects on practically 
defined off-medication motor scores, which were sustained beyond the period of 
exposure (NCT01971242).47  In TAO, a randomized placebo-controlled trial of 45 
non-diabetic patients with schizophrenia, exenatide for 3 months (n=40) did not 
change cognition or psychosocial function (NCT01794429).48  
 
Completed mechanistic randomized non-placebo-controlled trials of GLP-1RAs 
(Table 2b)  
 
Cardiovascular effects of GLP-1RAs in patients with diabetes  
AWARD-6 randomized 599 T2D patients to dulaglutide vs liraglutide over 26 weeks, 
and did not find any change in PR interval on electrocardiogram (NCT01624259).49  
62 T2D patients with HF (EF ≤50% or diastolic function) were randomized to 
liraglutide or glimepiride over 18 weeks, showing no change in longitudinal fractional 
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reserve index on exercise tissue Doppler echocardiography (NCT01425580).50  In a 
randomized trial of 60 patients with newly diagnosed and treatment-naïve T2D 
randomized to liraglutide or metformin, six-month treatment with liraglutide reduced 
arterial stiffness, LV myocardial strain, LV twisting and untwisting and N-terminal pro-
B-type natriuretic peptide by reducing oxidative stress, whilst these measured 
markers were unchanged in the metformin group (except for improved flow mediated 
dilation) (NCT03010683).51  In a randomized trial of 44 T2D patients on metformin, 
the addition of liraglutide improves several cardiovascular risk markers, but there was 
no change for arterial stiffness parameters (NCT01208012).52  
 
Cardiovascular effects of GLP-1RAs in patients without diabetes  
In 50 patients with impaired glucose tolerance (but without diabetes) and abdominal 
obesity, randomized to exenatide vs metformin for 3 months, exenatide therapy had 
similar effects of microvascular endothelial function as metformin (NCT00546728).53  
 
Metabolic and liver effects of GLP-1RAs in patients with diabetes  
In 93 T2D patients with NAFLD, randomized to liraglutide vs metformin vs gliclazide, 
over 168 days follow-up, reductions in intrahepatic fat were greater with liraglutide 
and metformin than with gliclazide (NCT03068065).54  In addition, compared with 
gliclazide, liraglutide and metformin monotherapies reduced body fat mass measured 
on dual energy X-ray absorptiometry.55  In the LIGHT-ON randomized active 
comparator trial, 75 T2D patients with simple liver steatosis randomized to liraglutide 
vs insulin glargine vs sitagliptin over 26 weeks, both liraglutide and sitagliptin reduced 
intrahepatic lipid, and reduced visceral adipose tissue measured by MRI 
(NCT02147925).56  
 
Metabolic effects of GLP-1RAs in patients without diabetes  
In a randomized parallel group trial of 183 patients with impaired glucose regulation 
and PCOS, randomized to 3 groups (exenatide vs metformin vs exenatide + 
metformin), over 12 weeks, there was reduced testosterone and free androgen index 
in all 3 groups (although there was no reported between-group P value) 
(NCT03352869).57  
 
Neurological effects of GLP-1RAs in patients with diabetes  
In 46 T2D patients with diabetic peripheral neuropathy, randomized in parallel groups 
to exenatide vs insulin glargine over 18 months, there was no change in confirmed 
clinical neuropathy, intra-epidermal nerve fiber density or measures of cardiac 
autonomic neuropathy (NCT00855439).58  
 
Neurological effects of GLP-1RAs in patients without diabetes  
In 45 non-diabetic patients with idiopathic Parkinson’s disease of moderate severity, 
randomized to exenatide vs controls in parallel groups, over 12 and 14 months (after 
2-month washout), the exenatide group had clinically relevant improvements in 
Parkinson’s disease across motor and cognitive measures, compared with the 
control group (NCT01174810).59  A randomized parallel group trial of 44 non-diabetic 
obese subclinical binge eating participants randomized to liraglutide or control 
groups, showed that over 12 weeks, liraglutide patients were less likely to binge eat 
(NCT01739049).60  
 
Ongoing mechanistic trials of SGLT2 inhibitors (Supplemental Tables 1a-p)  
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The wealth of ongoing SGLT2 inhibitor mechanistic trials broadly place an emphasis 
on investigating (i) cardiac (ii) vascular/hemodynamic and (iii) renal mechanisms. 
However, as noted in the supplementary tables, other pathways are also being 
pursued.  
 
(i) Cardiac - Many trials are studying the effects of SGLT2 inhibition on the heart, 
including cardiac structure (mass, volumes), function (systolic, diastolic), myocardial 
perfusion, myocardial metabolic activity and epicardial fat.  In particular, there are a 
large number of trials in patients with HF and either reduced or preserved EF.  
Multiple imaging modalities including ultrasound, MRI, 31-phosphorus MRS, single 
photon emission computed tomography and positron emission tomography are being 
employed and a host of cardiac biomarkers measured.  
 
(ii) Vascular function (central and peripheral e.g. aorta, carotid, femoral, radial) and 
invasive hemodynamics are being investigated using, among other techniques, flow 
mediated dilatation, tonometry, ultrasound, MRI and right heart catheterization.  
There are also studies of body composition, tissue sodium and water content, muscle 
mitochondrial function, as well as hepatic and pancreatic fat with techniques 
including dual energy X-ray absorptiometry and MRS.  
 
(iii) Renal - Glomerular filtration, renal tubular function, and kidney perfusion are 
being explored with MRI, various radionuclide imaging investigations, measurement 
of biomarkers in blood and urine and renal biopsy.  
 
Ongoing mechanistic trials of SGLT2 inhibitors in patients without diabetes  
In addition to patients with T2D, studies are also being conducted in healthy 
volunteers, individuals with prediabetes and patients with a variety of other conditions 
including type 1 diabetes, post-transplantation diabetes mellitus (post-renal 
transplant), NAFLD/non-alcoholic steatohepatitis and PCOS.  
 
Ongoing mechanistic trials of GLP-1RAs (Supplemental Tables 2a-j)  
 
Trials with GLP-1RAs are investigating mechanisms relating to (i) fat/weight/appetite 
reduction, (ii) cardiac structure and function, and (iii) vascular function.  
 
(i) Appetite/weight studies include MRI of the brain.  Dual energy X-ray 
absorptiometry, computed tomography, MRI and MRS are assessing body 
composition, body fat and liver fat.  Scintigraphy is being utilized to study gastric 
emptying.  
 
(ii) Cardiac studies include patients with coronary artery disease and HF with 
preserved as well as reduced EF. The techniques employed include 
echocardiography, MRI and MRS.  
 
(iii) Vascular (central and peripheral) studies, including assessment of endothelial 
function, arterial stiffness and evaluation of the carotid arteries.  Common vascular 
measures include flow mediated dilatation, pulse wave velocity and carotid intima 
medial thickness.  Positron emission tomography/computed tomography is also being 
used to assess vascular inflammation and coronary artery calcium score.  
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Ongoing mechanistic trials of GLP-1RAs in patients without diabetes  
GLP-1 RAs are also being studied in patients other than those with T2D, including 
individuals with obesity and after bariatric surgery, as well as people with chronic 
obstructive pulmonary disease, PCOS, NAFLD/non-alcoholic steatohepatitis, 
osteoarthritis, human immunodeficiency virus, Alzheimer’s disease, Parkinson’s 
disease, schizophrenia, tobacco-dependence, alcohol-dependence and 
craniopharyngioma.  
 
Two exemplar trials  
 
We detail and discuss two mechanistic trials investigating an SGLT2 inhibitor and a 
GLP-1RA respectively – these prospective randomized clinical trials employ state-of-
the-art imaging techniques which investigate multiple organ systems and different 
vascular beds, over a moderate length of time.  
 
1. SUGAR-DM-HF  
 
Empagliflozin in HF with reduced EF: A randomized, double blind, placebo-controlled 
investigation of the effects of empagliflozin on cardiovascular, renal and metabolic 
measures over 36 weeks in 105 patients with HF with reduced EF.61  A multicenter 
study recruiting from 15 hospital sites in the West of Scotland.  The key inclusion 
criteria are HF (LV EF ≤40%, New York Heart Association class II-IV), T2D (glycated 
hemoglobin ≤97 mmol/mol) or prediabetes (glycated hemoglobin 39-47 mmol/mol), 
age ≥18 years and with an estimated glomerular filtration rate ≥30 ml/min/1.73m2.  It 
is due to report in late 2020.  The co-primary outcomes are LV end-systolic volume 
index and LV global longitudinal strain, both measured using cardiac MRI.  
Secondary outcomes include microvascular perfusion (cardio-renal) and extracellular 
volume fraction, both measured using MRI, quality of life score (Kansas City 
Cardiomyopathy Questionnaire), and exercise capacity (six minute walk test).  Study 
medication is discontinued at week 36, and patients return for MRI at week 40 – this 
will establish whether structural remodeling occurs as opposed to a diuretic or 
hemodynamic effect.  
 
2. LIRAFLAME  
 
Liraglutide and vascular inflammation: A randomized, double blind, placebo-
controlled investigation of the effects of liraglutide on vascular inflammation over 26 
weeks, in 100 participants with T2D.62  The key inclusion criteria are age >50 years 
with a glycated hemoglobin ≥48 mmol/mol, estimated glomerular filtration rate ≥30 
ml/min/1.73m2 and on stable glucose-lowering medication.  The primary outcomes 
are change in vascular inflammation (as measured by 18F-fluorodeoxyglucose 
positron emission tomography/computed tomography).  Secondary outcomes are 
change in endothelial function (EndoPAT, sublingual glycocalyx measurement), 
coronary artery calcium score and carotid intima media thickness (ultrasound).  Other 
outcome measures include autonomic nervous system function (cardiovascular 
autonomic neuropathy indices).  
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These two trials give a snapshot of the types of techniques being used to investigate 
mechanistic pathways but of course, many other techniques are being used in a 
variety of studies highlighted in the tables.  
 
Conclusion  
 
In summary, recent outcome trials have revealed two classes of drugs which not only 
reduce blood glucose but also reduce clinical events.  These drugs are now 
recommended by major guideline changes.  We remain almost totally ignorant on 
their mechanisms of benefit.  A plethora of research activity is underway to determine 
mechanisms of action across key areas of interest, as we have carefully summarized 
in this review.  Very few trials are investigating the mechanism in those without 
diabetes.  We believe our list of trials will help many researchers in the field and will 
help inform better trial designs in the future. Over the next 1-4 years many of these 
studies will report. Hopefully, these new studies will allow us to better understand 
how SGLT2 inhibitors and GLP-1RAs reduce hard outcomes.  
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Highlights  
 
• It remains uncertain how SGLT2 inhibitors and GLP-1RAs reduce 
cardiovascular events and multiple mechanistic studies are currently being 
conducted across both classes using a range of techniques and across 
differing populations.  
• SGLT2 inhibitor mechanistic trials focus on a range of pathways including 
those linked to hyperglycemia, hemodynamic/volume effects, cardiovascular 
and renal effects and cardiac metabolism.  
• SGLT2 inhibitor trials are studying populations with established cardiovascular 
disease (including coronary artery disease and heart failure), liver disease 
(e.g. non-alcoholic fatty liver disease, non-alcoholic steatohepatitis), renal 
impairment (including post-renal transplant), obesity and hypertension; and 
have enrolled patients with and without type 2 diabetes (e.g. healthy, type 1 
diabetes, gestational diabetes).  
• GLP-1RA mechanistic trials focus on weight reduction and blood pressure 
lowering effects, vascular, cardiac, inflammatory and renal effects.  
• GLP-1RA trials are studying populations with obesity, coronary artery disease, 
heart failure, human immunodeficiency virus, osteoarthritis, chronic obstructive 
pulmonary disease, liver disease, Alzheimer’s disease, Parkinson’s disease, 
schizophrenia, tobacco-dependence, alcohol-dependence and 
craniopharyngioma; and have also included patients with and without type 2 
diabetes (e.g. healthy, prediabetes, type 1 diabetes).  
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Figures and Figure Legends  
 
Figure 1. Overview of completed and ongoing mechanistic sodium-glucose co-transporter 2 inhibitor trials: pathways 
under investigation, different investigative approaches utilized, populations targeted and primary outcomes (reported 
trials are underlined with results in italics). NCT indicates Clinicaltrials.gov registration number. Trial acronyms are 
included (if available).  
 
Abbreviations: 23Na, 23 sodium; 31P, 31 phosphorus; 6MWT, six minute walk test; Ang, angiotensin; BOLD, blood-oxygen-level-
dependent; CAD, coronary artery disease; cIMT, carotid intima-media thickness; CKD, chronic kidney disease; CMR, cardiac 
magnetic resonance; CV, cardiovascular; DEXA, dual energy X-ray absorptiometry; EAT, epicardial adipose tissue; ECV, 
extracellular volume fraction; EndoPAT, peripheral arterial tone; FMD, flow-mediated dilatation; fMRI, functional magnetic 
resonance imaging; GFR, glomerular filtration rate; GLS, global longitudinal strain; H2O2, hydrogen peroxide; HF, heart failure; 
HFpEF, heart failure with preserved ejection fraction; HFmrEF, heart failure with mid-range ejection fraction; HFrEF, heart failure 
with reduced ejection fraction; HRV, heart rate variability; IL, interleukin; KCCQ, Kansas City Cardiomyopathy Questionnaire; 
LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV(i), left ventricular end-systolic volume 
(indexed); LVM(i), left ventricular mass (indexed); MFR, myocardial flow reserve; MI, myocardial infarction; MPR, myocardial 
perfusion reserve; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NAA, N Acetyl-Aspartate; NAFLD; 
NASH; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NT-proBNP, N-terminal pro-B-type natriuretic peptide; 
PADP, pulmonary artery diastolic pressure; PCOS, polycystic ovarian syndrome; PCr/ATP, phosphocreatinine/adenosine 
triphosphate; PET, positron emission tomography; PYY, Peptide-YY; Rb-82, rubidium-82; RHI, reactive hyperemia index; SPECT, 
single photon emission computed tomography; STEMI, ST-segment elevation myocardial infarction; T1D, type 1 diabetes; T2D, 
type 2 diabetes; U ACR, urinary albumin creatinine ratio; VO2, peak oxygen consumption; Vv(Int/cortex), cortical interstitial fractional 
volume.  
 
Figure 2. Overview of completed and ongoing mechanistic glucagon-like peptide-1 receptor agonist trials: pathways under 
investigation, different investigative approaches utilized, populations targeted and primary outcomes (reported trials are 
underlined with results in italics). NCT indicates Clinicaltrials.gov registration number. Trial acronyms are included (if 
available).  
 
Abbreviations: 18F, 18-fluorodeoxyglucose; Ach, acetylcholine; ADAS-cog, Alzheimer’s Disease Assessment Scale; AF, atrial 
fibrillation; AGEs, advanced glycation end products; AHI, Apnea-Hypopnea Index; AI, augmentation index; ASCVD, atherosclerotic 
cardiovascular disease; BOLD, blood-oxygen-level-dependent; CABG, coronary artery bypass graft; CAD, coronary artery disease; 
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CCN, confirmed clinical neuropathy; CFR, coronary flow reserve; CMR, cardiac magnetic resonance; CT, computed tomography; 
CV, cardiovascular; DCE, dynamic contrast-enhanced; DEXA, dual energy X-ray absorptiometry; DSE, dobutamine stress 
echocardiography; dysfx, dysfunction; E, early transmitral peak flow rate; Ea, early peak mitral annular septal tissue velocity; EAT, 
epicardial adipose tissue; EEG, electroencephalography; EMG, electromyography; EPCs, endothelial progenitor cells; FAI, free 
androgen index; FBF, forearm blood flow; FCR, food-cue reactivity; FDG, fluorodeoxyglucose; FMD, flow-mediated dilatation; fMRI, 
functional magnetic resonance imaging; fx, function; GFR, glomerular filtration rate; HR, heart rate; IGT, impaired glucose tolerance; 
IMT, intima-media thickness; KISS, kidney injury summary score; KOOS, Knee injury and Osteoarthritis Outcome Score; LA, left 
atrium; LFRI, longitudinal functional reserve index; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; 
MISS, myocardial injury summary score; MRE, magnetic resonance elastography; MRI, magnetic resonance imaging; MRS, 
magnetic resonance spectroscopy; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NSTEMI, non-ST 
segment elevation myocardial infarction; OGTT, oral glucose tolerance test; PAI-1, plasminogen activator inhibitor 1; PET, positron 
emission tomography; PWV, pulse wave velocity; rCBF, regional cerebral blood flow; RHI, reactive hyperemia index; RHR, resting 
heart rate; rRNA, ribosomal ribonucleic acid; SF-36, short form health survey; STEMI, ST-segment elevation myocardial infarction; 
T1D, type 1 diabetes; T2D, type 2 diabetes; TBR, target-to-background ratio; TDI, Transition Dyspnea Index; U ACR, urinary 
albumin creatinine ratio; UAER, urinary albumin excretion rate.  
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Tables 
 
Table 1a: Completed SGLT2 inhibitor mechanistic randomized placebo-controlled trials  
PATIENTS WITH DIABETES 
Outcome 
(Cardiac, 
Biomarkers 
Symptoms, 
Fitness) 
Technique Trial 
Registration 
Full Official Title SGLT2 
inhibitor vs 
comparator 
Duration Glycemi
c status 
Population N Date 
Complet
e 
Main Results 
Symptoms, 
fitness, 
biomarkers 
6MWT, KCCQ, 
CHQ-SAS dyspnea 
score, Clinical 
Congestion Score, 
PGI-S. PGI of 
Dyspnea Severity, 
PGI-C, NT-proBNP 
NCT03448406 
(EMPERIAL-
preserved) 
(*6MWT) 
A Phase III Randomised, Double-blind 
Trial to Evaluate the Effect of 12 Weeks 
Treatment of Once Daily EMPagliflozin 10 
mg Compared With Placebo on ExeRcise 
Ability and HF Symptoms, In Patients With 
Chronic HeArt FaiLure With Preserved EF 
Empagliflozin 
vs placebo 
12 
weeks 
(*) (also 
6 weeks 
for 
6MWT) 
± T2D HFpEF (LV 
EF >40%, 
NYHA II-IV, 
raised NT-
proBNP) 
315 2019/10 ↔ 6MWT.14 (other data 
awaited). 
NCT03448419 
(EMPERIAL-
reduced) 
(*6MWT) 
A Phase III Randomised, Double-blind 
Trial to Evaluate the Effect of 12 Weeks 
Treatment of Once Daily EMPagliflozin 10 
mg Compared With Placebo on ExeRcise 
Ability and HF Symptoms, In Patients With 
Chronic HeArt FaiLure With Reduced EF 
Empagliflozin 
vs placebo 
12 
weeks 
(*) (also 
6 weeks 
for 
6MWT) 
± T2D HFrEF (LV 
EF ≤40%, 
NYHA II-IV, 
raised NT-
proBNP) 
312 2019/10 ↔ 6MWT.14 (other data 
awaited). 
Biomarkers NT-proBNP, BNP NCT02653482 
(DEFINE-HF) 
(*NT-proBNP, 
*KCCQ) 
Dapagliflozin Effect on Symptoms and 
Biomarkers in Patients with HF 
Dapagliflozin 
vs placebo 
12 
weeks 
± T2D HFrEF (LV 
EF ≤40%) 
263 2019/06 ↔ NT-proBNP but ↑ proportion 
experiencing clinically 
meaningful improvements in HF-
related health status.13 
Symptoms KCCQ 
Cardiac 
structure: LV 
mass 
indexed 
Cardiac MRI NCT02998970 
(EMPA-
HEART) (*) 
Effects of Empagliflozin on Cardiac 
Structure, Function, and Circulating 
Biomarkers in Patients With T2D 
Empagliflozin 
vs placebo 
6 
months 
T2D Established 
CV disease 
(previous MI 
or previous 
coronary 
revasculariz
ation) 
97 2018/09 ↓ LV mass indexed 2.6 g/m2 
(P=0.01).12 (other data awaited). 
Catecholami
ne 
Blood sample 
Vascular 
assessment 
Aortic PWV and 
distensibility 
Outcome 
(Vascular, 
Musculoskel
etal) 
Technique Trial 
Registration 
Full Official Title SGLT2 
inhibitor vs 
comparator 
Duration Glycemi
c status 
Population N Date 
Complet
e 
Main Results 
Bone 
mineral 
density, 
body 
composition 
DEXA NCT03157414  
(EMPA-
RenalTx) 
Efficacy and Safety of Empagliflozin in 
Renal Transplant Recipients With Post-
Transplantation Diabetes 
Empagliflozin 
vs placebo 
24 
weeks 
Post-
transpla
ntation 
diabetes 
Renal 
transplant 
49 2018/06 No between-group difference in 
PWV.15 (other data awaited). 
Arterial 
stiffness 
SphygmoCor (radial 
artery applanation 
tonometry) 
Carotid PWV, 
carotid-femoral 
PWV, common 
carotid artery 
stiffness (β-stiffness) 
NCT03639545 
(*endothelial 
function & 
arterial 
stiffness) 
The Effects of Empagliflozin on Functional 
and Structural Arterial Wall Characteristics 
Empagliflozin 
vs 
empagliflozin 
+ metformin vs 
metformin vs 
12 
weeks 
T1D No 
advanced 
heart / 
kidney / liver 
failure 
40 2019/01 Empagliflozin on top of 
metformin improved FMD, RHI, 
PWV and β-stiffness.16 
30 
Endothelial 
function 
FMD, RHI placebo 
Outcome 
(Hepatic) 
Technique Trial 
Registration 
Full Official Title SGLT2 
inhibitor vs 
comparator 
Duration Glycemi
c status 
Population N Date 
Complet
e 
Main Results 
Liver fat MRI NCT02279407 
(EFFECT II) 
(*liver fat) 
A Double-blind Randomized Placebo-
controlled, Parallel-group 12 Week Study 
to Investigate the Effects of Omega-3 
Carboxylic Acids and Dapagliflozin on 
Liver Fat Content in T2D Patients 
Dapagliflozin 
vs OM-3CA vs 
dapagliflozin + 
OM-3CA vs 
placebo 
12 
weeks 
T2D NAFLD; 
Liver fat 
content as 
assessed by 
MRI >5.5% 
84 2015/12 Dapagliflozin + OM-3CA 
significantly ↓ liver fat content. 
Dapagliflozin monotherapy ↓ all 
measured hepatocyte injury 
biomarkers and FGF21.17 
FGF21 Plasma 
Liver fat MRS NCT02009488 
(*) 
A Double-Blind, Placebo-Controlled, 
Randomized, Parallel Groups, Multicenter 
Study to Investigate the Effects of 
Canagliflozin on Insulin Sensitivity, Hepatic 
Fat Content and Beta Cell Function in 
Subjects With T2D 
Canagliflozin 
vs placebo 
25 
weeks 
T2D Age 25-70 
years 
56 2017/01 ↔ intrahepatic triglyceride.18 
PATIENTS WITHOUT DIABETES 
Outcome 
(Hepatic) 
Technique Trial 
Registration 
Full Official Title SGLT2 
inhibitor vs 
comparator 
Duration Glycemi
c status 
Population N Date 
Complet
e 
Main Results 
Liver fat MRI NCT02313220 
(Dapalost) 
A 24-week, Single Centre, Randomized, 
Parallel-group, Double-blind, Placebo 
Controlled Phase II Study With an Optional 
28-week Open-label Extension to Evaluate 
the Efficacy on Body Weight of 
Dapagliflozin 10 mg Once Daily in 
Combination With Exenatide 2 mg Once 
Weekly in Obese Non-diabetic Subjects 
Dapagliflozin + 
exenatide vs 
placebo 
24 
weeks 
Non-
diabetic 
(prediab
etes 
allowed) 
BMI 30-45 
kg/m2 
50 2016/03 ↓ liver fat from baseline (but not 
significantly different between 
dapaglilfozin/exenatide vs 
placebo).19 
 
NCT indicates Clinicaltrials.gov registration number. N indicates number randomized. * indicates primary outcome.  
 
Abbreviations: 6MWT, six minute walk test; BMI, body mass index; BNP, B-type natriuretic peptide; CHQ-SAS, Chronic Heart Failure Questionnaire Self-Administered Standardized Format; CV, cardiovascular; DEXA, 
dual energy X-ray absorptiometry; EF, ejection fraction; FGF21, fibroblast growth factor 21; FMD, flow-mediated dilatation; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced 
ejection fraction; KCCQ, Kansas City Cardiomyopathy Questionnaire; LV, left ventricular; MI, myocardial infarction; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NAFLD, non-alcoholic 
fatty liver disease; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; OM-3CA, omega-3 (n-3) carboxylic acids; PGI-C, Patient Global Impression of Change; PGI-S, Patient 
Global Impression of Severity; PWV, pulse wave velocity; RHI, reactive hyperemia index; SGLT2, sodium-glucose co-transporter 2; T1D, type 1 diabetes; T2D, type 2 diabetes.  
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Table 1b: Completed SGLT2 inhibitor mechanistic randomized non-placebo-controlled trials  
PATIENTS WITH DIABETES 
Outcome (Liver) Technique Trial Registration Full Official Title SGLT2 inhibitor vs 
comparator 
Duration Glycemic 
status 
Population N Date 
Complete 
Main Results 
Liver fat change MRI-proton density 
fat fraction 
NCT02686476 (E-
LIFT) (*) 
Effect of Empagliflozin on 
Liver Fat Content in Patients 
With T2D: A 12-week 
Randomized Clinical Study 
Empagliflozin vs 
standard care (no 
empagliflozin) 
3 months T2D NAFLD 50 2017/12 ↓ liver fat (P<0.0001), 
improved ALT levels.22 
Outcome 
(Renal) 
Technique Trial Registration Full Official Title SGLT2 inhibitor vs 
comparator 
Duration Glycemic 
status 
Population N Date 
Complete 
Main Results 
GFR Urinary and plasma 
inulin concentrations 
NCT02682563 
(RED) (*GFR, 
*ERPF) 
A Randomized, Double-
blind, Comparator-controlled 
Trial to Assess the Effect of 
12-week Treatment With 
Dapagliflozin Versus 
Gliclazide on Renal 
Physiology and Biomarkers 
in Metformin-treated 
Patients With T2D 
Dapagliflozin vs 
gliclazide 
12 weeks T2D BMI >25 
kg/m2; eGFR 
≥60 
ml/min/1.73
m2 
44 2018/09 Dapagliflozin ↓ measured 
GFR, ↓ filtration fraction 
without ↑ renal vascular 
resistance.21 ERPF Urinary and plasma 
para-aminohippurate 
concentrations 
PATIENTS WITHOUT DIABETES 
Outcome 
(Vascular) 
Technique Trial Registration Full Official Title SGLT2 inhibitor vs 
comparator 
Duration Glycemic 
status 
Population N Date 
Complete 
Main Results 
Endothelial 
function 
EndoPAT: RHI, AIx NCT03008551 
(*RHI) 
The Effect of Empagliflozin 
Versus Metformin on 
Hormonal, Metabolic and 
Cardiovascular Risk Factors 
in Patients With PCOS - a 
Randomised Open-label 
Parallel Study 
Empagliflozin vs 
metformin 
3 months No diabetes, 
no 
prediabetes 
PCOS 40 2018/04 ↔ RHI or AIx.20 
 
NCT indicates Clinicaltrials.gov registration number. N indicates number randomized. * indicates primary outcome.  
 
Abbreviations: AIx, augmentation index; ALT, alanine transferase; BMI, body mass index; (e)GFR, (estimated) glomerular filtration rate; EndoPAT, peripheral arterial tone; ERPF, effective renal plasma flow; MRI, 
magnetic resonance imaging; NAFLD, non-alcoholic fatty liver disease; PCOS, polycystic ovary syndrome; RHI, reactive hyperemia index; SGLT2, sodium-glucose co-transporter 2; T2D, type 2 diabetes.  
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Table 2a: Completed GLP-1 receptor agonist mechanistic randomized placebo-controlled trials  
PATIENTS WITH DIABETES 
Outcome 
(Cardiovascular, 
Renal, 
Metabolic) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
comparator 
Duration Glycemic 
status 
Population N Date 
Complete 
Main Results 
Cardiac function Echocardiography NCT01800968 
(FIGHT) 
Functional Impact of GLP-1 for HF 
Treatment  
Liraglutide 
vs placebo 
180 
days 
± T2D Acute HF 
Syndrome, LV 
EF ≤40% 
300 2015/10 ↔ LV EF, ↔ LV end-
diastolic volume index, 
↔ LV end-systolic 
volume index, ↔ 6 
minute walk distance, 
↔ KCCQ summary 
scores.27 
NCT01472640 
(LIVE) (*LV 
function) 
A Randomised, Double-blind, Placebo-
controlled Study of the Effect of LIraglutide 
on Left VEntricular Function in Chronic HF 
Patients With and Without T2D 
Liraglutide 
vs placebo 
24 
weeks 
± T2D HF (EF ≤45%) 241 2015/10 ↔ LV EF, ↑ HR, more 
serious cardiac 
adverse events.28 
Infarct size Cardiac MRI NCT00835848 
(POSTCON II) 
(*) 
Pharmacological Postconditioning to 
Reduce Infarct Size Following Primary PCI 
in Patients With STEMI 
Exenatide vs 
placebo 
(saline) 
3 
months 
± Diabetes 
mellitus 
(exclude 
DKA) 
STEMI 387 
(148 
com
plete 
CM
R) 
2015/05 30% ↓ final infarct size 
in patients with short 
system delay (≤132 
minutes), but not in 
those with long system 
delay (>132 minutes) 
(post hoc analysis).29 
Salvage index Cardiac MRI NCT02001363 
(*) 
Protective Effect of GLP-1 on Reperfusion 
Injury in Patients With Acute Myocardial 
Infarction 
Liraglutide 
vs placebo 
3 
months 
after 
PPCI 
± Diabetes 
mellitus 
(exclude 
DKA) 
STEMI 96 2016/03 Improved myocardial 
salvage and infarct 
size.30 
LV function Conventional and 
speckle tracking 
echocardiography 
NCT01580514 
(EMPIRE) 
Cardioprotective Effects of Exenatide in 
Patients With STEMI Undergoing PPCI; 
Results of Exenatide Myocardial 
Protection In REvascularization (EMPIRE) 
Study 
Exenatide vs 
placebo 
(saline) 
3 days & 
6 
months 
(after 
PPCI) 
± Diabetes 
mellitus 
(exclude 
DKA) 
STEMI 116 
(58 
com
plete
d 6 
mon
ths) 
2011/08 At 6 months, ↓ E/e’ 
with improved strain 
parameters.31 
Resting heart 
rate 
Oscillometric 
technique 
NCT01744236 
(SAFEGUARD
: long-term 
study) 
(*resting HR 
variability) 
A Phase IV, Randomized, Double-blind, 
Placebo-controlled, Parallel-group Trial to 
Assess the Effect of 12-week Treatment 
With the GLP-1RA Liraglutide or DPP-4i 
Sitagliptin on the CV, Renal and 
Gastrointestinal System in Insulin-naïve 
Patients With T2D: long-term study 
Liraglutide 
vs sitagliptin 
vs placebo 
12 
weeks 
T2D BMI 25-40 
kg/m2 
56 2015/08 ↑ resting HR, ↓ systolic 
blood pressure, ↓ 
stroke volume, ↔ 
cardiac output, ↔ 
vascular resistance, ↔ 
arterial stiffness, ↔ 
SNS activity.63 
Systemic 
hemodynamics 
Finger 
plethysmography 
SNS activity HR variability 
Arterial stiffness Applanation 
tonometry 
Mean 24-hour 
heart rate 
Ambulatory blood 
pressure monitor 
NCT00516074 
(*) 
A Study to Assess the Effect of Exenatide 
Treatment on Mean 24-Hour HR in 
Patients With T2D 
Exenatide vs 
placebo 
12 
weeks 
T2D BMI >25 & 
<40 kg/m2 
54 2008/04 ↔ 24-hour HR.64 
Endothelial 
function 
Acetylcholine-
mediated forearm 
blood flow, venous 
occlusion 
plethysmography 
NCT00620282 
(*acetylcholine
-mediated 
forearm blood 
flow) 
The Effect of Liraglutide on Endothelial 
Function in Subjects With T2D: A 12-week 
Randomized, Double-blind, Placebo-
controlled, Parallel-group, Single-center 
Trial With an Open-label Glimepiride Arm 
Liraglutide 
vs placebo 
vs 
glimepiride 
12 
weeks 
T2D BMI ≤40 kg/m2 49 2010/05 ↔ endothelium-
dependent 
vasodilation.25 
Cardiac function Cardiac MRI NCT01761318 
(MAGNA 
VICTORIA) 
MAGNetic resonance Assessment of 
VICTOza efficacy in the Regression of CV 
dysfunction In type 2 diAbetes mellitus 
Liraglutide 
vs placebo 
26 
weeks 
T2D BMI ≥25 kg/m2 50 2016/03 ↓ early LV diastolic 
filling and LV filling 
pressure, ↓ LV systolic 
Vascular 
assessments 
Aorta and carotid 
vessel wall imaging 
33 
Heart, liver, 
kidney (not 
stated) 
MRS (*cardiac 
function) 
function.23 
Ectopic fat MRI NCT02660047 
(MAGNA 
VICTORIA) 
(*cardiac 
function) 
MAGNetic resonance Assessment of 
VICTOza efficacy in the Regression of CV 
dysfunction In type 2 diAbetes mellitus and 
South Asian Descent 
Liraglutide 
vs placebo 
26 
weeks 
T2D South Asian 
descent, ± 
ischemic heart 
disease 
47 2018/03 ↔ LV diastolic 
function, ↔ LV systolic 
function (LV EF), ↔ 
aortic PWV, ↔ 
myocardial triglyceride 
content, ↔ ECV.24 ↓ 
visceral adipose tissue 
volume (per-protocol 
analysis but not in 
intention-to-treat 
analysis).65 
Cardiac function 
Aortic stiffness PWV 
Carotid vessel (not stated) 
Heart, liver, 
kidney (not 
stated) 
MRS 
Myocardial T1 & 
ECV 
MRI mapping 
Cardiac function Dobutamine stress 
echocardiography 
NCT01595789 
(AddHope2) 
(*LV EF) 
Adding Liraglutide to the Backbone 
Therapy of Biguanide in Patients With 
Coronary Artery Disease and Newly 
Diagnosed T2D 
Liraglutide 
vs placebo 
(cross-over) 
12 
weeks 
(2 week 
washout
) 
T2D Stable 
coronary 
artery disease 
41 2015/07 ↔ LV EF at rest, at 
low stress, at peak 
stress, or at recovery; 
↔ WMSI at any stress 
levels; ↔ GLS and ↔ 
GLSR at rest; ↔ 
maximal exercise 
capacity.26 
WMSI 
GLS, GLSR 
Exercise 
capacity 
Cycle ergometer 
exercise tolerance 
test 
Outcome 
(Renal) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
comparator 
Duration Glycemic 
status 
Population N Date 
Complete 
Main Results 
GFR Inulin clearance NCT01744236 
(SAFEGUARD
: long-term 
study) (*GFR) 
A Phase IV, Randomized, Double-blind, 
Placebo-controlled, Parallel-group Trial to 
Assess the Effect of 12-week Treatment 
With the GLP-1RA Liraglutide or DPP-4i 
Sitagliptin on the CV, Renal and 
Gastrointestinal System in Insulin-naïve 
Patients With T2D: long-term study 
Liraglutide 
vs sitagliptin 
vs placebo 
12 
weeks 
T2D BMI 25-40 
kg/m2 
56 2015/08 ↔ GFR.34 
ERPF PAH clearance 
Outcome 
(Hepatobiliary, 
Gastric) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
comparator 
Duration Glycemic 
status 
Population N Date 
Complete 
Main Results 
Gallbladder 
volume 
Ultrasonography 
after high-fat meal 
NCT01744236 
(SAFEGUARD
: long-term 
study) 
A Phase IV, Randomized, Double-blind, 
Placebo-controlled, Parallel-group Trial to 
Assess the Effect of 12-week Treatment 
With the GLP-1RA Liraglutide or DPP-4i 
Sitagliptin on the CV, Renal and 
Gastrointestinal System in Insulin-naïve 
Patients With T2D: long-term study 
Liraglutide 
vs sitagliptin 
vs placebo 
12 
weeks 
T2D BMI 25-40 
kg/m2 
56 2015/08 ↔ gallbladder 
volume.35 
Liver fat content Proton MRS 52 ↔ hepatic steatosis or 
fibrosis.36 
Liver histological 
improvement 
Liver histology NCT01237119 
(LEAN) (*) 
48-week Phase II, Randomised, Double 
Blinded Placebo Controlled Multicentre 
Trial on Liraglutide's Safety, Efficacy and 
Action on Liver Histology and Metabolism 
in Overweight Patients With NASH +/- T2D 
Liraglutide 
vs placebo 
48 
weeks 
T2D NASH on liver 
biopsy, BMI 
≥25 kg/m2 
52 2014/07 Histological resolution 
of NASH.37 
Gastric 
emptying 
Scintigraphy NCT02647944 
(*) 
Pilot Study of the Effect of Liraglutide on 
Weight Loss and Gastric Functions in 
Obesity 
Liraglutide 
vs placebo 
5 & 16 
weeks 
± T2D (only 
metformin 
allowed) 
BMI ≥30 or 
≥27 kg/m2 with 
obesity-related 
co-morbidity 
40 2016/12 At 5 and 16 weeks, 
delayed gastric 
emptying.38 
Outcome 
(Neurological, 
Inflammation) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
comparator 
Duration Glycemic 
status 
Population N Date 
Complete 
Main Results 
Cerebral status Cerebral NCT02442791 GLP-1 Analogs for Neuroprotection After Exenatide vs 30, 90 & ± Diabetes Out of hospital 120 2016/06 ↔ neurological 
34 
Performance 
Category & modified 
Rankin Scale 
(GLIP1) Out-of-hospital Cardiac Arrest, a 
Randomized Clinical Trial 
placebo 180 
days 
mellitus 
(exclude 
DKA) 
cardiac arrest 
of presumed 
cardiac cause 
function at 30, 90 and 
180 days.44 
Central neuronal 
function, evoked 
brain potentials 
Electrical 
stimulation, EEG 
brain imaging 
NCT02138045 
(TODINELI) 
(*RIII 
withdrawal 
reflex activity, 
*evoked brain 
potentials) 
A Randomized, Double-blinded, Single-
centre, Parallel-group, Placebo-controlled, 
Prospective Trial of Neuroprotective Effect 
of Liraglutide for Treatment of Diabetic 
Neuropathy 
Liraglutide 
vs placebo 
26 
weeks 
T1D Symmetrical 
polyneuropath
y 
48 
(39 
com
plete
) 
2017/02 ↓ interleukin-6, 
unaltered neuronal 
function at central, 
autonomic or 
peripheral level, ↓ 
urine 
albumin/creatinine 
ratio.45 
Peripheral 
neuronal 
function, RIII 
withdrawal reflex 
activity 
Nerve conduction 
studies, 
electromyography 
Autonomic Cardiometric derived 
Inflammation Interleukin-6 
PATIENTS WITHOUT DIABETES 
Outcome 
(Cardiovascular) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
comparator 
Duration Glycemic 
status 
Population N Date 
Complete 
Main Results 
Myocardial 
infarct size 
Cardiac MRI NCT01254123 
(EXAMI) (*) 
Effect of Additional Treatment With 
EXenatide in Patients With an Acute 
Myocardial Infarction 
Exenatide vs 
placebo 
4 
months 
No T1D, no 
T2D 
STEMI 191 2009/11 ↔ myocardial infarct 
size (expressed as a 
% of area at risk).32 
Arterial stiffness PWV NCT01794429 
(TAO) 
Treatment of Antipsychotic-associated 
Obesity With a GLP-1 Analogue 
Exenatide vs 
placebo 
3 
months 
Non-diabetic Schizophrenia 
spectrum, BMI 
≥30 kg/m2 
45 
(40 
com
plete
) 
2015/06 ↓ PWV.33 
Outcome 
(Respiratory) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
comparator 
Duration Glycemic 
status 
Population N Date 
Complete 
Main Results 
Severity of OSA AHI NCT01557166 
(SCALE) (*) 
Effect of Liraglutide in Obese Subjects 
With Moderate or Severe OSA. A 32 Week 
Randomised, Double-blind, Placebo-
controlled, Parallel Group, Multi-centre and 
Multinational Trial 
Liraglutide 
vs placebo 
32 
weeks 
No diabetes 
(prediabetes 
allowed) 
Moderate-
severe OSA 
BMI ≥30 kg/m2 
359 2013/06 ↓ AHI43 
Outcome 
(Neurological, 
Musculoskeletal) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
comparator 
Duration Glycemic 
status 
Population N Date 
Complete 
Main Results 
Psychopatholog
y 
SQLS, CGI-S NCT01845259 
(GREAT) 
Does a GLP-1RA Change Glucose 
Tolerance in Antipsychotic-treated 
Patients? A Randomized, Double-blinded, 
Placebo-controlled Clinical Trial 
Liraglutide 
vs placebo 
16 
weeks & 
1 year 
Dysglycemia 
(no T1D, no 
T2D with 
HbA1c 
>6.5%) 
Schizophrenia, 
schizotypal 
disorder or 
paranoid 
psychosis 
103 
(88 
com
plete
d 1 
year
) 
2017/03 ↔ CGI-S or SQLS at 1 
year.46 
Parkinson’s 
severity 
MDS UPDRS NCT01971242 
(EXENATIDE-
PD) (*) 
A Randomised, Double Blind, Placebo 
Controlled, Single Centre, 60 Week Trial of 
Exenatide Once Weekly for the Treatment 
of Moderate Severity Parkinson's Disease 
Exenatide vs 
placebo 
60 
weeks 
No diabetes Parkinson’s 
disease 
62 2016/08 Positive effects on 
practically defined off-
medication motor 
scores, which were 
sustained beyond the 
period of exposure.47 
Cognition BACS NCT01794429 
(TAO) 
Treatment of Antipsychotic-associated 
Obesity With a GLP-1 Analogue 
Exenatide vs 
placebo 
3 
months 
Non-diabetic Schizophrenia 
spectrum, BMI 
≥30 kg/m2 
45 
(40 
com
plete
) 
2015/06 ↔ cognition or 
psychosocial 
function.48 (other data 
awaited). 
Body fat 
composition 
DEXA 
Outcome 
(Metabolic, 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
comparator 
Duration Glycemic 
status 
Population N Date 
Complete 
Main Results 
35 
Hepatobiliary) 
ETP Area under curve in 
TGT 
NCT02073929 
(LIPT) (*ETP) 
A Randomised, Double-blind, Placebo-
controlled Study of the Effect of Liraglutide 
in PCOS on Risk Markers of Vascular 
Thrombosis 
Liraglutide 
vs placebo 
26 
weeks 
No diabetes PCOS 72 2015/12 ↓ liver fat content, ↓ 
VAT, ↓ prevalence of 
NAFLD.39 Improved 
bleeding regularity, 
improved markers of 
ovarian function.40 ↓ 
MR-proANP.41 
Liver fat 1HMR spectroscopy 
VAT MRI 
Body 
composition 
DEXA 
Ovarian function Bleeding regularity 
Biomarker MR-proANP 
Maximum 
postprandial 
gallbladder EF 
Ultrasonography NCT02717858 
(*) 
A Single-centre, Randomised, Double-
blind, Placebo-controlled, Parallel Group 
Trial to Assess the Effects of Liraglutide on 
Gallbladder Emptying in Overweight and 
Obese Subjects 
Liraglutide 
vs placebo 
12 
weeks 
No T1D, no 
T2D 
BMI ≥27 kg/m2 52 2017/02 ↔ gallbladder EF.42 
Liver fat MRI NCT02313220 
(Dapalost) 
A 24-week, Single Centre, Randomized, 
Parallel-group, Double-blind, Placebo 
Controlled Phase II Study With an Optional 
28-week Open-label Extension to Evaluate 
the Efficacy on Body Weight of 
Dapagliflozin 10 mg Once Daily in 
Combination With Exenatide 2 mg Once 
Weekly in Obese Non-diabetic Subjects 
Exenatide + 
dapagliflozin 
vs placebo 
24 
weeks 
Non-diabetic 
(prediabetes 
allowed) 
BMI 30-45 
kg/m2 
50 2016/03 ↓ liver fat from 
baseline (but between-
group difference not 
significant).19 
 
NCT indicates Clinicaltrials.gov registration number. N indicates number randomized. * indicates primary outcome.  
 
Abbreviations: 1HMR, proton magnetic resonance; AHI, Apnea-Hypopnea Index; BACS, Brief Assessment of Cognition in Schizophrenia; BMI, body mass index; CGI-S, Clinical Global Impression-Severity; CV, 
cardiovascular; DEXA, dual energy X-ray absorptiometry; DKA, diabetic ketoacidosis; DPP-4i, dipeptidyl peptidase-4 inhibitor; ECV, extracellular volume; EEG, electroencephalography; EF, ejection fraction; ERPF, 
effective renal plasma flow; ETP, endogenous thrombin potential; GFR, glomerular filtration rate; GLP-1RA, glucagon-like peptide-1 receptor agonist; GLS, global longitudinal strain; GLSR, global longitudinal strain rate; 
HbA1c, glycated hemoglobin; HF, heart failure; HR, heart rate; KCCQ, Kansas City Cardiomyopathy Questionnaire; LV, left ventricular ; MDS UPDRS, Movement Disorder Society Unified Parkinson’s Disease Rating 
Scale; MRI, magnetic resonance imaging; MR-proANP, midregional-pro-atrial natriuretic peptide; MRS, magnetic resonance spectroscopy; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; 
OSA, obstructive sleep apnea; PAH, para-aminohippurate; PCOS, polycystic ovarian syndrome; (P)PCI, (primary) percutaneous coronary intervention; PWV, pulse wave velocity; SQLS, Schizophrenia Quality of Life 
Scale; SNS, sympathetic nervous system; STEMI, ST-segment elevation myocardial infarction; T1D, type 1 diabetes; T2D, type 2 diabetes; TGT, thrombin generation test; VAT, visceral adipose tissue; WMSI, wall 
motion score index.  
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Table 2b: Completed GLP-1 receptor agonist mechanistic randomized non-placebo-controlled trials  
PATIENTS WITH DIABETES 
Outcome 
(Cardiovascular) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
comparator 
Duration Glycemic 
status 
Population N Date 
Complete 
Main Results 
PR interval Electrocardiography NCT01624259 
(AWARD-6) 
A Randomized, Open-Label, 
Parallel-Arm Study Comparing the 
Effect of Once-Weekly Dulaglutide 
With Once-Daily Liraglutide in 
Patients With T2D (Assessment of 
Weekly AdministRation of 
LY2189265 in Diabetes-6) 
Dulaglutide 
vs liraglutide 
26 
weeks 
T2D BMI ≤45 
kg/m2 
599 2013/11 ↔ PR interval.49 
EAT Echocardiography NCT02014740 
(*) 
Effect of Liraglutide on Epicardial Fat 
in Subjects With T2D 
Liraglutide 
vs metformin 
3 & 6 
months 
T2D BMI ≥27 
kg/m2 
95 2017/03 At 3 and 6 months, ↓ 
EAT (substantial and 
rapid) with liraglutide, ↔ 
EAT with metformin.66 
LFRIdiastolic/systolic Exercise TDE NCT01425580 
(*LFRI) 
Effects on Subclinical Heart Failure 
in T2D Subjects on Liraglutide 
Treatment vs Glimepiride Both in 
Combination With Metformin 
Liraglutide 
vs 
glimepiride 
18 
weeks 
T2D LV EF 
≤50% or 
diastolic 
dysfunctio
n 
62 2016/08 ↔ LFRIdiastolic/systolic, 
liraglutide ↑ HR.50 
Liraglutide ↑ diurnal 
variation in hourly mean 
HR followed by ↑ in 
mean daytime HR.67 
HRV 24-hour Holter 
monitor 
Carotid-femoral PWV Tonometry  NCT03010683 
(*PWV, AIx, 
CFR, 
endothelial 
glycocalyx 
thickness) 
Effects of Agonists of GLP-1R on 
Arterial Stiffness, Endothelial 
Glycocalyx and Coronary Flow 
Reserve in Patients With CAD and 
Patients With Diabetes Mellitus 
Liraglutide 
vs metformin 
3 & 6 & 
12 
months 
T2D 3 groups: 
T2D no 
CAD, T2D 
with CAD, 
30 obese 
BMI >30 
with 
abnormal 
OGTT 
60 2017/12 6 month: Liraglutide 
Improves arterial 
stiffness, LV myocardial 
strain, LV twisting and 
untwisting and NT-
proBNP.51 (other data 
awaited). 
AIx Arteriography 
CFR in LAD artery after 
infusion of adenosine 
Doppler 
echocardiography 
Endothelial glycocalyx 
thickness 
PBR of sublingual 
arterial microvessels 
LV strain Speckle tracking 
echocardiography 
FMD Brachial artery 
Retinal capillary blood 
flow 
Scanner laser 
doppler flowmetry 
(increase of retinal 
blood flow after 
flicker stimulation) 
NCT01208012 
(*retinal 
capillary blood 
flow) 
Impact of Liraglutide on Endothelial 
Function and Microvascular Blood 
Flow in T2D 
Liraglutide + 
metformin vs 
metformin 
6 & 12 
weeks 
T2D Age 30-65 
years 
44 2010/11 Addition of liraglutide ↑ 
microvascular response 
to flicker light, ↔ arterial 
stiffness, ↓ ADMA, ↓ E-
selectin, ↓ PAI-1, ↓ intact 
proinsulin, ↔ hs-CRP, 
↔ MCP-1, ↔ VCAM.52 
Arterial stiffness Applanation 
tonometry from 
radial artery 
Biomarkers of sub-
clinical inflammation and 
cardiovascular risk 
PAI-1, hs-CRP, 
VCAM, E-selectin, 
ADMA 
Outcome (Metabolic, 
Hepatic) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
comparator 
Duration Glycemic 
status 
Population N Date 
Complete 
Main Results 
Intrahepatic fat Quantitative 
ultrasound 
NCT03068065 
(*intrahepatic 
fat) 
Comparison of Efficacy of 
Liraglutide, Metformin and Gliclazide 
MR on Hepatic Lipid Content in 
Patients With T2D and NAFLD 
Liraglutide 
vs metformin 
vs gliclazide 
-7±3 
days & 
168±3 
days 
T2D NAFLD 93 
(87 
com
plete
) 
2015/10 Reductions in 
intrahepatic fat were 
greater with liraglutide 
than with gliclazide.54 
Liraglutide ↓ body fat 
mass.55 
Body composition DEXA 
Intrahepatic lipid MRI-PDFF NCT02147925 
(LIGHT-ON) 
(*intrahepatic 
lipids) 
Efficacy Study of Liraglutide vs 
Sitagliptin vs Insulin Glargine Per 
Day on Liver Fat When Combined 
With Metformin in T2D Subjects With 
Liraglutide 
vs insulin 
glargine vs 
sitagliptin 
26 
weeks 
T2D NAFLD 75 2017/04 Both liraglutide and 
sitagliptin ↓ intrahepatic 
lipid, ↓ VAT.56 SAT, VAT MRI IDEAL IQ 
37 
NAFLD 
Outcome (Neurological) Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
comparator 
Duration Glycemic 
status 
Population N Date 
Complete 
Main Results 
Confirmed clinical 
neuropathy 
Composite score NCT00855439 
(*confirmed 
clinical 
neuropathy) 
A Single-center, Proof of Concept, 
Randomized, Controlled Parallel 
Group Clinical Trial of the Effects of 
Exenatide vs. a Long Acting Insulin 
Analog to Evaluate the Efficacy of 
Exenatide in Patients With Diabetic 
Neuropathy and T2D 
Exenatide vs 
insulin 
glargine 
18 
months 
T2D Diabetic 
peripheral 
neuropath
y 
46 2014/05 ↔ confirmed clinical 
neuropathy, ↔ IENFD 
density, ↔ measures of 
cardiac autonomic 
neuropathy.58 
Cardiac autonomic 
neuropathy 
Cardiovascular 
reflex tests and 
measures of HRV 
Measures of small fiber 
neuropathy 
IENFD 
PATIENTS WITHOUT DIABETES 
Outcome 
(Cardiovascular) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
comparator 
Duration Glycemic 
status 
Population N Date 
Complete 
Main Results 
Digital reactive 
hyperemic index 
EndoPAT 2000 NCT00546728 
(*) 
The Chronic and Acute Postprandial 
Vascular Effects of Exenatide vs 
Metformin in Abdominally Obese 
Patients With IGT 
Exenatide vs 
metformin 
3 
months 
IGT (no 
diabetes) 
Abdominal 
obesity 
50 2011/07 Exenatide therapy had 
similar effects on 
microvascular 
endothelial function as 
metformin.53 
Outcome (Neurological) Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
comparator 
Duration Glycemic 
status 
Population N Date 
Complete 
Main Results 
Motor symptoms UPDRS-off-
medication motor 
subscore 
NCT01174810 
(*) 
An Open Label, Single Site, 12 
Month, Phase II, Randomised 
Controlled Trial Evaluating the 
Safety and Efficacy of Exendin-4 
(Exenatide) in the Treatment of 
Patients With Moderate Severity 
Parkinson's Disease 
Exenatide vs 
no 
intervention 
12 & 14 
months 
No diabetes Idiopathic 
Parkinson’
s disease 
of 
moderate 
severity 
45 2013/03 Clinically relevant 
improvements in 
Parkinson’s disease 
across motor and 
cognitive measures.59 
Binge eating behavior Binge eating scale 
score 
NCT01739049 
(*) 
The Influence of Appetite-Related 
Central and Gut Hormones in 
Modulating Binge Eating Behaviour 
in Obese and Overweight Healthy 
Subjects 
Liraglutide + 
lifestyle 
counselling 
vs lifestyle 
counselling  
12 
weeks 
No diabetes BMI 30-45 44 2015/01 Less likely to binge 
eat.60 
 
NCT indicates Clinicaltrials.gov registration number. N indicates number randomized. * indicates primary outcome.  
 
Abbreviations: ADMA, asymmetric dimethylarginine; AIx, augmentation index; BMI, body mass index; CAD, coronary artery disease; CFR, coronary flow reserve; DEXA, dual-energy X-ray absorptiometry; EAT, 
epicardial adipose tissue; EF, ejection fraction; EndoPAT, Peripheral Arterial Tone; FMD, flow-mediated dilatation; GLP-1RA, glucagon-like peptide-1 receptor agonist; HR, heart rate; HRV, heart rate variability; hs-
CRP, high-sensitivity C-reactive protein; IDEAL IQ, iterative decomposition of water and fat with echo asymmetry and least-squares estimation; IENFD, intra-epidermal nerve fiber density; IGT, impaired glucose 
tolerance; LAD, left anterior descending; LFRI, longitudinal functional reserve index; LV, left ventricular; MCP-1, monocyte chemotactic protein 1; MRI, magnetic resonance imaging; NAFLD, non-alcoholic fatty liver 
disease; NT-proBNP, N-terminal pro-B-type natriuretic peptide; OGTT, oral glucose tolerance test; PAI-1, plasminogen activator inhibitor 1; PBR, perfused boundary region; PDFF, proton density fat fraction; PWV, 
pulse wave velocity; SAT, subcutaneous adipose tissue; T2D, type 2 diabetes; TDE, tissue Doppler echocardiography; UPDRS, Unified Parkinson’s Disease Rating Scale; VAT, visceral adipose tissue; VCAM, vascular 
cell adhesion molecule.  
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1 
Supplemental Tables  
 
Supplemental Table 1a: Ongoing SGLT2 inhibitor mechanistic randomized placebo-controlled trials (cardiac)  
PATIENTS WITH DIABETES 
Outcome (Cardiac 
Structure, 
Function) 
Technique Trial Registration Full Official Title SGLT2 inhibitor vs 
Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Systolic (EF) & 
diastolic function 
Echocardiography NCT03087773 
(EMMY) 
Impact of EMpagliflozin on Cardiac Function and 
Biomarkers of HF in Patients With Acute MYocardial 
Infarction 
Empagliflozin vs placebo 6 & 26 
weeks 
± T2D Acute MI 476 2021/04 
Systolic (LV EF) & 
diastolic function, 
strain (LV GLS) at 
rest & stress 
NCT03198585 
(Empire HF) 
Empagliflozin in HF Patients with Reduced EF: A 
Randomized Clinical Trial 
Empagliflozin vs placebo 90 days ± T2D HFrEF (LV 
EF ≤40%, 
NYHA I-III) 
189 2019/10 
(awaited) 
LV EDV, systolic 
(LV EF) & diastolic 
(E/E’) function 
NCT02932436 
(EmDia) (*E/E’) 
A Phase IV, Single-center, Randomized, Double-
blind, Placebo-controlled, Parallel Group Study on 
the Effects of Empagliflozin on LV Diastolic Function 
Compared to Usual Care in Individuals With T2D 
Empagliflozin vs placebo 1 & 12 
(*) 
weeks 
T2D Diastolic 
dysfunction 
158 2020/06 
LVM, systolic (EF) 
& diastolic (E/E’) 
function, strain 
(GLS) 
NCT03717194 
(ERTU-GLS) 
(*GLS) 
A Phase 3, Randomized, Double-blind, Placebo-
controlled, Parallel-group, to Evaluate the Effect of 
Ertugliflozin on Cardiac Function in Patients With 
T2D Who Have Inadequate Glycemic Control and 
Stage B HF 
Ertugliflozin vs placebo 12 & 24 
weeks 
T2D Stage B HF 
(on basis of 
structural or 
functional 
markers) 
120 2020/10 
LV ESV index, 
strain (GLS) 
CMR NCT03485092 
(SUGAR-DM-HF) 
(*LV ESV index, 
*GLS) 
Studies of Empagliflozin and its Cardiovascular, 
Renal and Metabolic Effects in Patients with 
Diabetes Mellitus (or Prediabetes) and HF 
Empagliflozin vs placebo 36 
weeks 
T2D or 
prediabete
s 
HFrEF (LV 
EF ≤40%, 
NYHA II-IV) 
105 2020/08 
LV function Echocardiography NCT03151343 
(SIMPLE) 
Effects of SGLT-2 Inhibitor on Myocardial Perfusion, 
Function and Metabolism in T2DM Patients at High 
CV Risk: The SIMPle Randomized Clinical Trial 
Empagliflozin vs placebo 13 
weeks 
T2D High CV risk 92 2020/04 
LVM CMR NCT02956811 
(DAPA-LVH) 
(*LVM) 
Does Dapagliflozin Regress LVH In Patients With 
T2D? 
Dapagliflozin vs placebo 52 
weeks 
T2D Echocardiog
raphic LVH 
66 2019/04 
(awaited) Strain (GLS) (not stated) 
Diastolic function 
Subclinical 
diastolic function 
Supine bicycle 
diastolic stress 
echocardiography 
NCT02751398 
(IDDIA) 
(*subclinical 
diastolic function) 
Impact of Dapagliflozin on DIAstolic Dysfunction in 
T2D Patients 
Dapagliflozin vs placebo 24 
weeks 
T2D ≥ Grade 1 
diastolic 
function at 
resting 
echocardiog
raphy 
60 2020/01 
Resting diastolic 
function 
Echocardiography 
LV ESV, LV EDV, 
LV EF, RV EDV, 
RV ESV, RV EF 
CMR NCT02397421 
(REFORM) (*LV 
ESV, *LV EDV) 
Research Into the Effect of SGLT2 Inhibition on LV 
Remodeling in Patients With HF and Diabetes 
Mellitus 
Dapagliflozin vs placebo 1 year T2D HF (LV EF 
≤45%, 
NYHA I-III) 
56 2017/08 
(awaited) 
Cardiac 
morphology 
NCT03118336 
(EMPACEF) (*) 
Impact of Empagliflozine on Cardiac Ectopic Fat Empagliflozin vs placebo 12 
weeks 
T2D Age >18 
years 
56 2020/02 
LVM index NCT04071626 
(EMMED-HF) 
Evaluating Metabolic Mechanisms of Ertugliflozin in 
Diabetes & HF 
Ertugliflozin vs placebo 12 
weeks 
T2D or 
insulin 
resistance 
Stable 
HFpEF (LV 
EF >50%) 
52 2021/06 
Outcome (Cardiac 
Hemodynamics) 
Technique Trial Registration Full Official Title SGLT2 inhibitor vs 
Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
LV contractile 
reserve, PCWP to 
cardiac index ratio 
Right heart 
catheterization during 
rest & exercise 
NCT03198585 
(Empire HF) 
Empagliflozin in HF Patients with Reduced EF: A 
Randomized Clinical Trial 
Empagliflozin vs placebo 90 days ± T2D HFrEF (LV 
EF ≤40%, 
NYHA I-III) 
189 2019/10 
(awaited) 
CO, CVP, PCWP, Invasive NCT03151343 Effects of SGLT-2 Inhibitor on Myocardial Perfusion, Empagliflozin vs placebo 13 T2D High CV risk 92 2020/04 
2 
PAP, SvO2 at rest 
& exercise 
hemodynamics (SIMPLE) 
(*PCWP) 
Function and Metabolism in T2DM Patients at High 
CV Risk: The SIMPle Randomized Clinical Trial 
weeks 
CO, Stroke 
volume 
(not stated) NCT03132181 
(EMPA) (*CO) 
Empagliflozin as a Modulator of Systemic Vascular 
Resistance and Cardiac Output in Patients With T2D 
Empagliflozin vs placebo 3 
months 
T2D Age 18-74 
years 
40 2019/01 
(awaited) 
Outcome (Cardiac 
Perfusion, 
Metabolism, Fat, 
Fibrosis) 
Technique Trial Registration Full Official Title SGLT2 inhibitor vs 
Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Final infarct size CMR NCT03591991 (*) Effectiveness of Empagliflozin on Cardiac-renal 
Injury in Patients With Acute STEMI After Primary 
Percutaneous Coronary Intervention 
Empagliflozin vs placebo 3 
months 
± T2D STEMI 128 2019/09 
(awaited) 
Myocardial fibrosis 
& ECV 
CMR T1 mapping 
(pre- & post-
gadolinium contrast) 
NCT03485092 
(SUGAR-DM-HF) 
Studies of Empagliflozin and its Cardiovascular, 
Renal and Metabolic Effects in Patients with 
Diabetes Mellitus (or Prediabetes) and HF 
Empagliflozin vs placebo 36 
weeks 
T2D or 
prediabete
s 
HFrEF (LV 
EF ≤40%, 
NYHA II-IV) 
105 2020/08 
Microvascular 
perfusion 
Cardiac DCE-MRI 
(gadolinium contrast) 
Myocardial flow 
reserve 
Rb-82 PET NCT03151343 
(SIMPLE) (*) 
Effects of SGLT-2 Inhibitor on Myocardial Perfusion, 
Function and Metabolism in T2DM Patients at High 
CV Risk: The SIMPle Randomized Clinical Trial 
Empagliflozin vs placebo 13 
weeks 
T2D High CV risk 92 2020/04 
Myocardial lipid 
content 
MRS NCT03007329 
(EXENDA) 
A 24 Week Monocentric Prospective Randomized, 
Placebo-controlled Trial to Evaluate Efficacy of 
Combination of Exenatide and Dapagliflozin 
Compared to Dapagliflozin and Placebo and Its 
Effects on Hepatic, Myocardial and Pancreatic Fat 
Distribution in Patients With Uncontrolled T2DM 
Dapagliflozin + 
exenatide vs 
dapagliflozin + placebo 
24 
weeks 
T2D BMI ≥25 
kg/m2 
90 2020/03 
Cardiac energetics 
& metabolism 
(PCr/ATP ratio) 
31P-MRS NCT03332212 
(EMPA-VISION) 
(*) 
A Randomised, Double-blind, Placebo-controlled, 
Mechanistic Cardiac Magnetic Resonance Study to 
Investigate the Effects of Empagliflozin Treatment on 
Cardiac Physiology and Metabolism in Patients With 
HF 
Empagliflozin vs placebo 12 
weeks 
± T2D HFrEF (LV 
EF ≤40%, 
raised NT-
proBNP) + 
HFpEF (LV 
EF ≥50%, 
raised NT-
proBNP) 
86 2020/04 
ECV CMR NCT03782259 
(*ECV) 
Effects of SGLT-2 Inhibition With Dapagliflozin on 
Myocardial Fibrosis and Inflammation as Assessed 
by Cardiac MRI With T1- and T2-mapping in Patients 
With T2D 
Dapagliflozin vs placebo 12 
months 
T2D Age ≥18 
years 
60 2020/12 
T2 relaxation time 
Epicardial fat 
EAT volume NCT03118336 
(EMPACEF) 
(*EAT volume) 
Impact of Empagliflozine on Cardiac Ectopic Fat Empagliflozin vs placebo 12 
weeks 
T2D Age >18 
years 
56 2020/02 
Myocardial 
triglyceride 
Proton MRS 
Cardiac energetics 
& metabolism 
(PCr/ATP ratio) 
(not stated) 
Outcome 
(Autonomic 
Function) 
Technique Trial Registration Full Official Title SGLT2 inhibitor vs 
Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
CV autonomic 
balance 
CV reflex test with 
finger 
plethysmography 
(Nexfin) 
NCT03361098 
(DECREASE) 
Combined Effects of SGLT2 Inhibition and GLP-1 
Receptor Agonism on Food Intake, Body Weight and 
Central Satiety and Reward Circuits in Obese T2DM 
Patients 
Dapagliflozin + 
exenatide vs 
dapagliflozin + placebo 
vs exenatide + placebo 
vs double placebo 
10 days 
& 16 
weeks 
T2D Obesity 
(BMI 30-40 
kg/m2) 
64 2020/01 
PATIENTS WITHOUT DIABETES 
Outcome (Cardiac 
Structure, 
Technique Trial Registration Full Official Title SGLT2 inhibitor vs 
Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
3 
Function) 
LV ESV, LV EDV, 
LV EF index 
CMR NCT03485222 
(EMPA-TROPISM 
(ATRU-4)) (*LV 
ESV, *LV EDV) 
Are the "Cardiac Benefits" of Empagliflozin 
Independent of Its Hypoglycemic Activity? 
Empagliflozin vs placebo 6 
months 
No 
diabetes 
HF (LV EF 
<50%, 
NYHA II-III) 
80 2020/12 
 
NCT indicates Clinicaltrials.gov registration number. * indicates primary outcome. Cardiac biomarkers are listed in Supplemental Tables 1i-j.  
 
Abbreviations: 31P, 31-phosphorus; BMI, body mass index; CMR, cardiac magnetic resonance imaging; CO, cardiac output; CV, cardiovascular; CVP, central venous pressure; DCE, dynamic contrast enhanced; EAT, 
epicardial adipose tissue; ECV, extracellular volume fraction; EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; GLP-1, glucagon-like peptide-1; GLS, global longitudinal strain; HF, heart 
failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LV, left ventricular; LVH, left ventricular hypertrophy; LVM, left ventricular mass; MI, myocardial infarction; 
MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PAP, pulmonary artery pressure; PCr/ATP, 
phosphocreatinine/adenosine triphosphate; PCWP, pulmonary capillary wedge pressure; PET/CT, positron emission tomography/computed tomography; Rb-82, rubidium-82; RV, right ventricular; SGLT2, sodium-
glucose co-transporter 2; STEMI, ST-segment elevation myocardial infarction; SvO2, mixed venous oxygen saturation; T2D(M), type 2 diabetes (mellitus).  
 
4 
Supplemental Table 1b: Ongoing SGLT2 inhibitor mechanistic randomized non-placebo-controlled trials (cardiac)  
PATIENTS WITH DIABETES 
Outcome (Cardiac) Technique Trial Registration Full Official Title SGLT2 inhibitor 
vs Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Systolic (LV EF) & 
diastolic (E/e’) function 
(not stated) UMIN000017669 
(CANDLE) 
Safety of Canagliflozin in Diabetic Patients with 
Chronic HF: Randomized, Non-Inferiority Trial 
Canagliflozin vs 
glimepiride 
24 
weeks 
T2D Chronic HF 
(NYHA I-III) 
250 2018/09 
(awaited) 
Myocardial perfusion SPECT (global & regional 
MPR index) 
NCT03208465 
(ELITE) (*global 
MPR index) 
Empagliflozin Versus Sitagliptin Therapy for 
Improvement of MPR in Diabetic Patients With 
CAD 
Empagliflozin vs 
sitagliptin 
6 
months 
T2D Stable CAD 100 2019/08 
(awaited) 
LV mass index, LA 
volume index, LA 
stiffness 
Echocardiography NCT03753087 A Phase 4, Single-center, Randomized, Parallel 
Group Study to Assess Effects of Empagliflozin 
on Exercise Capacity and LV Diastolic Function 
in Patients With HFpEF and T2D 
Empagliflozin vs 
standard care 
24 
weeks 
T2D HFpEF (LV 
EF ≥50%) 
100 2020/05 
Diastolic function at rest 
& stress, PASP 
Epicardial fat thickness 
(EAT) 
NCT02235298 (*) Effects of Dapagliflozin on Epicardial Fat in 
Subjects With T2D 
Dapagliflozin + 
metformin vs 
metformin 
6 
months 
T2D BMI ≥27 
kg/m2 
100 2020/06 
Speckle-Tracking 
echocardiography 
NCT03871621 
(ELUCIDATE) 
(*GLS) 
The Echocardiographic LV Functional Changes 
of Uncontrolled Diabetes by the Intervention of 
Dapagliflozin Treatment Trial 
Dapagliflozin vs 
standard care 
24 
weeks 
T2D LV EF ≥50% 90 2020/07 
GLS 
LV mass 
LA volume 
Systolic (LV EF) & 
diastolic (E/E’) function, 
strain (GLS), LA volume 
3D Echocardiography EUDRACT Code 
2016-0022250-10 
(EMPA-HEART)1 
(*GLS) 
Impact of Empagliflozin on Subclinical LV 
Dysfunctions and on the Mechanisms Involved in 
Myocardial Disease Progression in T2D 
Empagliflozin vs 
sitagliptin 
1 & 6 
months 
T2D LV EF ≥50% 75 2019/07 
(awaited) 
Cardiac autonomic 
function tests 
R-R interval during Valsalva 
maneuver, deep-breathing, 
lying-to-standing 
Stroke volume, cardiac 
output 
Continuous beat-to-beat 
hemodynamic monitor 
(NexFin®) 
NCT03433248 
(RACELINES) 
Renal Actions of Combined Empagliflozin and 
LINagliptin in Type 2 diabetES 
Empagliflozin 
then add 
linagliptin vs 
linagliptin then 
add 
empagliflozin vs 
gliclazide 
8 & 16 
weeks 
T2D BMI >25 
kg/m2, eGFR 
≥45 
ml/min/1.73
m2 
66 2020/12 
Autonomic nervous 
system function 
Heart rate Automated oscillometric BP 
monitor (Dinamap®) 
2, 8, 10 
& 16 
weeks 
Autonomic function HRV (LF:HF ratio, SDNN, 
rmsSD) 
NCT02973477 
(*LF:HF ratio) 
Dapagliflozin and Measures of Cardiovascular 
Autonomic Function in Patients With T2D 
Dapagliflozin (12 
weeks) vs 
glimepiride or 
vice versa (2 
week washout) 
26 
weeks 
T2D Age ≥18 
years 
45 2019/08 
(awaited) 
CARTs 
(expiration/inspiration ratio, 
Valsalva ratio, 30:15 ratio) 
HRV, HR turbulence, QT 
interval 
NCT03178591 
(*all listed 
measures) 
Effects of DPP-4 Inhibitor Vs SGLT2 Inhibitor on 
Ischemic Burden in Stable Ischemic Heart 
Disease Patients 
Dapagliflozin vs 
vildagliptin 
6 
months 
T2D Stable 
documented 
CAD 
43 2018/07 
(awaited) 
ST segment depression Ambulatory ECG monitoring 
Myocardial dysfunction Exercise stress test 
 
EUDRACT indicates www.clinicaltrialsregister.eu/ registration number. NCT indicates Clinicaltrials.gov registration number. UMIN indicates www.umin.ac.jp/ctr registration number. * indicates primary outcome. Cardiac 
biomarkers are listed in Supplemental Tables 1i-j.  
 
Abbreviations: 3D, three-dimensional; BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; CARTs, cardiac autonomic reflex testing; DPP-4, dipeptidyl peptidase-4; EAT, epicardial adipose tissue; 
ECG, electrocardiography; EF, ejection fraction; eGFR, estimated glomerular filtration rate; GLS, global longitudinal strain; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HR, heart rate; HRV, 
heart rate variability; LA, left atrial; LF:HF, low frequency: high frequency; LV, left ventricular; MPR, myocardial perfusion reserve; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; rmsSD, 
root mean square of the successive differences; SDNN, standard deviation of normal-to-normal R-R intervals; SGLT2, sodium-glucose co-transporter 2; SPECT, single photon emission computed tomography; T2D, 
type 2 diabetes.  
 
5 
Supplemental Table 1c: Ongoing SGLT2 inhibitor mechanistic randomized placebo-controlled trials (vascular)  
PATIENTS WITH DIABETES 
Outcome (Vascular) Technique Trial 
Registration 
Full Official Title SGLT2 inhibitor 
vs Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Diabetic retinopathy Digital retinal 
photography 
NCT03173963 Empagliflozin in Early Diabetic Kidney Disease Empagliflozin vs 
placebo 
3 years T2D eGFR >60 
ml/min/1.73m2, 
American Indian 
heritage 
300 2024/08 
Carotid-femoral PWV Vascular explorer NCT02932436 
(EmDia) 
A Phase IV, Single-center, Randomized, Double-blind, 
Placebo-controlled, Parallel Group Study on the 
Effects of Empagliflozin on LV Diastolic Function 
Compared to Usual Care in Individuals With T2D 
Empagliflozin vs 
placebo 
1 & 12 
weeks 
T2D Diastolic 
dysfunction 
158 2020/06 
AIx 
Arterial stiffness index, 
reflection index 
Photo 
plethysmography 
Pulse wave analysis (not stated) NCT03151343 
(SIMPLE) 
Effects of SGLT-2 Inhibitor on Myocardial Perfusion, 
Function and Metabolism in T2DM Patients at High CV 
Risk: The SIMPle Randomized Clinical Trial 
Empagliflozin vs 
placebo 
13 
weeks 
T2D High CV risk 92 2020/04 
Ambulatory AIx, 
ambulatory PWV 
Mobil-O-Graph 
monitor 
NCT02887677 A Study of the Effects of Dapagliflozin on Ambulatory 
Aortic Pressure, Arterial Stiffness and Urine Albumin 
Excretion in Patients With T2D 
Dapagliflozin vs 
placebo 
12 
weeks 
T2D Age 19-75 years 85 2019/10 
(awaited) 
Vascular stiffness Central systolic 
pressure, pulse 
pressure 
NCT03128528 
(ELSI) 
Randomized, Double-blind, Placebo Controlled, 
Parallel-group, Prospective Clinical Study to Analyse 
the Effect of Empagliflozin on Reduction of Tissue 
Sodium Content in Patients With Chronic HF 
Empagliflozin vs 
placebo 
14 
weeks 
± T2D 
(exclude if 
HbA1c 
≥10%, FPG 
≥240 mg/dl) 
HFrEF (LV EF 
<40%) or HFmrEF 
(LV EF 40-49%) 
84 2019/12 
Endothelial function FMD 
Arterial stiffness Pulse wave 
analysis 
NCT03361098 
(DECREASE) 
Combined Effects of SGLT2 Inhibition and GLP-1 
Receptor Agonism on Food Intake, Body Weight and 
Central Satiety and Reward Circuits in Obese T2DM 
Patients 
Dapagliflozin + 
exenatide vs 
dapagliflozin + 
placebo vs 
exenatide + 
placebo vs 
double placebo 
10 days 
& 16 
weeks 
T2D Obesity (BMI 30-
40 kg/m2) 
64 2020/01 
Tonometry NCT03660683 Cardio-Protective of Effect of Saxagliptin and 
Dapagliflozin Combination on Endothelial Progenitor 
Cells in Patients With T2D 
Dapagliflozin vs 
dapagliflozin + 
saxagliptin vs 
placebo 
16 
weeks 
T2D CV disease 45 2020/07 
Vessel health Arterial tonometry 
(SphygmoCor CP 
system) 
NCT02964585 Role of Canagliflozin on Gene Expression and 
Function of CD34+ Endothelial Progenitor Cells and 
Renal Function in Patients With T2D 
Canagliflozin vs 
placebo 
12 
weeks 
T2D BMI 25-39.9 kg/m2 40 2020/04 
Vascular resistance (not stated) NCT03132181 
(EMPA) (*) 
Empagliflozin as a Modulator of Systemic Vascular 
Resistance and Cardiac Output in Patients With T2D 
Empagliflozin vs 
placebo 
3 
months 
T2D Age 18-74 years 40 2019/01 
(awaited) 
 
NCT indicates Clinicaltrials.gov registration number. * indicates primary outcome.  
 
Abbreviations: AIx, augmentation index; BMI, body mass index; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; FMD, flow-mediated dilatation; GLP-1, 
glucagon-like peptide-1; HbA1c, glycated hemoglobin; HF, heart failure; HFmrEF, heart failure with mid-range ejection fraction; HFrEF, heart failure with reduced ejection fraction; LV, left ventricular; PWV, pulse wave 
velocity; SGLT2, sodium-glucose co-transporter 2; T2D(M), type 2 diabetes (mellitus).  
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Supplemental Table 1d: Ongoing SGLT2 inhibitor mechanistic randomized non-placebo-controlled trials (vascular)  
PATIENTS WITH DIABETES 
Outcome 
(Vascular) 
Technique Trial Registration Full Official Title SGLT2 inhibitor vs 
Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Arterial stiffness (not stated) NCT01001962 
(PREHYPD) 
Double Blind Comparison Study of JARDIANCE® 
(Empagliflozin) in Prehypertensives T2D With 
Metformin 
Empagliflozin vs 
metformin 
36 
months 
T2D Prehypertensives 
(systolic BP 130-
140 mmHg) 
1054 2020/01 
Subclinical 
atherosclerosis 
cIMT NCT03377335 
(*cIMT) 
Effect of Dapagliflozin on Cardio-Metabolic Risk 
Factors in Patients With T2D 
Dapagliflozin vs 
metformin 
6 
months 
T2D BP ≤140/90 
mmHg, BMI ≥20 
kg/m2 
186 2019/01 
(awaited) 
Endothelial 
function 
FMD 
Arterial stiffness Cardio-ankle 
vascular index 
NCT02528019 (*) Effects of the DPP-4 or SGLT2 Inhibitors on the 
Metabolic Cardiovascular Systems in Patients With 
T2D 
SGLT2 inhibitor vs 
DPP-4 inhibitor vs 
glimepiride 
6 
months 
T2D Age 30-90 years 100 2018/08 
(awaited) 
Endothelial 
function 
FMD at rest & 
after IRI 
NCT02919345 
(ADDENDA) (*) 
Comparative Study of Dapagliflozin Versus 
Glibenclamide Effect on Endothelial Function of 
Coronary Artery Disease Patients 
Dapagliflozin vs 
glibenclamide 
12 
weeks 
T2D Chronic coronary 
artery disease 
98 2019/03 
(awaited) 
FMD UMIN000024001 (*) A Randomized Comparison of the Effect of 
Empagliflozin for Endothelial Function in T2D 
Metformin + glargine 
then empagliflozin vs 
metformin + glargine 
then glimepiride 
12 
weeks + 
12 
weeks 
T2D BMI ≤45 kg/m2; 
Age 20-80 
80 2020/03 
Total systemic 
vascular 
resistance 
Continuous 
beat-to-beat 
hemodynamic 
monitor 
(NexFin®) 
NCT03433248 
(RACELINES) 
Renal Actions of Combined Empagliflozin and 
LINagliptin in Type 2 diabetES 
Empagliflozin then add 
linagliptin vs linagliptin 
then add empagliflozin 
vs gliclazide 
8 & 16 
weeks 
T2D BMI >25 kg/m2, 
eGFR ≥45 
ml/min/1.73m2 
66 2020/12 
Microvascular 
function 
Arterial stiffness Radial artery 
applanation 
tonometry 
(SphygmoCor®) 
Endothelial 
function 
(not stated) NCT02649465 Pleiotropic Effects and Safety of SGLT2 Inhibitor 
Versus Sulfonylurea in Patients With T2D and Non-
alcoholic Fatty Liver 
Tofogliflozin vs 
glimepiride 
48 
weeks 
T2D NAFLD 40 2020/09 
 
NCT indicates Clinicaltrials.gov registration number. UMIN indicates www.umin.ac.jp/ctr registration number. * indicates primary outcome.  
 
Abbreviations: BMI, body mass index; BP, blood pressure; cIMT, carotid intima-media thickness; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; FMD, flow-mediated dilatation; IRI, ischemia 
and reperfusion injury; NAFLD, non-alcoholic fatty liver disease; SGLT2, sodium-glucose co-transporter 2; T2D, type 2 diabetes.  
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Supplemental Table 1e: Ongoing SGLT2 inhibitor mechanistic randomized placebo-controlled trials (renal)  
PATIENTS WITH DIABETES 
Outcome (Renal) Technique Trial 
Registration 
Full Official Title SGLT2 inhibitor 
vs Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Proteinuria, U 
ACR 
Urine sample NCT02547935 
(*) 
An Exploratory Phase II/III, Randomized, Double-blind, 
Placebo Controlled, Parallel Design Study to Evaluate 
the Efficacy, Safety and Pharmacodynamics of 
Dapagliflozin and Dapagliflozin in Combination With 
Saxagliptin in CKD Patients With T2DM and Albuminuria 
Treated With ACEi or ARB 
Dapagliflozin vs 
dapagliflozin + 
saxagliptin vs 
placebo 
24 
weeks 
T2D CKD (eGFR 25-
75 
ml/min/1.73m2), 
albuminuria (U 
ACR 30-3500 
mg/g) 
459 2018/05 
(awaited) 
Vv(Int/cortex) Renal biopsy NCT03173963 
(*Vv(Int/cortex)) 
Empagliflozin in Early Diabetic Kidney Disease Empagliflozin vs 
placebo 
3 years T2D eGFR >60 
ml/min/1.73m2, 
American Indian 
heritage 
300 2024/08 
Glomerular 
morphometric 
measurements 
Podocyte 
measures 
Total interstitial 
volume 
MRI 
Estimated 
extracellular 
volume, renal 
function 
Cr-51 EDTA clearance NCT03198585 
(Empire HF) 
Empagliflozin in HF Patients with Reduced EF: A 
Randomized Clinical Trial 
Empagliflozin vs 
placebo 
90 days ± T2D HFrEF (LV EF 
≤40%, NYHA I-
III), eGFR >30 
ml/min/1.73m2 
189 2019/10 
(awaited) 
Total & regional 
renal blood 
flow/perfusion 
MRI pCASL (non-
contrast) 
NCT03485092 
(SUGAR-DM-
HF) 
Studies of Empagliflozin and its Cardiovascular, Renal 
and Metabolic Effects in Patients with Diabetes Mellitus 
(or Prediabetes) and HF 
Empagliflozin vs 
placebo 
36 
weeks 
T2D or 
prediabete
s 
HFrEF (LV EF 
≤40%, NYHA II-
IV), eGFR ≥30 
ml/min/1.73m2 
105 2020/08 
Renal DCE-MRI 
(gadolinium contrast) 
Renal function Cr-51 EDTA clearance NCT03151343 
(SIMPLE) 
Effects of SGLT-2 Inhibitor on Myocardial Perfusion, 
Function and Metabolism in T2DM Patients at High CV 
Risk: The SIMPle Randomized Clinical Trial 
Empagliflozin vs 
placebo 
13 
weeks 
T2D High CV risk, 
eGFR >30 
92 2020/04 
U ACR Urine sample 
NCT02887677 A Study of the Effects of Dapagliflozin on Ambulatory 
Aortic Pressure, Arterial Stiffness and Urine Albumin 
Excretion in Patients With T2D 
Dapagliflozin vs 
placebo 
12 
weeks 
T2D Age 19-75 years 85 2019/10 
(awaited) 
Renal biomarkers 24-hour urine NCT03361098 
(DECREASE) 
Combined Effects of SGLT2 Inhibition and GLP-1 
Receptor Agonism on Food Intake, Body Weight and 
Central Satiety and Reward Circuits in Obese T2DM 
Patients 
Dapagliflozin + 
exenatide vs 
dapagliflozin + 
placebo vs 
exenatide + 
placebo vs 
double placebo 
10 days 
& 16 
weeks 
T2D Obesity (BMI 30-
40 kg/m2) 
64 2020/01 
Microalbuminuria, 
natriuresis 
Urine sample NCT02397421 
(REFORM) 
Research Into the Effect of SGLT2 Inhibition on LV 
Remodeling in Patients With HF and Diabetes Mellitus 
Dapagliflozin vs 
placebo 
1 year T2D HF (LV EF 
≤45%, NYHA I-
III) 
56 2017/08 
(awaited) 
Renal function U ACR NCT03660683 Cardio-Protective of Effect of Saxagliptin and 
Dapagliflozin Combination on Endothelial Progenitor 
Cells in Patients With T2D 
Dapagliflozin vs 
dapagliflozin + 
saxagliptin vs 
placebo 
16 
weeks 
T2D CV disease 45 2020/07 
Kidney podocyte 
health 
Urine exosome assay 
Renal biomarker Cystatin C NCT03132181 
(EMPA) 
Empagliflozin as a Modulator of Systemic Vascular 
Resistance and Cardiac Output in Patients With T2D 
Empagliflozin vs 
placebo 
3 
months 
T2D Age 18-74 years 40 2019/01 
(awaited) 
PATIENTS WITHOUT DIABETES          
Outcome (Renal) Technique Trial 
Registration 
Full Official Title SGLT2 inhibitor 
vs Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Renal oxygenation BOLD-MRI NCT03093103 
(EMPA-REIN) 
Effects of the SGLT2 Inhibitor Empagliflozin on Renal 
Tissue Oxygenation in Non-diabetic Subjects 
Empagliflozin (4 
weeks) vs 
18 
months 
Healthy or 
prediabete
eGFR >60 
ml/min/1.73m2, 
45 2018/12 
(awaited) Renal clearance Diurnal & nocturnal 
8 
clearance (sodium, 
potassium, uric acid, 
calcium, phosphate, 
glucose, lithium) 
(*renal 
oxygenation) 
Placebo s U ACR <3.3 
mg/mmol (<30 
mg/g), normal 
renal ultrasound, 
normal urine 
dipstick 
RRI Renal ultrasound 
Renal volume 
 
NCT indicates Clinicaltrials.gov registration number. * indicates primary outcome.  
 
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BOLD, blood-oxygen-level-dependent; CKD, chronic kidney disease; Cr, chromium; CV, 
cardiovascular; DCE, dynamic contrast enhanced; EDTA, ethylenediamine tetraacetic acid; EF, ejection fraction; eGFR, estimated glomerular filtration rate; GLP-1, glucagon-like peptide-1; HF, heart failure; HFrEF, 
heart failure with reduced ejection fraction; LV, left ventricular; MRI, magnetic resonance imaging; NYHA, New York Heart Association; pCASL, pseudo-continuous arterial spin labelling; PET/CT, positron emission 
tomography/computed tomography; RRI, renal resistive index; SGLT2, sodium-glucose co-transporter 2; T2D(M), type 2 diabetes (mellitus); Vv(Int/cortex), cortical interstitial fractional volume; U ACR, urinary albumin 
creatinine ratio.  
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Supplemental Table 1f: Ongoing SGLT2 inhibitor mechanistic randomized non-placebo-controlled trials (renal)  
PATIENTS WITH DIABETES 
Outcome (Renal) Technique Trial Registration Full Official Title SGLT2 inhibitor 
vs Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Renal function U ACR, urine L-FABP UMIN000017669 
(CANDLE) 
Safety of Canagliflozin in Diabetic 
Patients with Chronic HF: 
Randomized, Non-Inferiority Trial 
Canagliflozin vs 
glimepiride 
24 
weeks 
T2D Chronic HF 
(NYHA I-III) 
250 2018/09 
(awaited) 
Basal NO activity of 
renal vasculature 
Response of RPF to L-NMMA infusion NCT02752113 
(ELMI) (*basal NO 
activity) 
Prospective, Randomized, 
Controlled, Parallel-arm Study to 
Assess the Effects of the 
Combined Therapy of 
Empagliflozin and Linagliptin 
Compared to Metformin and 
Insulin Glargine on Renal and 
Vascular Changes in T2D 
Empagliflozin + 
linagliptin vs 
metformin + 
insulin glargine 
3 
months 
T2D eGFR ≥60 
ml/min/1.73
m2, no loop 
diuretics 
101 2019/05 
(awaited) 
Oxidative stress level 
of renal vasculature 
Response of RPF to vitamin C infusion 
Glomerular pressure & 
intraglomerular 
resistances 
Pglom, Ra, Re 
Renal function Urinary albumin, L-FABP UMIN000024001 A Randomized Comparison of the 
Effect of Empagliflozin for 
Endothelial Function in T2D 
Metformin + 
glargine then 
empagliflozin vs 
metformin + 
glargine then 
glimepiride 
12 
weeks + 
12 
weeks 
T2D BMI ≤45 
kg/m2; Age 
20-80 
80 2020/03 
Glomerular podocyte 
injury 
Renal nephrin NCT04127084 
(*renal nephrin, 
TGF-β1) 
Effects of SGLT2 Inhibition 
Treatment on Different Levels of 
Albuminuria in Patients With T2D: 
a Prospective Interventional Study 
Dapagliflozin 
(open label) 
12 
weeks 
T2D eGFR ≥45 
ml/min/1.73
m2, 3 groups 
with different 
levels of 
albuminuria 
70 2021/08 
Glomerular & 
tubulointerstitial 
fibrosis 
TGF-β1 
GFR Inulin-clearance technique NCT03433248 
(RACELINES) 
(*GFR by inulin-
clearance) 
Renal Actions of Combined 
Empagliflozin and LINagliptin in 
Type 2 diabetES 
Empagliflozin 
then add 
linagliptin vs 
linagliptin then 
add 
empagliflozin vs 
gliclazide 
2, 8, 10 
& 16 
weeks 
T2D BMI >25 
kg/m2, eGFR 
≥45 
ml/min/1.73
m2 
66 2020/12 
Renal tubular function 24-hour urine (sodium, potassium, chloride, 
calcium, magnesium, phosphate, uric acid, 
bicarbonate, ammonium, urea & glucose 
excretion, urine osmolality, urinary pH) 
8 & 16 
weeks 
Renal damage 24-hour urinary albumin excretion, U ACR 
 
NCT indicates Clinicaltrials.gov registration number. UMIN indicates www.umin.ac.jp/ctr registration number. * indicates primary outcome.  
 
Abbreviations: BMI, body mass index; (e)GFR, (estimated) glomerular filtration rate; HF, heart failure; L-FABP, liver-type fatty acid binding protein; L-NMMA, NG-monomethyl-L-arginine; NO, nitric oxide; NYHA, New 
York Heart Association; Pglom, glomerular pressure; pH, potential of hydrogen; Ra, afferent arteriolar resistance; Re, efferent arteriolar resistance; RPF, renal plasma flow;  SGLT2, sodium-glucose co-transporter 2; 
T2D, type 2 diabetes; TGF, transforming growth factor; U ACR, urinary albumin creatinine ratio.  
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Supplemental Table 1g: Ongoing SGLT2 inhibitor mechanistic randomized placebo-controlled trials (respiratory, symptoms, fitness)  
PATIENTS WITH DIABETES 
Outcome 
(Respiratory, 
Symptoms, 
Fitness) 
Technique Trial Registration Full Official Title SGLT2 inhibitor 
vs Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Fitness, symptoms 6MWT, KCCQ NCT03877224 
(DETERMINE-
preserved) 
(*6MWT) 
International, Multicentre, Parallel-group, Randomised, Double-
blind, Placebo-controlled, Phase III Study Evaluating the Effect of 
Dapagliflozin on Exercise Capacity in HF Patients With Preserved 
EF 
Dapagliflozin vs 
placebo 
16 
weeks 
± T2D HFpEF 
(LV EF 
>40%, 
NYHA II-
IV, raised 
NT-
proBNP) 
500 2020/07 
Wearable 
activity monitor 
(accelerometer) 
14 
weeks 
KCCQ-CSS NCT04157751 
(EMPULSE) 
A Multicentre, Randomised, Double-blind, 90-day Superiority Trial 
to Evaluate the Effect on Clinical Benefit, Safety and Tolerability of 
Once Daily Oral EMPagliflozin 10 mg Compared to Placebo, 
Initiated in Patients Hospitalised for acUte Heart faiLure (de Novo 
or Decompensated Chronic HF) Who Have Been StabilisEd 
Empagliflozin vs 
placebo 
90 days ± T2D Acute HF 
(reduced 
or 
preserved 
LV EF, 
raised NT-
proBNP) 
500 2021/07 
6MWT, KCCQ NCT03030235 
(PRESERVED-
HF) 
Effects of Dapagliflozin on Biomarkers, Symptoms and Functional 
Status in Patients With PRESERVED EF HF 
Dapagliflozin vs 
placebo 
12 
weeks 
± T2D HF (LV EF 
≥45%, 
NYHA II-
IV, raised 
NT-
proBNP), 
diuretic 
320 2021/02 
6MWT, KCCQ NCT03877237 
(DETERMINE-
reduced) (*6MWT) 
International, Multicentre, Parallel-group, Randomised, Double-
blind, Placebo-controlled, Phase III Study Evaluating the Effect of 
Dapagliflozin on Exercise Capacity in HF Patients With Reduced 
EF 
Dapagliflozin vs 
placebo 
16 
weeks 
± T2D HFrEF (LV 
EF ≤40%, 
NYHA II-
IV, raised 
NT-
proBNP) 
312 2020/02 
Wearable 
activity monitor 
(accelerometer) 
14 
weeks 
KCCQ, EQ-5D-
5L, patient-worn 
accelerometers 
NCT03198585 
(Empire HF) 
Empagliflozin in HF Patients with Reduced EF: A Randomized 
Clinical Trial 
Empagliflozin vs 
placebo 
90 days ± T2D HFrEF (LV 
EF ≤40%, 
NYHA I-III) 
189 2019/10 
(awaited) 
Quality of life Medical 
Outcomes Study 
SF-36  
NCT03215069 
(EMPA post-GDM) 
Empagliflozin and the Preservation of Beta-cell Function in Women 
With Recent Gestational Diabetes 
Empagliflozin vs 
placebo 
48 
weeks 
Gestational 
diabetes 
6-36 
months 
postpartu
m, age 20-
50 years 
120 2022/09 
Pulmonary 
congestion 
Lung ultrasound NCT03485092 
(SUGAR-DM-HF) 
Studies of Empagliflozin and its Cardiovascular, Renal and 
Metabolic Effects in Patients with Diabetes Mellitus (or 
Prediabetes) and HF 
Empagliflozin vs 
placebo 
36 
weeks 
T2D or 
prediabetes 
HFrEF (LV 
EF ≤40%, 
NYHA II-
IV) 
105 2020/08 
Quality of life SF-12 NCT03723252 
(DEAN) 
Efficacy and Safety of Dapagliflozin in NASH: a Multicentre, 
Randomized, Placebo-controlled Trial 
Dapagliflozin vs 
placebo 
12 
months 
± T2D NASH as 
determine
d by liver 
biopsies 
100 2021/11 
Fitness, symptoms EuroQol EQ-5D-
5L, MLHFQ, 
Patient-worn 
accelerometer 
NCT03151343 
(SIMPLE) 
Effects of SGLT-2 Inhibitor on Myocardial Perfusion, Function and 
Metabolism in T2DM Patients at High CV Risk: The SIMPle 
Randomized Clinical Trial 
Empagliflozin vs 
placebo 
13 
weeks 
T2D High CV 
risk 
92 2020/04 
11 
Quality of life WHO Well Being 
Index 
NCT03007329 
(EXENDA) 
A 24 Week Monocentric Prospective Randomized, Placebo-
controlled Trial to Evaluate Efficacy of Combination of Exenatide 
and Dapagliflozin Compared to Dapagliflozin and Placebo and Its 
Effects on Hepatic, Myocardial and Pancreatic Fat Distribution in 
Patients With Uncontrolled T2DM 
Dapagliflozin + 
exenatide vs 
dapagliflozin + 
placebo 
24 
weeks 
T2D BMI ≥25 
kg/m2 
90 2020/03 
Energy 
expenditure 
Indirect 
calorimetry 
Dyspnea symptom Visual analogue 
scale 
NCT03128528 
(ELSI) 
Randomized, Double-blind, Placebo Controlled, Parallel-group, 
Prospective Clinical Study to Analyse the Effect of Empagliflozin 
on Reduction of Tissue Sodium Content in Patients With Chronic 
HF 
Empagliflozin vs 
placebo 
14 
weeks 
± T2D 
(exclude if 
HbA1c 
≥10%, FPG 
≥240 mg/dl) 
HFrEF (LV 
EF <40%) 
or 
HFmrEF 
(LV EF 40-
49%) 
84 2019/12 
Resting energy 
expenditure 
Indirect 
calorimetry, 
activity monitors, 
IPAQ 
NCT02798744 
(SEESAW) 
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight 
Regulation: A Randomised Double-blind Placebo-controlled Trial 
Empagliflozin vs 
placebo 
24 
weeks 
T2D BMI ≥25 
kg/m2 
76 2019/07 
(awaited) 
Indirect 
calorimetry 
NCT03361098 
(DECREASE) 
Combined Effects of SGLT2 Inhibition and GLP-1 Receptor 
Agonism on Food Intake, Body Weight and Central Satiety and 
Reward Circuits in Obese T2DM Patients 
Dapagliflozin + 
exenatide vs 
dapagliflozin + 
placebo vs 
exenatide + 
placebo vs 
double placebo 
10 days 
& 16 
weeks 
T2D Obesity 
(BMI 30-
40 kg/m2) 
64 2020/01 
Functional 
capacity 
VO2 max, 
exercise time, 
METs 
NCT02751398 
(IDDIA) 
Impact of Dapagliflozin on DIAstolic Dysfunction in T2D Patients Dapagliflozin vs 
placebo 
24 
weeks 
T2D ≥ Grade 1 
diastolic 
function at 
resting 
echocardi
ography 
60 2020/01 
PA diastolic 
pressure 
CardioMEMs PA 
pressure monitor 
NCT03030222 
(EMBRACE-HF) 
(*PA diastolic 
pressure) 
Empagliflozin Evaluation by Measuring Impact on Hemodynamics 
in Patients With HF 
Empagliflozin vs 
placebo 
8-12 
weeks 
± T2D HF 
(preserved 
or reduced 
LV EF, 
NYHA II-
IV), 
CardioME
Ms 
60 2019/12 
PA systolic 
pressure, mean 
PA pressure 
1-12 
weeks 
Fitness, symptoms 6MWT, KCCQ 6 & 12 
weeks 
Fitness, symptoms 6MWT, CPET, 
MLHFQ, SF-36  
NCT02397421 
(REFORM) 
Research Into the Effect of SGLT2 Inhibition on LV Remodeling in 
Patients With HF and Diabetes Mellitus 
Dapagliflozin vs 
placebo 
1 year T2D HF (LV EF 
≤45%, 
NYHA I-III) 
56 2017/08 
(awaited) 
Peak VO2 Metabolic gas 
exchange 
NCT04071626 
(EMMED-HF) (*) 
Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & HF Ertugliflozin vs 
placebo 
12 
weeks 
T2D or 
insulin 
resistance 
Stable 
HFpEF 
(LV EF 
>50%) 
52 2021/06 
Resting metabolic 
rate 
Indirect 
calorimetry 
NCT03801642 Randomized Controlled Pilot Trial Of Dapagliflozin In Alzheimer's 
Disease 
Dapagliflozin vs 
placebo 
12 
weeks 
± T2D 
(metformin 
allowed) 
Probable 
Alzheimer’
s disease, 
MMSE 15-
26, age 
50-85 
years 
48 2020/10 
ReeVue 
(trademark) 
machine 
NCT02964585 Role of Canagliflozin on Gene Expression and Function of CD34+ 
Endothelial Progenitor Cells and Renal Function in Patients With 
T2D 
Canagliflozin vs 
placebo 
12 
weeks 
T2D BMI 25-
39.9 kg/m2 
40 2020/04 
Resting energy (not stated) NCT03132181 Empagliflozin as a Modulator of Systemic Vascular Resistance and Empagliflozin vs 3 T2D Age 18-74 40 2019/01 
12 
expenditure (EMPA) Cardiac Output in Patients With T2D placebo months years (awaited) 
PATIENTS WITHOUT DIABETES          
Outcome 
(Respiratory, 
Symptoms, 
Fitness) 
Technique Trial Registration Full Official Title SGLT2 inhibitor 
vs Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Cardiorespiratory 
fitness 
VO2 
consumption 
NCT03485222 
(EMPA-TROPISM 
(ATRU-4)) 
Are the "Cardiac Benefits" of Empagliflozin Independent of Its 
Hypoglycemic Activity? 
Empagliflozin vs 
placebo 
6 
months 
No diabetes HF (LV EF 
<50%, 
NYHA II-
III) 
80 2020/12 
Fitness, symptoms 6MWT, KCCQ-
12 
 
NCT indicates Clinicaltrials.gov registration number. * indicates primary outcome.  
 
Abbreviations: 6MWT, six minute walk test; BMI, body mass index; CPET, cardiopulmonary exercise test; CV, cardiovascular; EF, ejection fraction; EQ-5D-5L, EuroQol 5 Dimensions 5 Levels; FPG, fasting plasma 
glucose; GLP-1, glucagon-like peptide-1; HbA1c, glycated hemoglobin; HF, heart failure; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure 
with reduced ejection fraction; IPAQ, International Physical Activity Questionnaire; KCCQ(-CSS), Kansas City Cardiomyopathy Questionnaire – (Clinical Summary Score); LV, left ventricular; METs, maximum exercise 
capacity; MLHFQ, Minnesota Living With Heart Failure Questionnaire; MMSE, Mini-Mental State Examination; NASH, non-alcoholic steatohepatitis; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New 
York Heart Association; PA, pulmonary artery; SF-12; 12-item short form health survey; SF-36, 36-item short form health survey; SGLT2, sodium-glucose co-transporter 2; T2D(M), type 2 diabetes (mellitus); VO2, peak 
oxygen consumption; WHO, World Health Organization.  
 
13 
Supplemental Table 1h: Ongoing SGLT2 inhibitor mechanistic randomized non-placebo-controlled trials (respiratory, symptoms, 
fitness)  
PATIENTS WITH DIABETES 
Outcome (Respiratory, 
Symptoms, Fitness) 
Technique Trial 
Registration 
Full Official Title SGLT2 inhibitor 
vs Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Quality of life, symptoms MLHFQ UMIN00001766
9 (CANDLE) 
Safety of Canagliflozin in Diabetic Patients with Chronic 
HF: Randomized, Non-Inferiority Trial 
Canagliflozin vs 
glimepiride 
24 
weeks 
T2D Chronic 
HF (NYHA 
I-III) 
250 2018/09 
(awaited) 
NCT03753087 
(*6MWT) 
A Phase 4, Single-center, Randomized, Parallel Group 
Study to Assess Effects of Empagliflozin on Exercise 
Capacity and LV Diastolic Function in Patients With 
HFpEF and T2D 
Empagliflozin vs 
standard care 
24 
weeks 
T2D HFpEF 
(LV EF 
≥50%) 
100 2020/05 
Exercise capacity 6MWT 
VO2 max on CPET EUDRACT Code 
2016-0022250-
10 (EMPA-
HEART)1 
Impact of Empagliflozin on Subclinical LV Dysfunctions 
and on the Mechanisms Involved in Myocardial Disease 
Progression in T2D 
Empagliflozin vs 
sitagliptin 
1 & 6 
months 
T2D LV EF 
≥50% 
75 2019/07 
(awaited) 
Respiratory quotients (not stated) NCT02649465 Pleiotropic Effects and Safety of SGLT2 Inhibitor Versus 
Sulfonylurea in Patients With T2D and Non-alcoholic 
Fatty Liver 
Tofogliflozin vs 
glimepiride 
48 
weeks 
T2D NAFLD 40 2020/09 
Energy expenditure 
PATIENTS WITHOUT DIABETES 
Outcome (Respiratory, 
Symptoms, Fitness) 
Technique Trial 
Registration 
Full Official Title SGLT2 inhibitor 
vs Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Time spent sedentary & in 
moderate-to-vigorous 
physical activity intensity 
Accelerometer NCT02695810 
(PRE-D) 
Effect of Dapagliflozin, Metformin and Physical Activity 
on Glucose Variability, Body Composition and 
Cardiovascular Risk in Pre-diabetes 
Dapagliflozin vs 
metformin vs 
exercise vs no 
intervention 
13 & 26 
weeks 
Prediabetes BMI ≥25 
kg/m2 
120 2019/01 
(awaited) 
Respiratory exchange ratio Indirect 
calorimetry 
Basal metabolic rate 
Cardiorespiratory fitness VO2 max 
Self-rated health & quality of 
life, sleep habits 
Questionnaire 
 
EUDRACT indicates www.clinicaltrialsregister.eu/ registration number. NCT indicates Clinicaltrials.gov registration number. UMIN indicates www.umin.ac.jp/ctr registration number. * indicates primary outcome.  
 
Abbreviations: 6MWT, six minute walking test; BMI, body mass index; CPET, cardiopulmonary exercise testing; EF, ejection fraction; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart 
failure with reduced ejection fraction; LV, left ventricular; MLHFQ, Minnesota Living With Heart Failure Questionnaire; NAFLD, non-alcoholic fatty liver disease; NYHA, New York Heart Association; SGLT2, sodium-
glucose co-transporter 2; T2D, type 2 diabetes; VO2, peak oxygen consumption.  
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Supplemental Table 1i: Ongoing SGLT2 inhibitor mechanistic randomized placebo-controlled trials (metabolic, biomarkers)  
PATIENTS WITH DIABETES 
Outcome 
(Cardiac 
Biomarkers) 
Technique Trial Registration Full Official Title SGLT2 inhibitor 
vs Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Cardiac 
biomarkers 
NT-proBNP NCT03087773 (EMMY) 
(*NT-proBNP) 
Impact of EMpagliflozin on Cardiac Function and 
Biomarkers of HF in Patients With Acute MYocardial 
Infarction 
Empagliflozin vs 
placebo 
6 & 26 
weeks 
± T2D Acute MI 476 2021/04 
NCT03030235 
(PRESERVED-HF) 
(*NT-proBNP) 
Effects of Dapagliflozin on Biomarkers, Symptoms 
and Functional Status in Patients With PRESERVED 
EF HF 
Dapagliflozin vs 
placebo 
6 & 12 
weeks 
± T2D HF (LV EF 
≥45%, 
NYHA II-IV, 
raised NT-
proBNP), 
diuretic 
320 2021/02 
BNP 12 
weeks 
NT-proBNP, hs-cTnI, MR-
proADM 
NCT03198585 (Empire 
HF) (*NT-proBNP) 
Empagliflozin in HF Patients with Reduced EF: A 
Randomized Clinical Trial 
Empagliflozin vs 
placebo 
90 days ± T2D HFrEF (LV 
EF ≤40%, 
NYHA I-III) 
189 2019/10 
(awaited) 
BNP, hs-TnI NCT02932436 (EmDia) A Phase IV, Single-center, Randomized, Double-
blind, Placebo-controlled, Parallel Group Study on 
the Effects of Empagliflozin on LV Diastolic Function 
Compared to Usual Care in Individuals With T2D 
Empagliflozin vs 
placebo 
1 & 12 
weeks 
T2D Diastolic 
dysfunction 
158 2020/06 
NT-proBNP, MR-proANP, 
MR-proADM, GAL-3, hs-
TnT, GDF-15, PlGF, sFlt-1 
NCT03151343 
(SIMPLE) 
Effects of SGLT-2 Inhibitor on Myocardial Perfusion, 
Function and Metabolism in T2DM Patients at High 
CV Risk: The SIMPle Randomized Clinical Trial 
Empagliflozin vs 
placebo 
13 
weeks 
T2D High CV risk 92 2020/04 
NT-proBNP NCT03128528 (ELSI) Randomized, Double-blind, Placebo Controlled, 
Parallel-group, Prospective Clinical Study to Analyse 
the Effect of Empagliflozin on Reduction of Tissue 
Sodium Content in Patients With Chronic HF 
Empagliflozin vs 
placebo 
14 
weeks 
± T2D 
(exclude if 
HbA1c 
≥10%, 
FPG ≥240 
mg/dl) 
HFrEF (LV 
EF <40%) or 
HFmrEF (LV 
EF 40-49%) 
84 2019/12 
BNP NCT02956811 (DAPA-
LVH) 
Does Dapagliflozin Regress LVH In Patients With 
T2D? 
Dapagliflozin vs 
placebo 
4, 17, 34 
& 52 
weeks 
T2D Echocardiog
raphic LVH 
66 2019/04 
(awaited) 
NT-proBNP NCT03398577 Effects of SGLT2 Inhibitor on Markers of 
Inflammation, Atherosclerosis and LV Strain in 
Diabetic Patients With Coronary Artery Disease 
Dapagliflozin vs 
placebo 
3 
months 
T2D Stable 
ischemic 
heart 
disease 
61 2018/12 
(awaited) 
NCT03030222 
(EMBRACE-HF) 
Empagliflozin Evaluation by Measuring Impact on 
Hemodynamics in Patients With HF 
Empagliflozin vs 
placebo 
6 & 12 
weeks 
± T2D HF 
(preserved 
or reduced 
LV EF, 
NYHA II-IV), 
CardioMEM
s 
60 2019/12 
BNP 
NCT02397421 
(REFORM) 
Research Into the Effect of SGLT2 Inhibition on LV 
Remodeling in Patients With HF and Diabetes 
Mellitus 
Dapagliflozin vs 
placebo 
1 year T2D HF (LV EF 
≤45%, 
NYHA I-III) 
56 2017/08 
(awaited) 
NT-proBNP NCT03132181 (EMPA) Empagliflozin as a Modulator of Systemic Vascular 
Resistance and Cardiac Output in Patients With T2D 
Empagliflozin vs 
placebo 
3 
months 
T2D Age 18-74 
years 
40 2019/01 
(awaited) 
Outcome 
(Metabolic, 
Biomarkers) 
Technique Trial Registration Full Official Title SGLT2 inhibitor 
vs Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
DNA & Blood samples NCT03485092 (SUGAR- Studies of Empagliflozin and its Cardiovascular, Empagliflozin vs 36 T2D or HFrEF (LV 105 2020/08 
15 
epigenetics DM-HF) Renal and Metabolic Effects in Patients with 
Diabetes Mellitus (or Prediabetes) and HF 
placebo weeks prediabete
s 
EF ≤40%, 
NYHA II-IV) 
Inflammatory 
markers of 
NASH 
(not stated) NCT03723252 (DEAN) Efficacy and Safety of Dapagliflozin in NASH: a 
Multicentre, Randomized, Placebo-controlled Trial 
Dapagliflozin vs 
placebo 
12 
months 
± T2D NASH as 
determined 
by liver 
biopsies 
100 2021/11 
Biomarkers of 
adipocyte 
function 
FFA, ADPN, leptin, TNF-α, 
IL-6, MCP-1, MAC-1, 
COLL-A1, FGF21 
NCT03151343 
(SIMPLE) 
Effects of SGLT-2 Inhibitor on Myocardial Perfusion, 
Function and Metabolism in T2DM Patients at High 
CV Risk: The SIMPle Randomized Clinical Trial 
Empagliflozin vs 
placebo 
13 
weeks 
T2D High CV risk 92 2020/04 
Biomarkers AGEs CML, sRAGE 
Appetite 
hormones 
Total PYY, ghrelin, GLP-1 NCT02798744 
(SEESAW) (*Total PYY) 
SGLT-2 Inhibitor Empagliflozin Effects on Appetite 
and Weight Regulation: A Randomised Double-blind 
Placebo-controlled Trial 
Empagliflozin vs 
placebo 
24 
weeks 
T2D BMI ≥25 
kg/m2 
76 2019/07 
(awaited) 
Appetite 
perceptions 
Questionnaires 
Microbiome Fecal samples 
Hormones Leptin, cortisol, ghrelin NCT03361098 
(DECREASE) 
Combined Effects of SGLT2 Inhibition and GLP-1 
Receptor Agonism on Food Intake, Body Weight and 
Central Satiety and Reward Circuits in Obese T2DM 
Patients 
Dapagliflozin + 
exenatide vs 
dapagliflozin + 
placebo vs 
exenatide + 
placebo vs 
double placebo 
16 
weeks 
T2D Obesity 
(BMI 30-40 
kg/m2) 
64 2020/01 
Microbiome Fecal samples 
Inflammatory 
markers 
hs-CRP, IL-1β, IL-1α, IL-8, 
IL-10, IL-17, TNF-α, MCP-
1, MMP-9 
NCT03398577 (*IL-1β) Effects of SGLT2 Inhibitor on Markers of 
Inflammation, Atherosclerosis and LV Strain in 
Diabetic Patients With Coronary Artery Disease 
Dapagliflozin vs 
placebo 
3 
months 
T2D Stable 
ischemic 
heart 
disease 
61 2018/12 
(awaited) 
hs-CRP, TNF-α, IL-6 NCT03782259 Effects of SGLT-2 Inhibition With Dapagliflozin on 
Myocardial Fibrosis and Inflammation as Assessed 
by Cardiac MRI With T1- and T2-mapping in Patients 
With T2D 
Dapagliflozin vs 
placebo 
12 
months 
T2D Age ≥18 
years 
60 2020/12 
Metabolomics 
changes 
Blood & urine samples 
(UHPL-QqQ/MS) 
NCT03919656 
(*metabolomics 
changes) 
SGLT-2 Inhibition and Cardiovascular Disease. 
Metabolomics Study of Potential Factors Involved in 
Cardio- and Nephroprotection 
Dapagliflozin vs 
placebo 
12 
weeks 
T2D BMI 27-39.9 
kg/m2 
60 2020/04 
Inflammatory 
markers 
NF-κB (DNA binding 
activity), p47phox, 
cytokine signaling 3, IL-1β, 
c-Jun N-terminal kinase 1, 
Toll-like receptor 4, TNF-α 
NCT02433678 (*NF-κB) An Investigation Into The Anti-hypertensive And 
Potential Anti-inflammatory Actions Of Dapagliflozin 
Dapagliflozin vs 
placebo 
12 
weeks 
T2D BMI ≥30 
kg/m2 
52 2018/11 
(awaited) 
Hypertension 
mediators 
Angiotensinogen, Ang II, 
renin, ANP, BNP, cGMP, 
cAMP 
Renin-
angiotensin 
system 
Ang 1-7 levels NCT03078101 (EMPRA) 
(*Ang 1-7 levels) 
Effect of Empagliflozin on the Renin-angiotensin 
System in Patients With CKD 
Empagliflozin vs 
placebo 
3 
months 
± T2D CKD (eGFR 
15-59 
ml/min/1.73
m2), U ACR 
<300 mg/g 
51 2019/08 
(awaited) 
OCR & ECAR PBMCs 
Salt sensitivity (not stated) 
Systemic NAA 
levels 
Blood & urine samples NCT03801642 Randomized Controlled Pilot Trial Of Dapagliflozin In 
Alzheimer's Disease 
Dapagliflozin vs 
placebo 
12 
weeks 
± T2D 
(metformin 
allowed) 
Probable 
Alzheimer’s 
disease, 
MMSE 15-
26, age 50-
85 years 
48 2020/10 
Catabolic/anabol
ic state 
Activated AKT & MTOR 
phosphorylation in 
lymphocytes 
Mitochondrial Platelet cytochrome 
16 
function oxidase activity 
Inflammation MCP-1, eotaxin-1, TNF-α, 
CRP 
hs-CRP, IL-6, TNF-α NCT03660683 (*CD34+) Cardio-Protective of Effect of Saxagliptin and 
Dapagliflozin Combination on Endothelial Progenitor 
Cells in Patients With T2D 
Dapagliflozin vs 
dapagliflozin + 
saxagliptin vs 
placebo 
16 
weeks 
T2D CV disease 45 2020/07 
Appetite 
controlling 
hormones 
Leptin, adiponectin, GLP-
1, ghrelin 
Gene 
expression 
CD34+ cell number, 
migratory function & gene 
expression NCT02964585 (*CD34+) Role of Canagliflozin on Gene Expression and Function of CD34+ Endothelial Progenitor Cells and 
Renal Function in Patients With T2D 
Canagliflozin vs 
placebo 
12 
weeks 
T2D BMI 25-39.9 
kg/m2 
40 2020/04 
Inflammatory 
markers 
hs-CRP, IL-6, TNF-α 8 & 16 
weeks 
 
NCT indicates Clinicaltrials.gov registration number. * indicates primary outcome.  
 
Abbreviations: ADPN, adiponectin; AGEs, advanced glycation end products; AKT, protein kinase B; Ang, angiotensin; ANP, atrial natriuretic peptide; BMI, body mass index; BNP, B-type natriuretic peptide; cAMP, cyclic 
adenosine monophosphate; cGMP, cyclic guanosine monophosphate; CKD, chronic kidney disease; COLL-A1, type-I collagen; CML, carboxy-methyl-lysine; CV, cardiovascular; DNA, deoxyribonucleic acid; ECAR, 
extracellular acidification rate; EF, ejection fraction; eGFR, estimated glomerular filtration rate; FFA, free fatty acid; FGF21, fibroblast growth factor 21; FPG, fasting plasma glucose; GAL-3, galectin-3; GDF-15, growth 
differentiation factor-15; GLP-1, glucagon-like peptide-1; HbA1c, glycated hemoglobin; HF, heart failure; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; 
HFrEF, heart failure with reduced ejection fraction; (hs)-CRP, (high-sensitivity) C-reactive protein; hs-(c)TnI, high-sensitivity (cardiac) troponin I; hs-TnT, high-sensitivity troponin T; IL, interleukin; LV, left ventricular; 
LVH, left ventricular hypertrophy; MAC-1, macrophage-1 antigen; MCP-1, Monocyte Chemoattractant Protein-1; MI, myocardial infarction; MMP, matrix metalloproteinase; MMSE, Mini-Mental State Examination; MR-
proADM, mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro-atrial natriuretic peptide; MTOR, mammalian target of rapamycin; NAA, N Acetyl-Aspartate; NASH, non-alcoholic steatohepatitis; NF-κB, 
nuclear factor kappa-light-chain-enhancer of activated B cells; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; OCR, oxygen consumption rate; PBMCs, peripheral blood 
mononuclear cells; PlGF, placental growth factor; PYY, Peptide-YY; sFlt-1, soluble fms-like tyrosine kinase-1; SGLT2, sodium-glucose co-transporter 2; sRAGE, soluble receptor for advanced glycation end products; 
T2D(M), type 2 diabetes (mellitus); TNF, tumor necrosis factor; U ACR, urinary albumin creatinine ratio; UHPL-QqQ/MS, Ultra-high-resolution liquid chromatography coupled to triple quadrupole mass spectrometry.  
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Supplemental Table 1j: Ongoing SGLT2 inhibitor mechanistic randomized non-placebo-controlled trials (metabolic, biomarkers)  
PATIENTS WITH DIABETES 
Outcome (Metabolic, 
Biomarkers) 
Technique Trial Registration Full Official Title SGLT2 inhibitor vs 
Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Cardiac biomarker NT-proBNP UMIN000017669 
(CANDLE) (*) 
Safety of Canagliflozin in Diabetic Patients 
with Chronic HF: Randomized, Non-
Inferiority Trial 
Canagliflozin vs 
glimepiride 
24 
weeks 
T2D Chronic HF 
(NYHA I-III) 
250 2018/09 
(awaited) 
Oxidative stress Plasma glutathione, 
serum lipid 
hydroperoxides, 
reactive oxygen 
species 
NCT03377335 Effect of Dapagliflozin on Cardio-Metabolic 
Risk Factors in Patients With T2D 
Dapagliflozin vs 
metformin 
6 
months 
T2D BP ≤140/90 
mmHg, BMI 
≥20 kg/m2 
186 2019/01 
(awaited) 
Inflammatory markers Plasma cytokines 
Gene expression microRNAs 
Inflammatory markers (not stated) NCT02528019 Effects of the DPP-4 or SGLT2 Inhibitors on 
the Metabolic Cardiovascular Systems in 
Patients With T2D 
SGLT2 inhibitor vs 
DPP-4 inhibitor vs 
glimepiride 
6 
months 
T2D Age 30-90 
years 
100 2018/08 
(awaited) 
Biomarkers ET-1, GDF-15, ST2, 
GAL-3, PICP, PTX3, 
hs-CRP, IL-6  
NCT03753087 A Phase 4, Single-center, Randomized, 
Parallel Group Study to Assess Effects of 
Empagliflozin on Exercise Capacity and LV 
Diastolic Function in Patients With HFpEF 
and T2D 
Empagliflozin vs 
standard care 
24 
weeks 
T2D HFpEF (LV 
EF ≥50%) 
100 2020/05 
Cardiac biomarker NT-proBNP 
Biomarkers (after reperfusion 
injury) 
Nitric oxide, 
isoprostane 
NCT02919345 
(ADDENDA) 
Comparative Study of Dapagliflozin Versus 
Glibenclamide Effect on Endothelial Function 
of Coronary Artery Disease Patients 
Dapagliflozin vs 
glibenclamide 
12 
weeks 
T2D Chronic 
coronary 
artery 
disease 
98 2019/03 
(awaited) 
Vascular & systemic 
inflammatory markers 
ICAM-1, VCAM-1, ET-
1, hs-CRP, TNF-α, IL-
6, IL-2 
Adipokines Adiponectin, leptin 
Cardiac biomarker NT-proBNP NCT03871621 
(ELUCIDATE) 
The Echocardiographic LV Functional 
Changes of Uncontrolled Diabetes by the 
Intervention of Dapagliflozin Treatment Trial 
Dapagliflozin vs 
standard care 
24 
weeks 
T2D LV EF ≥50% 90 2020/07 
Biomarkers FABP, GDF-15, 
PIIINP, Lp-PLA2 
Myocardial parietal stress 
biomarkers 
BNP, NT-proBNP, 
proadrenomedullin 
EUDRACT Code 
2016-0022250-10 
(EMPA-HEART)1 
Impact of Empagliflozin on Subclinical LV 
Dysfunctions and on the Mechanisms 
Involved in Myocardial Disease Progression 
in T2D 
Empagliflozin vs 
sitagliptin 
1 & 6 
months 
T2D LV EF ≥50% 75 2019/07 
(awaited) 
Inflammation/oxidative stress 
biomarkers 
hs-CRP, TNF-α, 
mieloperoxidase 
Cardiac remodeling/cytolysis 
biomarkers 
Type III pro-collagen, 
troponin 
Body volume biomarkers Total body water, 
plasma renin & 
aldosterone 
Inflammation IL-6, TNF-α NCT04127084 
(*IL-6, TNF-α, 
AGEs, 8-OHdG) 
Effects of SGLT2 Inhibition Treatment on 
Different Levels of Albuminuria in Patients 
With T2D: a Prospective Interventional Study 
Dapagliflozin 
(open label) 
12 
weeks 
T2D eGFR ≥45 
ml/min/1.73
m2, 3 groups 
with different 
levels of 
albuminuria 
70 2021/08 
Oxidative stress index AGEs, 8-OHdG 
Renin-angiotensin-aldosterone 
system biomarkers 
Renin, angiotensin, 
aldosterone 
Inflammation status CRP NCT03646292 Comparison of The Effects of TZDs, SGLT2 
Inhibitors Alone and TZD / SGLT2 Inhibitor 
Combination Therapy on NAFLD in T2D 
Patients With Fatty Liver 
Empagliflozin vs 
pioglitazone vs 
empagliflozin + 
pioglitazone 
6 
months 
T2D NAFLD 60 2021/02 
Cardiac biomarker BNP NCT02973477 Dapagliflozin and Measures of 
Cardiovascular Autonomic Function in 
Patients With T2D 
Dapagliflozin (12 
weeks) vs 
glimepiride or vice 
26 
weeks 
T2D Age ≥18 
years 
45 2019/08 
(awaited) 
18 
versa (2 week 
washout) 
Cardiac biomarkers NT-proBNP, hs-TnT NCT03178591 
(*all listed 
measures) 
Effects of DPP-4 Inhibitor Versus SGLT2 
Inhibitor on Ischemic Burden in Stable 
Ischemic Heart Disease Patients 
Dapagliflozin vs 
vildagliptin 
6 
months 
T2D Stable 
documented 
CAD 
43 2018/07 
(awaited) Inflammation hs-CRP, IL-6, TNF-α 
Oxidative stress MDA, 8-
isoprostaglandin F2 α 
(not stated) NCT02649465 Pleiotropic Effects and Safety of SGLT2 
Inhibitor Versus Sulfonylurea in Patients 
With T2D and Non-alcoholic Fatty Liver 
Tofogliflozin vs 
glimepiride 
48 
weeks 
T2D NAFLD 40 2020/09 
Cytokine TNF-α, leptin, 
adiponectin 
Hepatokine Selenoprotein P, 
LECT2 
Fatty acids profiles, gene 
expression profiles (& 
epigenomic changes) in liver & 
blood cells, microRNAs & 
exosome contents 
(not stated) 
PATIENTS WITHOUT DIABETES 
Outcome (Metabolic, 
Biomarkers) 
Technique Trial Registration Full Official Title SGLT2 inhibitor vs 
Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Hyperandrogenism Androgen profiles, free 
androgen index 
NCT02635386 Comparison of Dapagliflozin and Once-
weekly Exenatide, Co-administered or 
Alone, Dapagliflozin/Glucophage Extended 
Release and Phentermine/Topiramate 
Extended Release on Metabolic Profiles and 
Body Composition in Obese PCOS Women 
Dapagliflozin vs 
exenatide vs 
dapagliflozin + 
exenatide vs 
dapagliflozin + 
Glucophage vs 
phentermine + 
topiramate 
24 
weeks 
No T1D, 
no T2D 
Women, age 
18-45 years, 
PCOS, BMI 
>30<45 
kg/m2 
135 2020/09 
 
EUDRACT indicates www.clinicaltrialsregister.eu/ registration number. NCT indicates Clinicaltrials.gov registration number. UMIN indicates www.umin.ac.jp/ctr registration number. * indicates primary outcome.  
 
Abbreviations: 8-OHdG, 8-hydroxy-2’-deoxyguanosine; AGEs, advanced glycation end products; BMI, body mass index; BNP, B-type natriuretic peptide; BP, blood pressure; CAD, coronary artery disease; CRP, C-
reactive protein; DPP-4, dipeptidyl peptidase-4; EF, ejection fraction; eGFR, estimated glomerular filtration rate; ET-1, endothelin-1; FABP, fatty acid binding protein; GAL-3, galectin-3; GDF-15, growth differentiation 
factor-15; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; hs-CRP, high-sensitivity C-reactive protein; hs-TnT, high-sensitivity troponin T; ICAM-1, intercellular adhesion molecule-1; IL, interleukin; 
LECT2, leukocyte cell-derived chemotaxin 2; Lp-PLA2, lipoprotein-associated phospholipase A2; LV, left ventricular; MDA, malondialdehyde; microRNA, micro-ribonucleic acid; NAFLD, non-alcoholic fatty liver disease; 
NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PCOS, polycystic ovarian syndrome; PICP, carboxyterminal propeptide of type I collagen; PIIINP, procollagen type III N-
terminal peptide; PTX3, human pentraxin 3; SGLT2, sodium-glucose co-transporter 2; ST2, suppression of tumorigenicity-2; T1D, type 1 diabetes; T2D, type 2 diabetes; TNF, tumor necrosis factor; TZD, 
thiazolidinedione; VCAM-1, vascular cell adhesion molecule-1.  
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Supplemental Table 1k: Ongoing SGLT2 inhibitor mechanistic randomized placebo-controlled trials (hepatic)  
PATIENTS WITH DIABETES 
Outcome (Hepatic) Technique Trial 
Registration 
Full Official Title SGLT2 inhibitor 
vs Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Hepatic fat content MRS NCT03193684 Effect of Dapagliflozin on Hepatic Glucose Metabolism: Role of 
Autonomic Nervous System 
Dapagliflozin vs 
placebo 
12 
weeks 
± T2D Healthy 108 2023/01 
Scored liver histological 
improvement 
Liver biopsy NCT03723252 
(DEAN) (*scored 
liver histological 
improvement) 
Efficacy and Safety of Dapagliflozin in NASH: a Multicentre, 
Randomized, Placebo-controlled Trial 
Dapagliflozin vs 
placebo 
12 
months 
± T2D NASH as 
determined by 
liver biopsies 
100 2021/11 
Visceral fat Abdominal 
CT scan 
Liver fat Liver 
Fibroscan 
Hepatic lipid content MRS NCT03007329 
(EXENDA) (*) 
A 24 Week Monocentric Prospective Randomized, Placebo-
controlled Trial to Evaluate Efficacy of Combination of Exenatide 
and Dapagliflozin Compared to Dapagliflozin and Placebo and 
Its Effects on Hepatic, Myocardial and Pancreatic Fat 
Distribution in Patients With Uncontrolled T2DM 
Dapagliflozin + 
exenatide vs 
dapagliflozin + 
placebo 
24 
weeks 
T2D BMI ≥25 kg/m2 90 2020/03 
Liver fat content NCT02637973 
(EmLiFa) (*) 
Effects of Empagliflozin on Liver Fat Content, Energy 
Metabolism and Body Composition in Patients With T2D 
Empagliflozin vs 
placebo 
24 
weeks 
T2D (drug 
naïve) 
BMI <45 kg/m2 84 2018/08 
(awaited) 
Visceral fat mass Abdominal 
MRI 
NCT02956811 
(DAPA-LVH) 
Does Dapagliflozin Regress LVH In Patients With T2D? Dapagliflozin vs 
placebo 
52 
weeks 
T2D Echocardiogra
phic LVH 
66 2019/04 
(awaited) 
Hepatic triglyceride 
content 
Proton MRS NCT03118336 
(EMPACEF) 
Impact of Empagliflozine on Cardiac Ectopic Fat Empagliflozin vs 
placebo 
12 
weeks 
T2D Age >18 years 56 2020/02 
 
NCT indicates Clinicaltrials.gov registration number. * indicates primary outcome.  
 
Abbreviations: BMI, body mass index; CT, computed tomography; LVH, left ventricular hypertrophy; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NASH, non-alcoholic steatohepatitis; 
SGLT2, sodium-glucose co-transporter 2; T2D(M), type 2 diabetes (mellitus).  
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Supplemental Table 1l: Ongoing SGLT2 inhibitor mechanistic randomized non-placebo-controlled trials (hepatic)  
PATIENTS WITH DIABETES 
Outcome 
(Hepatic) 
Technique Trial Registration Full Official Title SGLT2 inhibitor vs 
Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Liver fat change MRI-PDFF NCT03646292 (*liver 
fat change) 
Comparison of The Effects of TZDs, SGLT2 Inhibitors Alone and 
TZD / SGLT2 Inhibitor Combination Therapy on NAFLD in T2D 
Patients With Fatty Liver 
Empagliflozin vs 
pioglitazone vs 
empagliflozin + 
pioglitazone 
6 
months 
T2D NAFLD 60 2021/02 
Liver fibrosis MRE 
Liver fat Fibroscan 
using CAP 
score 
NCT02875821 Effect of Ipragliflozin on Excessive Fat in T2D Patients With 
NAFLD Treated With Metformin and Pioglitazone 
Ipragliflozin + 
metformin + 
pioglitazone vs 
metformin + 
pioglitazone 
6 
months 
T2D NAFLD, 
BMI ≥23 
kg/m2 
44 2017/06 
(awaited) 
Histological 
features of NAFLD 
Histology NCT02649465 (*) Pleiotropic Effects and Safety of SGLT2 Inhibitor Versus 
Sulfonylurea in Patients With T2D and Non-alcoholic Fatty Liver 
Tofogliflozin vs 
glimepiride 
48 
weeks 
T2D NAFLD 40 2020/09 
 
NCT indicates Clinicaltrials.gov registration number. * indicates primary outcome.  
 
Abbreviations: BMI, body mass index; CAP, controlled attenuation parameter; MRE, magnetic resonance elastography; MRI-PDFF, MRI-proton density fat fraction; NAFLD, non-alcoholic fatty liver disease; SGLT2, 
sodium-glucose co-transporter 2; T2D, type 2 diabetes; TZD, thiazolidinedione.  
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Supplemental Table 1m: Ongoing SGLT2 inhibitor mechanistic randomized placebo-controlled trials (musculoskeletal)  
PATIENTS WITH DIABETES 
Outcome 
(Musculoskeletal
) 
Technique Trial 
Registration 
Full Official Title SGLT2 inhibitor vs 
Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Bone mineral 
density: lumbar 
spine, total hip, 
femoral neck 
DEXA NCT03386344 
(SOTA-BONE) 
A 26-week Randomized, Double-blind, Placebo-controlled, 
Parallel-group, Multicenter, Phase 3 Study With a 78-week 
Extension Period to Evaluate the Efficacy and Bone Safety of 
Sotagliflozin in Patients 55 Years or Older With T2D and 
Inadequate Glycemic Control 
Sotagliflozin dose 
1 vs sotagliflozin 
dose 2 vs placebo 
26 
weeks 
T2D Age ≥55 
years 
360 2020/12 
Body 
composition 
DEXA NCT03198585 
(Empire HF) 
Empagliflozin in HF Patients with Reduced EF: A Randomized 
Clinical Trial 
Empagliflozin vs 
placebo 
90 days ± T2D HFrEF (LV 
EF ≤40%, 
NYHA I-III) 
189 2019/10 
(awaited) 
Central 
abdominal fat 
mass 
DEXA at lumbar segments 
2-4 
NCT03215069 
(EMPA post-
GDM) 
Empagliflozin and the Preservation of Beta-cell Function in 
Women With Recent Gestational Diabetes 
Empagliflozin vs 
placebo 
48 
weeks 
Gestationa
l diabetes 
6-36 
months 
postpartu
m, age 20-
50 years 
120 2022/09 
Body fat mass (not stated) NCT03717194 
(ERTU-GLS) 
A Phase 3, Randomized, Double-blind, Placebo-controlled, 
Parallel-group, to Evaluate the Effect of Ertugliflozin on 
Cardiac Function in Patients With T2D Who Have Inadequate 
Glycemic Control and Stage B HF 
Ertugliflozin vs 
placebo 
12 & 24 
weeks 
T2D Stage B 
HF (on 
basis of 
structural 
or 
functional 
markers) 
120 2020/10 
Body 
composition 
Bioelectrical impedance 
analysis 
NCT03485092 
(SUGAR-DM-
HF) 
Studies of Empagliflozin and its Cardiovascular, Renal and 
Metabolic Effects in Patients with Diabetes Mellitus (or 
Prediabetes) and HF 
Empagliflozin vs 
placebo 
36 
weeks 
T2D or 
prediabete
s 
HFrEF (LV 
EF ≤40%, 
NYHA II-
IV) 
105 2020/08 
DEXA NCT03151343 
(SIMPLE) 
Effects of SGLT-2 Inhibitor on Myocardial Perfusion, Function 
and Metabolism in T2DM Patients at High CV Risk: The 
SIMPle Randomized Clinical Trial 
Empagliflozin vs 
placebo 
13 
weeks 
T2D High CV 
risk 
92 2020/04 
Adipose tissue Adipocyte differentiation, 
macrophage infiltration, 
extracellular matrix fibrosis 
Skin sodium 
content, muscle 
sodium content 
23Na-MRI NCT03128528 
(ELSI) (*skin 
sodium 
content) 
Randomized, Double-blind, Placebo Controlled, Parallel-group, 
Prospective Clinical Study to Analyse the Effect of 
Empagliflozin on Reduction of Tissue Sodium Content in 
Patients With Chronic HF 
Empagliflozin vs 
placebo 
14 
weeks 
± T2D 
(exclude if 
HbA1c 
≥10%, 
FPG ≥240 
mg/dl) 
HFrEF (LV 
EF <40%) 
or 
HFmrEF 
(LV EF 40-
49%) 
84 2019/12 
Water content of 
skin & muscle 
1H 
Body 
constitution 
Fluid status: lean body 
mass, adipose tissue 
mass, overhydration 
Body 
composition 
DEXA NCT02798744 
(SEESAW) 
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight 
Regulation: A Randomised Double-blind Placebo-controlled 
Trial 
Empagliflozin vs 
placebo 
24 
weeks 
T2D BMI ≥25 
kg/m2 
76 2019/07 
(awaited) 
Bioelectrical impedance 
analysis 
NCT03361098 
(DECREASE) 
Combined Effects of SGLT2 Inhibition and GLP-1 Receptor 
Agonism on Food Intake, Body Weight and Central Satiety and 
Reward Circuits in Obese T2DM Patients 
Dapagliflozin + 
exenatide vs 
dapagliflozin + 
placebo vs 
exenatide + 
placebo vs double 
placebo 
10 days 
& 16 
weeks 
T2D Obesity 
(BMI 30-
40 kg/m2) 
64 2020/01 
Fluid status NCT02397421 
(REFORM) 
Research Into the Effect of SGLT2 Inhibition on LV 
Remodeling in Patients With HF and Diabetes Mellitus 
Dapagliflozin vs 
placebo 
1 year T2D HF (LV EF 
≤45%, 
56 2017/08 
(awaited) 
22 
NYHA I-III) 
Body fluid status Bioimpedance NCT03078101 
(EMPRA) 
Effect of Empagliflozin on the Renin-angiotensin System in 
Patients With CKD 
Empagliflozin vs 
placebo 
3 
months 
± T2D CKD 
(eGFR 15-
59 
ml/min/1.7
3m2), U 
ACR <300 
mg/g 
51 2019/08 
(awaited) 
Body 
composition: 
total fat mass, 
total lean mass 
DEXA NCT03801642 Randomized Controlled Pilot Trial Of Dapagliflozin In 
Alzheimer's Disease 
Dapagliflozin vs 
placebo 
12 
weeks 
± T2D 
(metformin 
allowed) 
Probable 
Alzheimer’
s disease, 
MMSE 15-
26, age 
50-85 
years 
48 2020/10 
Body fat percent Tanita B350 Total Body 
Composition Analyzer 
NCT03660683 Cardio-Protective of Effect of Saxagliptin and Dapagliflozin 
Combination on Endothelial Progenitor Cells in Patients With 
T2D 
Dapagliflozin vs 
dapagliflozin + 
saxagliptin vs 
placebo 
16 
weeks 
T2D CV 
disease 
45 2020/07 
Muscle 
sympathetic 
nerve activity 
Microneurography 
(peroneal nerve) 
NCT03640221 
(*microneurogr
aphy) 
A Double-blind, Randomized, Parallel 2- Arm Study to 
Compare the Efficacy of Ertugliflozin Versus 
Hydrochlorothiazide in Reducing Sympathetic Neural 
Overactivity in Patients With Hypertension and Recently-
diagnosed T2D Who Are Receiving Background Standard-of-
care Cardio-metabolic Therapy With Metformin, an ACEi or 
ARB, and a Statin 
Ertugliflozin + HCT 
placebo vs 
ertugliflozin 
placebo vs HCT 
3 
months 
T2D Systolic 
BP 130-
150 on 
first 
screening 
visit, LV 
EF >50% 
45 2020/08 
Chest wall skin 
sympathetic 
nerve activity 
Standard surface ECG 
leads 
Adiposity Body composition scale NCT02964585 Role of Canagliflozin on Gene Expression and Function of 
CD34+ Endothelial Progenitor Cells and Renal Function in 
Patients With T2D 
Canagliflozin vs 
placebo 
12 
weeks 
T2D BMI 25-
39.9 kg/m2 
40 2020/04 
 
NCT indicates Clinicaltrials.gov registration number. * indicates primary outcome.  
 
Abbreviations: 1H, proton; 23Na-MRI, 23-sodium magnetic resonance imaging; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CKD, 
chronic kidney disease; CV, cardiovascular; DEXA, dual energy X-ray absorptiometry; ECG, electrocardiography; EF, ejection fraction; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; GLP-1, 
glucagon-like peptide-1; HbA1c, glycated hemoglobin; HCT, hydrochlorothiazide; HF, heart failure; HFmrEF, heart failure with mid-range ejection fraction; HFrEF, heart failure with reduced ejection fraction; LV, left 
ventricular; MMSE, Mini-Mental State Examination; NYHA, New York Heart Association; SGLT2, sodium-glucose co-transporter 2; T2D(M), type 2 diabetes (mellitus); U ACR, urinary albumin creatinine ratio.  
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Supplemental Table 1n: Ongoing SGLT2 inhibitor mechanistic randomized non-placebo-controlled trials (musculoskeletal)  
PATIENTS WITH DIABETES 
Outcome 
(Musculoskeletal) 
Technique Trial Registration Full Official Title SGLT2 inhibitor vs 
Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Total body fat 
mass 
DEXA NCT02564926 
(BEYOND) (*) 
Effects of Dapagliflozin Compared With 
Glimepiride on Body Composition in Patients 
With T2D Inadequately Controlled With 
Metformin 
Dapagliflozin + 
metformin vs glimepiride 
+ metformin 
52 
weeks 
T2D Age 19-75 years 125 2018/01 
(awaited) 
Subcutaneous & 
visceral fat volume 
(not stated) NCT02528019 Effects of the DPP-4 or SGLT2 Inhibitors on the 
Metabolic Cardiovascular Systems in Patients 
With T2DM 
SGLT2 inhibitor vs DPP-
4 inhibitor vs glimepiride 
6 
months 
T2D Age 30-90 years 100 2018/08 
(awaited) 
Body composition 
(% of fat mass, % 
free fat mass) 
DEXA NCT02919345 
(ADDENDA) 
Comparative Study of Dapagliflozin Versus 
Glibenclamide Effect on Endothelial Function of 
Coronary Artery Disease Patients 
Dapagliflozin vs 
glibenclamide 
12 
weeks 
T2D Chronic 
coronary artery 
disease 
98 2019/03 
(awaited) 
Body composition 
(body fluid 
volume, skeletal 
muscle mass, total 
fat mass) 
(not stated) UMIN000024001 A Randomized Comparison of the Effect of 
Empagliflozin for Endothelial Function in T2D 
Metformin + glargine 
then empagliflozin vs 
metformin + glargine 
then glimepiride 
12 
weeks + 
12 
weeks 
T2D BMI ≤45 kg/m2; 
Age 20-80 
80 2020/03 
Body fat content Bioimpedance 
analysis 
NCT03433248 
(RACELINES) 
Renal Actions of Combined Empagliflozin and 
LINagliptin in Type 2 diabetES 
Empagliflozin then add 
linagliptin vs linagliptin 
then add empagliflozin 
vs gliclazide 
8 & 16 
weeks 
T2D BMI >25 kg/m2, 
eGFR ≥45 
ml/min/1.73m2 
66 2020/12 
Skeletal muscle 
H2O2 
concentration, 
mitochondrial 
function & lipid 
peroxidation 
Skeletal muscle 
biopsies 
NCT03437330 
(*skeletal muscle 
H2O2 concentration) 
Empagliflozin Effect on Glucose Toxicity in T2D 
Patients – a Randomized, Open-label, 
Controlled, Parallel Group, Exploratory Study 
Empagliflozin vs insulin 
glargine 
12 
weeks 
T2D BMI 25-40 
kg/m2, age 40-
70 years 
50 2022/03 
Subcutaneous & 
visceral fat area 
DEXA NCT02875821 
(*visceral fat area) 
Effects of Ipragliflozin on Excessive Fat in T2D 
Patients With NAFLD Treated With Metformin 
and Pioglitazone 
Ipragliflozin + metformin 
+ pioglitazone vs 
metformin + pioglitazone 
6 
months 
T2D NAFLD, BMI 
≥23 kg/m2 
44 2017/06 
(awaited) 
PATIENTS WITHOUT DIABETES 
Outcome 
(Musculoskeletal) 
Technique Trial Registration Full Official Title SGLT2 inhibitor vs 
Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Total fat mass & 
fat distribution 
DEXA NCT02635386 Comparison of Dapagliflozin and Once-weekly 
Exenatide, Co-administered or Alone, 
Dapagliflozin/Glucophage Extended Release 
and Phentermine/Topiramate Extended Release 
on Metabolic Profiles and Body Composition in 
Obese PCOS Women 
Dapagliflozin vs 
exenatide vs 
dapagliflozin + exenatide 
vs dapagliflozin + 
Glucophage vs 
phentermine + 
topiramate 
24 
weeks 
No T1D, 
no T2D 
Women, age 18-
45 years, PCOS, 
BMI >30<45 
kg/m2 
135 2020/09 
Body fat (%) NCT02695810 
(PRE-D) 
Effect of Dapagliflozin, Metformin and Physical 
Activity on Glucose Variability, Body 
Composition and Cardiovascular Risk in Pre-
diabetes 
Dapagliflozin vs 
metformin vs exercise vs 
no intervention 
13 & 26 
weeks 
Prediabete
s 
BMI ≥25 kg/m2 120 2019/01 
(awaited) 
 
NCT indicates Clinicaltrials.gov registration number. UMIN indicates www.umin.ac.jp/ctr registration number. * indicates primary outcome.  
 
Abbreviations: BMI, body mass index; DEXA, dual energy X-ray absorptiometry; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; H2O2, hydrogen peroxide; NAFLD, non-alcoholic fatty liver 
disease; PCOS, polycystic ovarian syndrome; SGLT2, sodium-glucose co-transporter 2; T1D, type 1 diabetes; T2D(M), type 2 diabetes (mellitus).  
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Supplemental Table 1o: Ongoing SGLT2 inhibitor mechanistic randomized placebo-controlled trials (neurological)  
PATIENTS WITH DIABETES 
Outcome 
(Neurological) 
Technique Trial Registration Full Official Title SGLT2 inhibitor 
vs Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Autonomic nervous 
system 
Norepinephrine turnover rate NCT03193684 (*) Effect of Dapagliflozin on Hepatic Glucose 
Metabolism: Role of Autonomic Nervous System 
Dapagliflozin vs 
placebo 
12 
weeks 
± T2D Healthy 108 2023/01 
Cerebral perfusion ASL NCT03361098 
(DECREASE) 
(*neuronal activity) 
Combined Effects of SGLT2 Inhibition and GLP-
1 Receptor Agonism on Food Intake, Body 
Weight and Central Satiety and Reward Circuits 
in Obese T2DM Patients 
Dapagliflozin + 
exenatide vs 
dapagliflozin + 
placebo vs 
exenatide + 
placebo vs 
double placebo 
16 
weeks 
T2D Obesity (BMI 
30-40 kg/m2) 
64 2020/01 
Neuronal activity: 
central reward & 
satiety circuits 
BOLD fMRI 10 days 
& 16 
weeks 
Cerebral NAA MRS NCT03801642 
(*cerebral NAA) 
Randomized Controlled Pilot Trial Of 
Dapagliflozin In Alzheimer's Disease 
Dapagliflozin vs 
placebo 
12 
weeks 
± T2D 
(metformin 
allowed) 
Probable 
Alzheimer’s 
disease, 
MMSE 15-26, 
age 50-85 
years 
48 2020/10 
Cerebral metabolism FDG-PET 
Cognitive performance ADAS-cog 14, Trailmaking 
B, Stroop Word Color test 
Memory performance Logical Memory II test 
 
NCT indicates Clinicaltrials.gov registration number. * indicates primary outcome.  
 
Abbreviations: ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; ASL, arterial spin labelling; BMI, body mass index; BOLD, blood-oxygen-level-dependent; FDG-PET, fluorodeoxyglucose positron 
emission tomography; fMRI, functional magnetic resonance imaging; GLP-1, glucagon-like peptide-1; MMSE, Mini-Mental State Examination; MRS, magnetic resonance spectroscopy; NAA, N Acetyl-Aspartate; SGLT2, 
sodium-glucose co-transporter 2; T2D(M), type 2 diabetes (mellitus).  
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Supplemental Table 1p: Ongoing SGLT2 inhibitor mechanistic randomized non-placebo-controlled trials (neurological)  
PAITENTS WITH DIABETES 
Outcome (Neurological) Technique Trial 
Registration 
Full Official Title SGLT2 inhibitor 
vs Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Olfactory brain activation fMRI NCT03961659 
(*olfactory 
brain 
activation) 
A Prospective, Randomized, Open Label, Parallel, 16-week Study to 
Explore and Evaluate the Therapeutic Effects of Liraglutide, 
Dapagliflozin and Acarbose on the Cognitive Function, Olfactory 
Function, and Odor-induced Brain Activation in Overweight/Obese 
Patients With T2DM Inadequately Controlled With Metformin 
Monotherapy 
Dapagliflozin vs 
liraglutide vs 
acarbose 
16 
weeks 
T2D MMSE >24, 
right handed, 
age 40-75 
years, BMI 
≥25 kg/m2 
87 2021/02 
Cognitive function MoCA 
Autonomic nerve 
function 
(not 
stated) 
NCT02649465 Pleiotropic Effects and Safety of SGLT2 Inhibitor Versus Sulfonylurea 
in Patients With T2D and Non-alcoholic Fatty Liver 
Tofogliflozin vs 
glimepiride 
48 
weeks 
T2D NAFLD 40 2020/09 
 
NCT indicates Clinicaltrials.gov registration number. * indicates primary outcome.  
 
Abbreviations: BMI, body mass index; fMRI, functional magnetic resonance imaging; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; NAFLD, non-alcoholic fatty liver disease; SGLT2, 
sodium-glucose co-transporter 2; T2D(M), type 2 diabetes (mellitus).  
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Supplemental Table 2a: Ongoing GLP-1RA mechanistic randomized placebo-controlled trials (cardiovascular, renal)  
PATIENTS WITH DIABETES 
Outcome 
(Cardiovascular, 
Renal) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Carotid plaque volume 
& composition 
3 Tesla MRI NCT02162550 
(*carotid 
plaque 
volume) 
Effect of Bydureon on Carotid Atherosclerosis 
Progression in T2DM 
Exenatide vs 
placebo 
18 
months 
T2D Age 21-75 years 148 2019/09 
(awaited) 
Reactive hyperemic 
index 
Peripheral artery 
tonometry 
Non-calcified plaque 
volume 
CT angiography NCT03985384 
(STOP) (*) 
Effect of Semaglutide on Coronary Atherosclerosis 
Plaque Progression in T2D 
Semaglutide 
vs placebo 
12 
months 
T2D ≥1 CV risk factor or 
prior ASCVD 
140 2020/09 
NT-proBNP Blood sample NCT03017352 
(MAG1C) 
Meal-time Administration of Exenatide for 
Glycaemic Control in T1D Cases: A Randomised, 
Placebo-controlled Trial 
Exenatide vs 
placebo 
6 
months 
T1D BMI >22 kg/m2 108 2019/06 
(awaited) 
MISS Cardiac biomarker score NCT02251431 
(EXTEND-
CRS) (*all 
listed 
measures) 
MB001-067 A Prospective, Double Blind, Placebo 
Controlled, Parallel Group, Randomized Trial Of 
Extended Release Exenatide Versus Placebo 
(Cohort A) And A Prospective, Single Group, 
Open-Label, Blinded Outcome Trial Of Extended 
Release Exenatide (Cohort B) In Diabetic Patients 
With Type 4 Cardiorenal Syndrome (EXTEND-
CRS TRIAL) Amendment 3 
Exenatide vs 
placebo 
38 
weeks 
T2D eGFR 50-90 
ml/min/1.73m2 
104 2020/06 
KISS Kidney biomarker score 
Cardiac fibrosis CMR LGE 
LV strain Echocardiographic strain-
rate imaging 
Vascular function Pulse wave velocity NCT01612468 
(Lira-1) 
Liraglutide in T1D. A Randomised, Double-blind, 
Placebo Controlled Study of the Effect of 
Liraglutide as an Additional Treatment to Insulin on 
HbA1c, Body Weight and Hypoglycaemia in Poorly 
Regulated T1D Patients 
Liraglutide 
vs placebo 
24 
weeks 
T1D BMI >25 kg/m2 100 2015/02 
(awaited 
secondary 
outcomes) 
Atherosclerosis cIMT 
Vascular inflammation  FDG PET/CT NCT03449654 
(LIRAFLAME) 
(*vascular 
inflammation) 
Effect of Liraglutide on Vascular Inflammation in 
T2D: A Randomized, Placebo-controlled, Double-
blind, Parallel Clinical PET/CT Trial The Liraflame 
Trial 
Liraglutide 
vs placebo 
26 
weeks 
T2D Age >50 years, 
eGFR ≥30 
ml/min/1.73m2, 
stable/no treatment 
of 
hypercholesterolemi
a 4 weeks before 
baseline PET/CT 
100 2019/10 
(awaited) Endothelial function EndoPAT 
Sublingual glycocalyx 
measurement 
Coronary 
atherosclerosis 
Coronary artery calcium 
score 
Artery wall thickening cIMT 
Autonomic nervous 
system function 
CV autonomic neuropathy 
indices 
Maximum TBR in 
carotid arteries 
18F-FDG NCT04032197 
(*18F-FDG 
TBR) 
A Trial Investigating the Effect of Semaglutide on 
Atherosclerosis in Patients With Cardiovascular 
Disease and T2D 
Semaglutide 
vs placebo 
26 
weeks 
T2D Established CV 
disease, age ≥50 
years, BMI ≤39.9 
kg/m2 
100 2021/09 
68Ga-DOTATATE 
MPR (not stated) 
Total wall volume of 
most diseased carotid 
artery 
(not stated) 52 
weeks 
Myocardial lipid 
content 
MRS NCT03007329 
(EXENDA) 
A 24 Week Monocentric Prospective Randomized, 
Placebo-controlled Trial to Evaluate Efficacy of 
Combination of Exenatide and Dapagliflozin 
Compared to Dapagliflozin and Placebo and Its 
Effects on Hepatic, Myocardial and Pancreatic Fat 
Distribution in Patients With Uncontrolled T2DM 
Exenatide + 
dapagliflozin 
vs 
dapagliflozin 
+ placebo 
24 
weeks 
T2D BMI ≥25 kg/m2 90 2020/03 
Albuminuria Urine sample NCT03029351 
(1981 GLP) (*) 
GLP-1RA Therapy and Albuminuria in Patients 
With T2D 
Exenatide vs 
placebo 
13, 26, 
39 & 56 
weeks 
T2D Microalbuminuria or 
macroalbuminuria 
90 2020/02 
LV EF 3D echocardiography NCT02650596 
(*LV EF) 
Effects of Liraglutide on LV Function in Chronic HF 
Patients With T2D 
Liraglutide 
vs placebo 
3 
months 
T2D Chronic HF (NYHA I, 
II or III) 
68 2018/02 
(awaited) NT-proBNP Blood sample 
27 
Fitness 6-minute walk distance 
CV autonomic balance CV reflex test with finger 
plethysmography (Nexfin) 
NCT03361098 
(DECREASE) 
Combined Effects of SGLT2 Inhibition and GLP-1 
Receptor Agonism on Food Intake, Body Weight 
and Central Satiety and Reward Circuits in Obese 
T2DM Patients 
Exenatide + 
dapagliflozin 
vs exenatide 
+ placebo vs 
dapagliflozin 
+ placebo vs 
double 
placebo 
10 days 
& 16 
weeks 
T2D Obesity (BMI 30-40 
kg/m2) 
64 2020/01 
Arterial stiffness Pulse wave analysis 
Renal biomarkers 24-hour urine 
LV systolic (EF) & 
diastolic function 
Echocardiography NCT04057261 
(Lirabolic) 
Effect of Liraglutide on the Metabolic Profile in 
Patients With T2D and CV Disease 
Liraglutide 
vs placebo 
3 
months 
T2D Existing CV disease 50 2021/11 
NT-proBNP Blood test 
Heart rate variability 24-hour ECG 
Diastolic function Echocardiography NCT02655770 
(*CMR 
diastolic 
properties) 
Influence of Liraglutide on Diastolic Cardiac 
Function and Myocardial Perfusion as Determined 
by MRI in Patients With T2D: a Double-blind 
Randomized Parallel-group Trial 
Liraglutide 
vs placebo 
18 
weeks 
T2D LV EF >50%, 
diastolic dysfunction 
40 2020/06 
CMR 
Myocardial perfusion MRI 
EAT inflammation mRNA & protein 
expression of TNF-α & IL-
6 
NCT03260881 
(*EAT 
inflammation) 
Effects of Liraglutide on Epicardial Fat Pro-
Inflammatory Genes in T2D and CAD 
Liraglutide 
vs placebo + 
low calorie 
diet 
12 
weeks 
T2D CAD who require 
CABG, BMI ≥27 
kg/m2 
40 2021/06 
EAT thickness Ultrasound 
Arterial stiffness Pulse wave velocity, pulse 
wave analysis 
NCT04126603 Impact of Semaglutide (Long Acting GLP-1 
Agonist) on Peripheral Blood Derived CD34+ 
EPCs and Subcutaneous Fat Derived MSCs in 
T2D Subjects 
Semaglutide 
vs placebo 
24 
weeks 
T2D BMI 25-45 kg/m2, 
additional CV 
disease risk factor 
40 2021/11 
PATIENTS WITHOUT DIABETES 
Outcome 
(Cardiovascular) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Symptoms NYHA, KCCQ NCT02930265 Clinical Study of Liraglutide in Improving Cardiac 
Function for Patients With Ischemic 
Cardiomyopathy 
Liraglutide 
vs placebo 
6 
months 
Not stated Ischemic HF (NYHA 
II-IV, LV EF ≤40%) 
400 2018/03 
(awaited) LV EF (not stated) 
Fitness 6-minute walk test 
Epicardial fat Chest CT NCT04019197 
(*epicardial 
fat) 
Effects of GLP-1RAs on Cardiometabolic 
Alterations in HIV-associated Lipohypertrophy 
Semaglutide 
vs placebo 
56 
weeks 
No 
diabetes 
HIV-1 infection & 
lipohypertrophy vs 
overweight/obese 
controls without HIV  
208 2024/03 
Arterial stiffness Pulse wave velocity 
Endothelial function EndoPAT 
Biomarkers Natriuretic peptides 
Final infarct size CMR NCT01938235 
(EMPRES) 
(*final infarct 
size) 
Exenatide for Myocardial Protection During 
Reperfusion Study: A Double-blind, Placebo-
controlled Trial 
Exenatide 
(IV 24 
hours) vs 
placebo 
3 
months 
Not stated 
(no 
diabetes 
requiring 
insulin) 
Admission for 
primary PCI for 
STEMI 
198 2018/01 
(awaited) 
LV EF 72 hours 
& 3 
months 
LV volume 
LV EF Echocardiography NCT02577848 
(*LV EF) 
Effects of Liraglutide on LV Function in Patients 
With NSTEMI 
Liraglutide 
(7 days) vs 
placebo 
3 
months 
Not stated NSTEMI 90 2016/10 
(awaited) Fitness Six minute walk test 
 
NCT indicates Clinicaltrials.gov registration number. * indicates primary outcome.  
 
Abbreviations: 18F, 18-fluorodeoxyglucose; 3D, three-dimensional; 68Ga-DOTATATE, gallium-68 dodecanetetraacetic acid-tyrosine-3-octreotate; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; 
CABG, coronary artery bypass graft; CAD, coronary artery disease; cIMT, carotid intima-media thickness; CMR, cardiac magnetic resonance imaging; CT, computed tomography; CV, cardiovascular; EAT, epicardial 
adipose tissue; ECG, electrocardiography; EF, ejection fraction; eGFR, estimated glomerular filtration rate; EndoPAT, Peripheral Arterial Tone; EPC, endothelial progenitor cells; FDG, fluorodeoxyglucose; GLP-1(RA), 
glucagon-like peptide-1 (receptor agonist); HF, heart failure; IL, interleukin; IV, intravenous; KCCQ, Kansas City Cardiomyopathy Questionnaire; KISS, kidney injury summary score; LGE, late gadolinium enhancement; 
LV, left ventricular; MISS, myocardial injury summary score; MPR, myocardial perfusion reserve; MRI, magnetic resonance imaging; mRNA, messenger ribonucleic acid; MRS, magnetic resonance spectroscopy; MSC, 
mesenchymal stromal cell; NSTEMI, non-ST segment elevation myocardial infarction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary 
28 
intervention; PET, positron emission tomography; SGLT2, sodium-glucose co-transporter 2; STEMI, ST-segment elevation myocardial infarction; T1D, type 1 diabetes; T2D(M), type 2 diabetes (mellitus); TBR, target-to-
background ratio; TNF, tumor necrosis factor.  
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Supplemental Table 2b: Ongoing GLP-1RA mechanistic randomized non-placebo-controlled trials (cardiovascular, renal)  
PATIENTS WITH DIABETES 
Outcome 
(Cardiovascular, 
Renal) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Peripheral arterial 
tone 
EndoPAT 2000 NCT03804411 Search for Highly Specific Predictors of 
Response to Different Hypoglycemic Therapy for 
Cardiovascular Prognosis 
Automated decision-
making system vs 
standard 
recommendations – 
includes GLP-1 
analogues, SGLT2 
inhibitors, DPP-4 
inhibitors 
6 & 12 
months 
T2D Age 17-70 years 800 2020/05 
Atherosclerosis cIMT 
Cardiac biomarker NT-proBNP 
LV EF, LV mass 
index 
Echocardiography 
Global longitudinal 
strain 
2D speckle-
tracking 
echocardiography 
Endothelial 
damage 
Molecular-genetic 
markers 
Claudication 
distance 
Standardized 
treadmill testing 
NCT04146155 
(LEADPACE 
STUDY) 
(*claudication 
distance) 
Liraglutide Efficacy and Action on T2D With 
Peripheral Atherosclerotic intErmittent 
Claudication: a Prospective, 24-week, 
Multicenter, Randomized, Controlled Clinical 
Study 
Liraglutide + standard-
of-care vs standard-of-
care 
24 weeks T2D Lower extremity 
peripheral arterial 
disease with 
symptom 
200 2021/12 
Ankle-brachial 
index 
Sphygmomanomet
er cuff 
Endothelial 
function 
FMD of brachial 
artery 
Muscle 
microvascular 
perfusion 
Contrast 
enhanced 
ultrasound 
Non-covered stent 
struts, late lumen 
loss/neointima 
thickness, minimal 
lumen area 
OCT NCT02621489 
(Rebuild) (*non-
covered stent 
struts) 
Effects on Re-endothelialisation With Bydureon 
Treatment Add on to Insulin Versus Insulin 
Alone, Both in Combination With Metformin in 
T2D Subjects 
Exenatide + metformin + 
Humulin vs metformin + 
Humulin 
12 weeks T2D Eligible for PCI with 
application of DES, 
due to ACS 
100 2021/12 
FFR, CFR, IMR Maximum 
hyperemia 
LV systolic & 
diastolic function 
Echocardiography 
Recovery from 
endothelial 
damage 
High resolution 
ultrasound 
Endothelial 
function: RHI 
EndoPAT 2000 NCT03824002 
(*RHI) 
Arterial Stiffness and Endothelial Function 
Indexes, Relationships With Clinical and 
Laboratory Variables in a Group of Diabetic 
Patients in Treatment With Dulaglutide: a Case-
control Study 
Dulaglutide vs no 
dulaglutide 
3 & 9 
months 
T2D Age 18-90 years 92 2018/04 
(awaited) 
Carotid-femoral 
PWV 
SphygmoCor 
Cardiac structure 
& function 
CMR: peak early 
diastolic strain 
rate, peak systolic 
strain, LV EF, LV 
volumes & mass 
NCT02043054 
(LYDIA) (*peak 
early diastolic 
strain rate) 
Impact of Liraglutide on Cardiac Function and 
Structure in Young Adults With T2D: an Open-
label, Randomised Active-comparator Trial 
Liraglutide vs sitagliptin 26 weeks T2D BMI ≥30 kg/m2 90 2017/09 
(awaited) 
Cardiac fibrosis CMR: T1 mapping 
Microvascular 
function 
CMR: myocardial 
perfusion reserve 
Heart rate 
variability 
24-hour monitor NCT02503943 
(BLOOD 
STUDY) 
What is the Effects of Incretin on the Blood 
Pressure and Lipid in Overweight or Obese 
Diabetes Patients With Masked Hypertension: 
Liraglutide + mitiglinide 
vs metformin + 
mitiglinide vs mitiglinide 
12 & 24 
weeks 
T2D Grade 1 
hypertension or 
masked 
90 2016/09 
(awaited) 
Atherosclerosis cIMT 
30 
Hemodynamics PWV Liraglutide Plus Mitiglinide Comparing Metformin 
Plus Mitiglinide or Mitiglinide Alone 
4, 8, 12, 
16, 20 & 
24 weeks 
hypertension, BMI 
24-32 kg/m2 or WC 
≥90 cm (male) & WC 
≥85 cm (female) 
Urinary sodium & 
microalbumin 
24-hour urine 
Urine albumin 
excretion rates 
24-hour urine NCT02690883 
(*) 
Effect of Exenatide on 24h-Urinary Albumin 
Excretion Rates in Patients With Diabetic 
Nephropathy: a 24-Week Study 
Exenatide + insulin 
glargine vs insulin 
glargine + lispro insulin 
24 weeks T2D BMI 18-35 kg/m2 90 2017/10 
(awaited) 
Cardiac function Echocardiography NCT02303730 Exenatide BID Compared With Insulin Glargine 
to Change Liver Fat Content in NAFLD Patients 
With T2D 
Exenatide vs insulin 
glargine 
24 weeks T2D NAFLD 76 2017/11 
(awaited) 
Endothelial 
dependent 
vasodilation 
FMD of brachial 
artery 
NCT00353834 
(*FMD) 
The Effect of Exenatide Compared to Lantus 
Insulin on Vascular Function Before and After a 
Meal Tolerance Test in Patients With T2D 
Exenatide vs insulin 
glargine 
3 months T2D Age 18-75 years 72 2010/09 
(awaited) 
Endothelium 
independent 
vasodilation 
Trinitroglycerin 
stimulated arterial 
dilation 
Arterial stiffness AI by PWA 
LV mass index, 
relative wall 
thickness 
Echocardiography NCT01435980 Study of Comparison the Treatment Effect 
Between Gastric Bypass and Exenatide in T2D 
Exenatide vs gastric 
bypass vs no 
intervention 
1 year T2D Age 18-60 years 60 2016/02 
(awaited) 
Left atrial EAT Multi detector 
cardiac CT 
NCT03856632 
(LEAF) (*left 
atrial EAT) 
Novel Medical Adjunctive Therapy to Catheter 
Ablation For AF 
Liraglutide + risk factor 
modification vs risk 
factor modification 
3 months 
(prior to 
ablation) 
± T2D Persistent AF, 
wishes to undergo 
catheter ablation 
procedure for AF 
60 2022/12 
Atrial function & 
size 
Echocardiography 1 year 
post-
ablation 
Microvascular 
blood volume 
(not stated) NCT03883412 
(ZQL007) 
(*microvascular 
blood volume) 
Effect of Exercise and/or Liraglutide on Vascular 
Dysfunction and Insulin Sensitivity in T2D 
Liraglutide + exercise vs 
liraglutide alone vs 
exercise alone 
16 weeks T2D Age 21-60 years 60 2022/03 
AIx, FMD, PWV 
Post ischemic flow 
velocity 
LV EF Echocardiography NCT02092597 
(SAFEGUARD) 
(*all listed 
measures) 
Safety Evaluation of Adverse Reactions in 
Diabetes 
Exenatide vs linagliptin 
vs gliclazide 
90 days T2D ACE inhibitors or 
ATII receptor 
blockers for ≥3 
months before 
enrollment 
42 2016/09 
(awaited) IMT (not stated) 
PWV 
Tubular function 
KIM-1 
PATIENTS WITHOUT DIABETES 
Outcome 
(Vascular, Renal) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Vascular function FMD of brachial 
artery 
NCT03101930 
(*FMD, U ACR) 
Cardiovascular Effects of GLP-1 Receptor 
Activation 
Liraglutide vs sitagliptin 
vs hypocaloric diet; all 
subjects Exendin (9-39) 
or placebo in crossover 
1 & 14 
weeks 
Prediabete
s 
BMI ≥30 kg/m2 160 2021/09 
U ACR Urine sample 14 weeks 
 
NCT indicates Clinicaltrials.gov registration number. * indicates primary outcome.  
 
Abbreviations: 2D, two-dimensional; ACS, acute coronary syndrome; ACE, angiotensin-converting enzyme; AF, atrial fibrillation; AI(x), augmentation index; ATII, angiotensin II; BID, bis in die (Latin: twice a day); BMI, 
body mass index; CFR, coronary flow reserve; (c)IMT, (carotid) intima-media thickness; CMR, cardiac magnetic resonance; CT, computer tomography; DES, drug-eluting stent; DPP-4, dipeptidyl peptidase-4; EAT, 
epicardial adipose tissue; EF, ejection fraction; EndoPAT, Peripheral Arterial Tone; FFR, fractional flow reserve; FMD, flow-mediated dilatation; GLP-1, glucagon-like peptide-1; IMR, index of microcirculatory resistance; 
KIM-1, kidney injury molecule-1; LV, left ventricular; NAFLD, non-alcoholic fatty liver disease; NT-proBNP, N-terminal pro-B-type natriuretic peptide; OCT, optical coherence tomography; PCI, percutaneous coronary 
intervention; PWA, pulse wave analysis; PWV, pulse wave velocity; RHI, reactive hyperemia index; SGLT2, sodium-glucose co-transporter 2; T2D, type 2 diabetes; U ACR, urinary albumin creatinine ratio; WC, waist 
circumference.  
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Supplemental Table 2c: Ongoing GLP-1RA mechanistic randomized placebo-controlled trials (metabolic, biomarkers, hepatic)  
PATIENTS WITH DIABETES 
Outcome (Metabolic, 
Biomarkers, Hepatic) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Gastric emptying of 
solids half-time 
Scintigraphy NCT03523273 
(*) 
Pilot Study of the Effect of Liraglutide 3.0 
mg on Weight Loss and Gastric Functions 
in Obesity 
Liraglutide vs 
placebo 
5 & 16 
weeks 
± T2D 
(metformin 
allowed) 
BMI ≥30 kg/m2 or 
≥27 kg/m2 with 
obesity-related co-
morbidity 
112 2022/12 
Biomarkers hs-CRP NCT03017352 
(MAG1C) 
Meal-time Administration of Exenatide for 
Glycaemic Control in T1D Cases: A 
Randomised, Placebo-controlled Trial 
Exenatide vs 
placebo 
6 
months 
T1D BMI >22 kg/m2 108 2019/06 
(awaited) 
Presence of NAFLD GGT, intra-hepatic fat, FGF21, 
whole body and visceral fat 
mass/fat-free mass, circulating 
lipids, ultrasound scan, 
fibroscan 
NCT01795248 The Impact of Liraglutide on Glucose 
Tolerance and the Risk of T2D in Women 
With Previous Gestational Diabetes 
Mellitus 
Liraglutide vs 
placebo 
52 & 
260 
weeks 
± Previous 
gestational 
diabetes 
mellitus 
± NAFLD 105 2020/08 
Cardio-metabolic risk 
measures 
Pro-collagen 3, hs-CRP, TNF-
α, adiponectin, PAI-1 
Gut microbiota (not stated) 
Hepatic lipid content MRS NCT03007329 
(EXENDA) 
(*hepatic lipid 
content) 
A 24 Week Monocentric Prospective 
Randomized, Placebo-controlled Trial to 
Evaluate Efficacy of Combination of 
Exenatide and Dapagliflozin Compared to 
Dapagliflozin and Placebo and Its Effects 
on Hepatic, Myocardial and Pancreatic Fat 
Distribution in Patients With Uncontrolled 
T2DM 
Exenatide + 
dapagliflozin vs 
dapagliflozin + 
placebo 
24 
weeks 
T2D BMI ≥25 kg/m2 90 2020/03 
Pancreatic lipid content 
Vasoactive hormones Plasma renin concentration & 
activity, angiotensin I & II, 
aldosterone, copeptin 
NCT04061200 
(EmpaSema) 
Renal Effects of Treatment With 
Empagliflozin Alone or in Combination 
With Semaglutide in Patients With T2D 
and Albuminuria - A Double Blinded, 
Randomised, Placebo Controlled, Parallel, 
Single Center Study 
Semaglutide vs 
placebo 
52 
weeks 
T2D U ACR >100 
mg/g, eGFR ≥30 
ml/min/1.73m2 
80 2021/08 
Inflammatory & 
endothelial biomarkers 
VWF, sVCAM-1, sICAM-1, E-
selectin, b-leucocytes, s-CRP, 
IL-6, osteopontin, TNF-α 
Hormones Leptin, cortisol, ghrelin NCT03361098 
(DECREASE) 
Combined Effects of SGLT2 Inhibition and 
GLP-1 Receptor Agonism on Food Intake, 
Body Weight and Central Satiety and 
Reward Circuits in Obese T2DM Patients 
Exenatide + 
dapagliflozin vs 
exenatide + 
placebo vs 
dapagliflozin + 
placebo vs 
double placebo 
16 
weeks 
T2D Obesity (BMI 30-
40 kg/m2) 
64 2020/01 
Microbiome Fecal samples 
Macrophage polarization Flow cytometry NCT02650206 
(*macrophage 
polarization) 
Effect of Liraglutide on Macrophage 
Polarization in Human Adipose Tissue and 
Peripheral Blood 
Liraglutide vs 
placebo 
30 
months 
T2D BMI 25-42 kg/m2 56 2018/08 
(awaited) Inflammation (localized) rtPCR in adipose tissue & 
blood macrophages: IL-6, IL-8, 
TNF-α, MCP-1, cell surface 
markers, adiponectin 
Inflammation (systemic) Plasma: IL-6, hs-CRP, cell 
surface markers, adiponectin 
Metabolomics profile Fold changes NCT04057261 
(Lirabolic) 
(*metabolomic
s profile) 
Effect of Liraglutide on the Metabolic 
Profile in Patients With T2D and CV 
Disease 
Liraglutide vs 
placebo 
3 
months 
T2D Existing CV 
disease 
50 2021/11 
Gut microbiome 
composition 
16S rRNA targeted gene 
sequencing of feces 
Inflammasome analyses CRP, IL-6, IL-1β, TNF-α 
Circulation inflammatory 
cell composition 
Flow cytometry analyses 
32 
CD34+ EPCs Number, function & gene 
expression of CD34+ EPCs 
NCT04126603 
(*) 
Impact of Semaglutide (Long Acting GLP-1 
Agonist) on Peripheral Blood Derived 
CD34+ EPCs and Subcutaneous Fat 
Derived MSCs in T2D Subjects 
Semaglutide vs 
placebo 
24 
weeks 
T2D BMI 25-45 kg/m2, 
additional CV 
disease risk factor 
40 2021/11 
mRNA Gene expression of 
subcutaneous adipose cell 
PATIENTS WITHOUT DIABETES 
Outcome (Metabolic, 
Biomarkers, Hepatic) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Visceral & subcutaneous 
abdominal fat 
Abdominal CT NCT04019197 
(*visceral & 
subcutaneous 
abdominal fat) 
Effects of GLP-1RAs on Cardiometabolic 
Alterations in HIV-associated 
Lipohypertrophy 
Semaglutide vs 
placebo 
56 
weeks 
No diabetes HIV-1 infection & 
lipohypertrophy vs 
overweight/obese 
controls without 
HIV 
208 2024/03 
Liver fat 
Inflammation Pro-inflammatory markers 
Gut hormones GIP, GLP-1 
Gut integrity I-FABP, zonulin-1, LPS 
Cytokines Adipokines 
Hyperandrogenism FAI NCT03480022 
(SAXAPCOS) 
(*) 
A Randomized Placebo-controlled Double 
Blind Trial of Liraglutide 3 mg [Saxenda] 
on Weight, Body Composition, Hormonal 
and Metabolic Parameters in Obese 
Women With PCOS 
Liraglutide vs 
placebo 
30 
weeks 
No T1D, no 
T2D 
PCOS, BMI ≥30 
kg/m2 or BMI ≥27 
kg/m2 with ≥1 
obesity-associated 
co-morbidity 
92 2020/11 
Liver fat content MRI-PDFF NCT03987451 
(*liver 
stiffness) 
Investigation of Efficacy and Safety of 
Semaglutide s.c. Once-weekly Versus 
Placebo in Subjects With NASH and 
Compensated Liver Cirrhosis 
Semaglutide vs 
placebo 
48 
weeks 
Not stated NASH 69 2021/02 
Liver stiffness MRE 
NCT03357380 
(*liver 
stiffness) 
A Trial Investigating the Effect of 
Subcutaneous Semaglutide on Liver 
Fibrosis Assessed by Magnetic 
Resonance Elastography in Subjects With 
NAFLD 
Semaglutide vs 
placebo 
24, 48 
(*) & 72 
weeks 
Not stated 
(no T1D) 
NAFLD 67 2020/03 
Relative liver fat content 
& absolute liver fat 
volume 
MRI-PDFF 
Inflammation hs-CRP NCT02664441 
(ECHO) 
GLP-1 Agonist Effects on Energy Balance 
in Hypothalamic Obesity 
Exenatide vs 
placebo 
36 
weeks 
Not stated 
(no insulin-
treated 
diabetes, no 
HbA1c 
≥10%) 
Craniopharyngiom
a or another tumor 
in hypothalamic 
area, 
hypothalamic 
obesity, age 10-25 
48 2020/03 
Inflammation CRP, IL-6, MCP-1 NCT03466021 Effects of GLP-1RA Treatment on 
Pulmonary Function and Quality of Life in 
Obese Patients With COPD 
Liraglutide vs 
placebo 
44 
weeks 
No diabetes COPD, BMI >27 
kg/m2 
40 2020/12 
 
NCT indicates Clinicaltrials.gov registration number. * indicates primary outcome.  
 
Abbreviations: 16S, sedimentation rate (Svedberg units); BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; CT, computed tomography; CV, cardiovascular; eGFR, 
estimated glomerular filtration rate; EPCs, endothelial progenitor cells; FAI, free androgen index; FGF21, fibroblast growth factor 21; GGT, gamma-glutamyl transferase; GIP, gastric inhibitory polypeptide; GLP-1(RA), 
glucagon-like peptide-1 (receptor agonist); HbA1c, glycated hemoglobin; HF, heart failure; HIV, human immunodeficiency virus; hs-CRP, high sensitivity C-reactive protein; HTN, hypertension; I-FABP, intestinal fatty-
acid binding protein; IL, interleukin; LPS, lipopolysaccharides; MCP-1, Monocyte Chemoattractant Protein-1; MRE, magnetic resonance elastography; MRI-PDFF, MRI-proton density fat fraction; mRNA, messenger 
ribonucleic acid; MRS, magnetic resonance spectroscopy; MSC, mesenchymal stromal cell; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PAI-1, plasminogen activator inhibitor-1; 
PCOS, polycystic ovarian syndrome; rRNA, ribosomal ribonucleic acid; rtPCR, reverse transcription polymerase chain reaction; s.c., subcutaneous; s-CRP, serum C-reactive protein; SGLT2, sodium-glucose co-
transporter 2; sICAM-1, soluble intercellular adhesion molecule-1; sVCAM-1, soluble vascular cell adhesion molecule-1; T1D, type 1 diabetes; T2D(M), type 2 diabetes (mellitus); TNF, tumor necrosis factor; U ACR, 
urinary albumin creatinine ratio; von Willebrand factor.  
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Supplemental Table 2d: Ongoing GLP-1RA mechanistic randomized non-placebo-controlled trials (metabolic, biomarkers, hepatic)  
PATIENTS WITH DIABETES 
Outcome (Metabolic, 
Biomarkers, 
Hepatic) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs Comparator Duration Glycemic 
Status 
Population N Date 
Complete 
Circulating EPCs Flow cytometry NCT04146155 
(LEADPACE 
STUDY) 
Liraglutide Efficacy and Action on T2D With 
Peripheral Atherosclerotic intErmittent 
Claudication: a Prospective, 24-week, 
Multicenter, Randomized, Controlled Clinical 
Study 
Liraglutide + standard-of-
care vs standard-of-care 
24 
weeks 
T2D Lower 
extremity 
peripheral 
arterial 
disease 
with 
symptom 
200 2021/12 
Endothelial 
activation 
E-Selectin, VCAM-1, 
ICAM-1, nitrotyrosine 
NCT02621489 
(Rebuild) 
Effects on Re-endothelialisation With 
Bydureon Treatment Add on to Insulin Versus 
Insulin Alone, Both in Combination With 
Metformin in T2D Subjects 
Exenatide + metformin + 
Humulin vs metformin + 
Humulin 
12 
weeks 
T2D Eligible for 
PCI with 
application 
of DES, 
due to 
ACS 
100 2021/12 
Inflammation CRP, IL-1β, IL-6, IL-8 
Matrix remodeling MMP-2, MMP-9 
Circulating EPCs (not stated) 
Gene expression Transcription factors of 
sirtuins & NOS 
Liver histology Liver puncture biopsy NCT03648554 
(REALIST) 
(*histological 
improvement) 
A Multicentre Controlled and Randomized 
Study Assessing the Effect of Dulaglutide add-
on to Dietary Reinforcement Versus Dietary 
Reinforcement Alone in Patients With T2D and 
Carriers of a NASH 
Dulaglutide vs reinforced 
dietary monitoring 
52 
weeks 
T2D NASH 93 2024/03 
Fibrosis Kleiner score, Fibrotest 
score, hyaluronic acid 
serum rate 
Endothelial function 
biomarkers 
sICAM-3, e-Selectin, 
Thrombomodulin, CRP, 
sICAM, sVCAM, SAA, 
EPCs, SDF-1, GLP-1 
NCT02043054 
(LYDIA) 
Impact of Liraglutide on Cardiac Function and 
Structure in Young Adults With T2D: an Open-
label, Randomised Active-comparator Trial 
Liraglutide vs sitagliptin 26 
weeks 
T2D BMI ≥30 
kg/m2 
90 2017/09 
(awaited) 
Liver fat content MRS NCT02303730 
(*) 
Exenatide BID Compared With Insulin 
Glargine to Change Liver Fat Content in 
NAFLD Patients With T2D 
Exenatide vs insulin 
glargine 
24 
weeks 
T2D NAFLD 76 2017/11 
(awaited) 
Endothelial 
activation 
ICAM, VCAM, 
endothelin 1 
NCT00353834 The Effect of Exenatide Compared to Lantus 
Insulin on Vascular Function Before and After 
a Meal Tolerance Test in Patients With T2D 
Exenatide vs insulin 
glargine 
3 
months 
T2D Age 18-75 
years 
72 2010/09 
(awaited) 
Inflammation CRP, TNF-α, IL-6 
Fibrinolysis PAI-1 protein, PAI-1 
activity 
Oxidative stress FOX2 
Biomarkers hs-CRP, adiponectin, 
TNF-α 
NCT01435980 Study of Comparison the Treatment Effect 
Between Gastric Bypass and Exenatide in T2D 
Exenatide vs gastric 
bypass vs no intervention 
1 year T2D Age 18-60 
years 
60 2016/02 
(awaited) 
Liver fat MRI-PDFF NCT03590626 
(D-LIFT) (*liver 
fat) 
Effect of Dulaglutide on Liver Fat in Patients 
With T2D and NAFLD: A Randomized 
Controlled Trial 
Dulaglutide vs standard 
treatment 
24 
weeks 
T2D NAFLD, 
hepatic 
steatosis 
60 2020/03 
LSM, CAP Fibroscan 
Cardiometabolic 
biomarkers 
IL-1, TNF-α, hs-CRP, 
leptin, adiponectin, 
homocysteine, fibrosis 
biomarkers 
Inflammation CRP, IL-6 NCT03856632 
(LEAF) 
Novel Medical Adjunctive Therapy to Catheter 
Ablation For AF 
Liraglutide + risk factor 
modification vs risk factor 
modification 
1 year 
post-
ablation 
± T2D Persistent 
AF, 
wishes to 
undergo 
catheter 
ablation 
procedure 
for AF 
60 2022/12 
34 
Liver fat content Liver MRS NCT03881995 
(Lixibrain01) 
Effect of Insulin Glargine and Lixisenatide 
Versus Insulin Glargine on Brain Insulin 
Sensitivity in Patients With T2D 
Lixisenatide + insulin 
glargine vs insulin glargine 
12 
weeks 
T2D BMI 25-45 
kg/m2 
40 2021/03 
PATIENTS WITHOUT DIABETES 
Outcome (Metabolic, 
Biomarkers, 
Hepatic) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs Comparator Duration Glycemic 
Status 
Population N Date 
Complete 
Genetic 
polymorphisms 
(not stated) NCT02488057 Improving Beta Cell Function in Mexican 
American Women With Prediabetes 
Liraglutide + weight loss 
vs diet-induced weight 
loss 
3 
months 
Prediabetes Mexican 
American 
women 
360 2019/03 
(awaited) 
Fatty liver Ultrasonography NCT03352869 Research of Exenatide for Management of 
Reproductive and Metabolic Dysfunction in 
Overweight/Obese PCOS Patients With IGR 
Exenatide vs metformin vs 
exenatide + metformin 
12 
weeks 
IGR PCOS 183 2018/07 
(awaited) Hyperandrogenism FAI 
NCT03383068 
(PCOS) 
(*pregnant rate) 
Research of Intensive Metabolic Intervention 
Before Pregnancy in PCOS 
Exenatide vs orlistat vs 
acarbose vs control 
(metformin-effective) 
24 
weeks 
Not stated PCOS 160 2020/06 
Pregnant rate Pregnant rate 
Biomarker PAI-1 NCT03101930 
(*) 
Cardiovascular Effects of GLP-1 Receptor 
Activation 
Liraglutide vs sitagliptin vs 
hypocaloric diet; all 
subjects Exendin (9-39) or 
placebo in crossover 
14 
weeks 
Prediabetes BMI ≥30 
kg/m2 
160 2021/09 
Inflammatory 
markers 
IL-6, TNF NCT03671733 Effects of GLP-1RAs on Weight and Metabolic 
Indicators in Obese Patients 
Liraglutide vs exenatide vs 
exenatide microspheres 
for injection 
3 
months 
Not stated (No 
acute 
complications 
of diabetes) 
BMI ≥28 
kg/m2 or 
abdominal 
obesity 
150 2020/09 
Hyperandrogenism Androgen profiles, free 
androgen index 
NCT02635386 Comparison of Dapagliflozin and Once-weekly 
Exenatide, Co-administered or Alone, 
Dapagliflozin/Glucophage Extended Release 
and Phentermine/Topiramate Extended 
Release on Metabolic Profiles and Body 
Composition in Obese PCOS Women 
Exenatide vs dapagliflozin 
vs exenatide + 
dapagliflozin vs 
dapagliflozin + 
Glucophage vs 
phentermine + topiramate 
24 
weeks 
No T1D, no 
T2D 
Women, 
age 18-45 
years, 
PCOS, 
BMI 
>30<45 
kg/m2 
135 2020/09 
Biomarker, 
hormones 
Lp(a), ApoA1, ApoB, 
FFA, hs-CRP, 
testosterone, DHEAS, 
LH, FSH 
NCT04029272 Study on the Effect of Metformin vs Metformin 
Combined With GLP-1RA (Exenatide) on 
Overweight/Obese Patients With PCOS 
Exenatide + metformin vs 
metformin 
12 
weeks 
No T1D, no 
T2D 
PCOS, 
BMI ≥25 
kg/m2 
80 2020/12 
Acne severity Acne severity score 
Ovarian volume, 
follicular number 
(not stated) 
Gut microbiota 
composition 
16S rRNA 
pyrosequencing 
NCT03986008 
(*gut microbiota 
composition) 
Effects of Benaglutide on Weight and Gut 
Microbiota in Obese Patients 
Benaglutide vs liraglutide 3 
months 
Not stated (No 
acute 
complications 
of diabetes) 
BMI ≥28 
kg/m2 or 
abdominal 
obesity 
60 2021/05 
Inflammatory 
markers 
IL-10, TNF 
Hepatic fat fraction MRI-PDFF (calculated 
via Dixon method) 
NCT03919929 
(TEAL) (*) 
Treating PCOS With Exenatide vs Active 
Lifestyle Intervention 
Exenatide vs diet 
intervention 
12 
weeks 
No diabetes PCOS 50 2024/07 
 
NCT indicates Clinicaltrials.gov registration number. * indicates primary outcome.  
 
Abbreviations: 16S, sedimentation rate (Svedberg units); ACS, acute coronary syndrome; AF, atrial fibrillation; Apo, apolipoprotein; BID, bis in die (Latin: twice a day); BMI, body mass index; CAP, controlled attenuation 
parameter; CRP, C-reactive protein; DES, drug-eluting stent; DHEAS, dehydroepiandrosterone sulfate; DPP-4, dipeptidyl peptidase-4; EPCs, endothelial progenitor cells; FAI, free androgen index; FFA, free fatty acid; 
FOX, ferrous oxidation-xylenol orange; FSH, follicle-stimulating hormone; GLP-1(RA), glucagon-like peptide-1 (receptor agonist); hs-CRP, high sensitivity C-reactive protein; IGR, impaired glucose regulation; IL, 
interleukin; LH, luteinizing hormone; Lp(a), lipoprotein(a); LSM, liver stiffness measurement; MMP, matrix metalloproteinase; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NAFLD, non-
alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NOS, nitric oxide synthase; PAI-1, plasminogen activator inhibitor-1; PCI, percutaneous coronary intervention; PCOS, polycystic ovarian syndrome; 
PDFF, proton density fat fraction; rRNA, ribosomal ribonucleic acid; SAA, serum amyloid A; SDF-1, stromal cell-derived factor-1; (s)ICAM, (soluble) intercellular adhesion molecule; (s)VCAM, (soluble) vascular cell 
adhesion molecule; T1D, type 1 diabetes; T2D, type 2 diabetes; TNF, tumor necrosis factor.  
35 
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Supplemental Table 2e: Ongoing GLP-1RA mechanistic randomized placebo-controlled trials (respiratory, symptoms, fitness)  
PATIENTS WITH DIABETES 
Outcome 
(Respiratory, 
Symptoms, 
Fitness) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs Comparator Duration Glycemic 
Status 
Population N Date 
Complete 
Quality of life SF-36 NCT01795248 The Impact of Liraglutide on Glucose Tolerance 
and the Risk of T2D in Women With Previous 
Gestational Diabetes Mellitus 
Liraglutide vs placebo 52 & 
260 
weeks 
± Previous 
gestational 
diabetes 
mellitus 
± NAFLD 105 2020/08 
WHO Well Being 
Index 
NCT03007329 
(EXENDA) 
A 24 Week Monocentric Prospective Randomized, 
Placebo-controlled Trial to Evaluate Efficacy of 
Combination of Exenatide and Dapagliflozin 
Compared to Dapagliflozin and Placebo and Its 
Effects on Hepatic, Myocardial and Pancreatic Fat 
Distribution in Patients With Uncontrolled T2DM 
Exenatide + dapagliflozin 
vs dapagliflozin + placebo 
24 
weeks 
T2D BMI ≥25 kg/m2 90 2020/03 
Energy 
expenditure 
Indirect 
calorimetry 
NCT03361098 
(DECREASE) 
Combined Effects of SGLT2 Inhibition and GLP-1 
Receptor Agonism on Food Intake, Body Weight 
and Central Satiety and Reward Circuits in Obese 
T2DM Patients 
Exenatide + dapagliflozin 
vs exenatide + placebo vs 
dapagliflozin + placebo vs 
double placebo 
10 days 
& 16 
weeks 
T2D Obesity (BMI 30-
40 kg/m2) 
64 2020/01 
NCT04057261 
(Lirabolic) 
Effect of Liraglutide on the Metabolic Profile in 
Patients With T2D and CV Disease 
Liraglutide vs placebo 3 
months 
T2D Existing CV 
disease 
50 2021/11 
Respiratory 
exchange ratio 
PATIENTS WITHOUT DIABETES 
Outcome 
(Respiratory, 
Symptoms, 
Fitness) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs Comparator Duration Glycemic 
Status 
Population N Date 
Complete 
Smoking 
cessation 
Point prevalence 
abstinence rate 
NCT03204396 
(SKIP) (*) 
Smoking Cessation Facilitated by GLP-1 
Analogues - a Randomized, Double-blind, 
Placebo-controlled Trial 
Dulaglutide vs placebo 12 
weeks 
Not stated Daily smokers who 
are willing to quit 
256 2020/03 
Energy 
expenditure 
Indirect 
calorimetry 
NCT04019197 Effects of GLP-1RAs on Cardiometabolic 
Alterations in HIV-associated Lipohypertrophy 
Semaglutide vs placebo 56 
weeks 
No diabetes HIV-1 infection & 
lipohypertrophy vs 
overweight/obese 
controls without 
HIV 
208 2024/03 
Doubly labeled 
water analysis 
NCT02664441 
(ECHO) 
GLP-1 Agonist Effects on Energy Balance in 
Hypothalamic Obesity 
Exenatide vs placebo 36 
weeks 
Not stated 
(no insulin-
treated 
diabetes, no 
HbA1c 
≥10%) 
Craniopharyngiom
a or another tumor 
in hypothalamic 
area, 
hypothalamic 
obesity, age 10-25 
48 2020/03 
Energy intake ASA24-Kids 
Energy 
expenditure 
Pedometer, 
indirect calorimetry 
NCT02860923 
(CRANIOEXE) 
Multicentre Double-blind Randomized Clinical Trial 
Assessing Efficacy and Safety of Exenatide in the 
Treatment of Hypothalamic Obesity After 
Craniopharyngioma Therapy 
Exenatide vs placebo 6 
months 
Not stated 
(no T1D, no 
insulin-
treated T2D)  
Treated 
craniopharyngiom
a, BMI >30 kg/m2 
42 2018/09 
(awaited) 
Dyspnea symptom TDI NCT03466021 
(*TDI) 
Effects of GLP-1RA Treatment on Pulmonary 
Function and Quality of Life in Obese Patients 
With COPD 
Liraglutide vs placebo 40 
weeks 
No T1D, no 
T2D 
COPD, BMI >27 
kg/m2 
40 2020/12 
Quality of life CAT-score, SF-36 44 
weeks Walking distance 6 minute walk test 
DLCO, 
FEV1/FVC, RV 
Spirometry 
AHI, ODI,  Sleep study 
37 
Epworth score 
Lung inflammation FDG-PET/CT 
 
NCT indicates Clinicaltrials.gov registration number. * indicates primary outcome.  
 
Abbreviations: AHI, Apnea-Hypopnea Index; ASA24-Kids Automated Self-Administered 24-Hour Dietary Recall for Children; BMI, body mass index; CAT-score, chronic obstructive pulmonary disease assessment test; 
COPD, chronic obstructive pulmonary disease; CV, cardiovascular; DLCO, diffusion capacity of the lung for carbon monoxide; FDG-PET/CT, fluorodeoxyglucose-positron emission tomography/computed tomography; 
FEV1, forced expiratory volume in one second; FVC, forced vital capacity; GLP-1(RA), glucagon-like peptide-1 (receptor agonist); HbA1c, glycated hemoglobin; HIV, human immunodeficiency virus; NAFLD, non-
alcoholic fatty liver disease; ODI, Oxygen Desaturation Index; RV, residual volume; SF-36, 36-item short form health survey; SGLT2, sodium-glucose co-transporter 2; T1D, type 1 diabetes; T2D(M), type 2 diabetes 
(mellitus); TDI, Transition Dyspnea Index; WHO, World Health Organization.  
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Supplemental Table 2f: Ongoing GLP-1RA mechanistic randomized non-placebo-controlled trials (respiratory, symptoms, fitness)  
PATIENTS WITH DIABETES 
Outcome 
(Respiratory, 
Symptoms, 
Fitness) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
Comparator 
Duration Glycemic Status Population N Date 
Complete 
Quality of life SF-36 score NCT02432976 
(ExeQOL) (*) 
Impact of Intravenous Exenatide Versus Insulin 
on Quality of Life in Cardiac Surgery Patients: an 
Ancillary Study of the ExSTRESS Phase II/III 
Clinical Trial 
Exenatide vs insulin 
lispro human analog 
3 
months 
Non-insulin requiring 
T2D & non-diabetic 
Planned 
CABG surgery 
544 2017/12 
(awaited) 
Epworth score, 
STOP Bang 
questionnaire 
Questionnaires NCT03036800 
(STRIVE) 
Effectiveness and Cost of Integrating a Protocol 
with Use of Liraglutide 3.0 mg into an Obesity 
Service 
Liraglutide + standard 
care vs standard care 
52 & 
104 
weeks 
± T2D or prediabetes or 
hypertension or 
obstructive sleep apnea 
BMI ≥35 
kg/m2, referred 
to Tier 3 
weight 
management 
service 
384 2021/12 
AHI, ODI, CPAP 
pressures 
Sleep study 
Quality of life QOLOD rating 
scale 
questionnaire 
NCT03648554 
(REALIST) 
(*histological 
improvement) 
A Multicentre Controlled and Randomized Study 
Assessing the Effect of Dulaglutide add-on to 
Dietary Reinforcement Versus Dietary 
Reinforcement Alone in Patients With T2D and 
Carriers of a NASH 
Dulaglutide vs 
reinforced dietary 
monitoring 
52 
weeks 
T2D NASH 93 2024/03 
EQ-5D, hospital 
anxiety & 
depression 
score 
NCT02043054 
(LYDIA) 
Impact of Liraglutide on Cardiac Function and 
Structure in Young Adults With T2D: an Open-
label, Randomised Active-comparator Trial 
Liraglutide vs 
sitagliptin 
26 
weeks 
T2D BMI ≥30 kg/m2 90 2017/09 
(awaited) 
Cardio-respiratory 
fitness, physical 
activity 
Graded VO2 
max test, 
accelerometer, 
inclinometer 
 
NCT indicates Clinicaltrials.gov registration number. * indicates primary outcome.  
 
Abbreviations: AHI, Apnea-Hypopnea Index; BMI, body mass index; CABG, coronary artery bypass graft; CPAP, continuous positive airway pressure; EQ-5D, EuroQol-5D; GLP-1RA, glucagon-like peptide-1 receptor 
agonist; NASH, non-alcoholic steatohepatitis; ODI, Oxygen Desaturation Index; QOLOD, Quality of Life, Obesity and Dietetics; SF-36, 36-item short form health survey; STOP Bang, Snoring?, Tired?, Observed?, 
Pressure?, Body Mass Index more than 35 kg/m2?, Age older than 50?, Neck size large?, Gender = Male?; T2D, type 2 diabetes; VO2, peak oxygen consumption.  
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Supplemental Table 2g: Ongoing GLP-1RA mechanistic randomized placebo-controlled trials (musculoskeletal)  
PATIENTS WITH DIABETES 
Outcome 
(Musculoskeletal) 
Technique Trial Registration Full Official Title GLP-1RA vs 
Comparator 
Duration Glycemic Status Population N Date 
Complete 
KOOS pain 
subscale 
KOOS NCT02905864 
(LOSEIT) (*) 
Effect of Liraglutide on Body Weight and Pain in 
Overweight or Obese Patients With Knee OA: A 
Randomised, Double Blind, Placebo-controlled, Parallel 
Group, Single-centre Trial 
Liraglutide 
vs placebo 
52 
weeks 
± T2D (only MF 
allowed) 
Knee OA, 
BMI ≥27 
kg/m2 
150 2019/03 
(awaited) 
Advanced 
glycation end 
products in skin 
Skin auto 
fluorescence 
NCT02910570 (*) The Association Between Weight Loss With Subsequent 
Maintenance Using Liraglutide and Changes in Skin 
Autofluorescence in Overweight or Obese Patients With 
Knee OA - a Substudy to "Effect of Liraglutide on Body 
Weight and Pain in Overweight or Obese Patients With 
Knee OA: A Randomised, Double Blind, Placebo-
controlled, Parallel Group, Single-centre Trial (Substudy of 
NCT02905864) 
Liraglutide 
vs placebo 
52 
weeks 
± T2D (only MF 
allowed) 
Knee OA, 
BMI ≥27 
kg/m2 
150 2019/03 
(awaited) 
Collagen II 
degradation 
fragment α-C2M 
Blood sampling NCT02928614 
(BIO-LOSEIT-II) 
(*) 
Biomarkers in Obese Patients With Knee OA Following 
Long-term Weight Maintenance (Substudy of 
NCT02905864) 
Liraglutide 
vs placebo 
52 
weeks 
± T2D (only MF 
allowed) 
Knee OA, 
BMI ≥27 
kg/m2 
150 2019/03 
(awaited) 
Knee-joint 
inflammation 
DCE-MRI NCT02928679 
(IM-LOSEIT-II) (*) 
Multi-parametric Imaging of the Knee in Obese Patients 
With Knee OA Following Liraglutide Treatment, 
Investigating the Impact on Inflammation (Substudy of 
NCT02905864) 
Liraglutide 
vs placebo 
52 
weeks 
± T2D (only MF 
allowed) 
Knee OA, 
BMI ≥27 
kg/m2 
150 2019/03 
(awaited) 
Knee-joint 
inflammation 
Grey-scale 
ultrasound 
NCT02931383 
(US-LOSEIT-II) (*) 
Ultrasound of the Knee in Obese Patients With Knee OA 
Following Liraglutide Treatment, Investigating the Impact 
on Inflammation (Substudy of NCT02905864) 
Liraglutide 
vs placebo 
52 
weeks 
± T2D (only MF 
allowed) 
Knee OA, 
BMI ≥27 
kg/m2 
150 2019/03 
(awaited) 
Body composition: 
bone mineral 
density, lean 
mass, fat mass 
DEXA NCT03017352 
(MAG1C) 
Meal-time Administration of Exenatide for Glycaemic 
Control in T1D Cases: A Randomised, Placebo-controlled 
Trial 
Exenatide vs 
placebo 
6 
months 
T1D BMI >22 
kg/m2 
108 2019/06 
(awaited) 
Body composition Bioelectrical 
impedance analysis 
NCT03361098 
(DECREASE) 
Combined Effects of SGLT2 Inhibition and GLP-1 
Receptor Agonism on Food Intake, Body Weight and 
Central Satiety and Reward Circuits in Obese T2DM 
Patients 
Exenatide + 
dapagliflozin 
vs exenatide 
+ placebo vs 
dapagliflozin 
+ placebo vs 
double 
placebo 
10 days 
& 16 
weeks 
T2D Obesity 
(BMI 30-40 
kg/m2) 
64 2020/01 
Bone resorption 
markers 
Serum: CTX-I, bone 
ALP, osteocalcin, 
P1NP 
NCT02473809 
(LIRABONE) 
(*CTX-I) 
The Effect of Liraglutide on Bone Turnover, Bone Mass 
and Bone Cell Function 
Liraglutide 
vs placebo 
Days 0, 
7, 28, 90 
& 180 
T2D Exclude 
body weight 
>140 kg, 
exclude 
osteoporosis 
60 2017/10 
(awaited) 
Bone mineral 
density 
DEXA Days 0, 
90 & 
180 Bone structure QCT, HRpQCT 
Body composition DEXA NCT02351232 
(Lira Pump) 
The Effects of Liraglutide in Patients With Insulin Pump 
Treated T1D: A Randomized Placebo-Controlled Trial 
Liraglutide 
vs placebo 
6 
months 
T1D (insulin pump 
≥1 year) 
BMI >25 
kg/m2 
44 2016/10 
(awaited) 
PATIENTS WITHOUT DIABETES 
Outcome 
(Musculoskeletal) 
Technique Trial Registration Full Official Title GLP-1RA vs 
Comparator 
Duration Glycemic Status Population N Date 
Complete 
Visceral adipose 
tissue mass 
MRI NCT03038620 (*) Impact of Liraglutide 3.0 on Body Fat Distribution, Visceral 
Adiposity, and Cardiometabolic Risk Markers In 
Overweight and Obese Adults at High Risk for 
Cardiovascular Disease 
Liraglutide 
vs placebo 
40 
weeks 
No T1D, no T2D BMI ≥30 
kg/m2 or ≥27 
kg/m2 with 
metabolic 
356 2020/12 
40 
syndrome 
Body fat Whole-body DEXA NCT04019197 (*) Effects of GLP-1RAs on Cardiometabolic Alterations in 
HIV-associated Lipohypertrophy 
Semaglutide 
vs placebo 
56 
weeks 
No diabetes HIV-1 
infection & 
lipohypertro
phy vs 
overweight/o
bese 
controls 
without HIV 
208 2024/03 
Central fat 
distribution & total 
fat mass 
DEXA NCT03480022 
(SAXAPCOS) 
A Randomized Placebo-controlled Double Blind Trial of 
Liraglutide 3 mg [Saxenda] on Weight, Body Composition, 
Hormonal and Metabolic Parameters in Obese Women 
With PCOS 
Liraglutide 
vs placebo 
30 
weeks 
No T1D, no T2D PCOS, BMI 
≥30 kg/m2 or 
BMI ≥27 
kg/m2 with 
≥1 obesity-
associated 
co-morbidity 
92 2020/11 
Bone mineral 
density 
DEXA NCT03341429 
(BARIOPTIMISE) 
A Double-blinded, Randomised, Placebo-controlled Trial of 
Liraglutide 3.0 mg in Patients With Poor Weight-loss and a 
Suboptimal GLP-1 Response Following Bariatric Surgery 
Liraglutide 
vs placebo 
24 
weeks 
Not stated (no 
diabetic 
gastroparesis) 
Post-
bariatric 
surgery 
70 2019/11 
(awaited) 
Body composition, 
body fat mass 
DEXA NCT02664441 
(ECHO) 
GLP-1 Agonist Effects on Energy Balance in Hypothalamic 
Obesity 
Exenatide vs 
placebo 
36 
weeks 
Not stated (no 
insulin-treated 
diabetes, no 
HbA1c ≥10%) 
Craniophary
ngioma or 
another 
tumor in 
hypothalami
c area, 
hypothalami
c obesity, 
age 10-25 
years 
48 2020/03 
Body composition DEXA NCT02860923 
(CRANIOEXE) 
Multicentre Double-blind Randomized Clinical Trial 
Assessing Efficacy and Safety of Exenatide in the 
Treatment of Hypothalamic Obesity After 
Craniopharyngioma Therapy 
Exenatide vs 
placebo 
6 
months 
Not stated (no 
T1D, no insulin-
treated T2D)  
Treated 
craniophary
ngioma, BMI 
>30 kg/m2 
42 2018/09 
(awaited) 
 
NCT indicates Clinicaltrials.gov registration number. * indicates primary outcome.  
 
Abbreviations: ALP, alkaline phosphatase; BMI, body mass index; C2M, type II collagen; CTX-I, collagen I cross-linked C-terminal telopeptide; DCE, dynamic contrast enhanced; DEXA, dual energy X-ray 
absorptiometry; GLP-1(RA), glucagon-like peptide-1 (receptor agonist); HIV, human immunodeficiency virus; (HRp)QCT, (high-resolution peripheral) quantitative computed tomography; KOOS, Knee injury and 
Osteoarthritis Outcome Score; MF, metformin; MRI, magnetic resonance imaging; OA, osteoarthritis; P1NP, procollagen type I N-terminal propeptide; PCOS, polycystic ovarian syndrome; SGLT2, sodium-glucose co-
transporter 2; T1D, type 1 diabetes; T2D(M), type 2 diabetes (mellitus).  
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Supplemental Table 2h: Ongoing GLP-1RA mechanistic randomized non-placebo-controlled trials (musculoskeletal)  
PATIENTS WITH DIABETES 
Outcome 
(Musculoskeletal) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Visceral DEXA NCT03087032 
(LiraGooD) 
Efficacy and Safety of Liraglutide-bolus (Liraglutide Plus Prandial Insulin) 
Versus Glargine-bolus Therapy in Overweight / Obese Patients With 
Uncontrolled T2D - A Multicenter Randomized Controlled Study 
Liraglutide + 
insulin lispro vs 
insulin glargine + 
insulin lispro 
24 
weeks 
T2D BMI ≥24 
kg/m2 
140 2020/12 
Body composition 
(fat mass) 
DEXA NCT03648554 
(REALIST) 
A Multicentre Controlled and Randomized Study Assessing the Effect of 
Dulaglutide add-on to Dietary Reinforcement Versus Dietary Reinforcement 
Alone in Patients With T2D and Carriers of a NASH 
Dulaglutide vs 
reinforced dietary 
monitoring 
52 
weeks 
T2D NASH 93 2024/03 
Subcutaneous, 
visceral & hepatic 
adiposity volumes 
MRI NCT02043054 
(LYDIA) 
Impact of Liraglutide on Cardiac Function and Structure in Young Adults With 
T2D: an Open-label, Randomised Active-comparator Trial 
Liraglutide vs 
sitagliptin 
26 
weeks 
T2D BMI ≥30 
kg/m2 
90 2017/09 
(awaited) 
Intra-abdominal 
visceral fat, 
abdominal 
subcutaneous fat 
MRI NCT02303730 Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content 
in NAFLD Patients With T2D 
Exenatide vs 
insulin glargine 
24 
weeks 
T2D NAFLD 76 2017/11 
(awaited) 
Total adipose 
tissue, visceral 
adipose tissue, 
subcutaneous 
adipose tissue 
Whole 
body MRI 
NCT03881995 
(Lixibrain01) 
Effect of Insulin Glargine and Lixisenatide Versus Insulin Glargine on Brain 
Insulin Sensitivity in Patients With T2D 
Lixisenatide + 
insulin glargine vs 
insulin glargine 
12 
weeks 
T2D BMI 25-45 
kg/m2 
40 2021/03 
Body fat, lean 
body mass 
BIA 
PATIENTS WITHOUT DIABETES 
Outcome 
(Musculoskeletal) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
Comparator 
Duration Glycemic 
Status 
Population N Date 
Complete 
Total fat mass & 
fat distribution 
DEXA NCT02635386 Comparison of Dapagliflozin and Once-weekly Exenatide, Co-administered 
or Alone, Dapagliflozin/Glucophage Extended Release and 
Phentermine/Topiramate Extended Release on Metabolic Profiles and Body 
Composition in Obese PCOS Women 
Exenatide vs 
dapagliflozin vs 
exenatide + 
dapagliflozin vs 
dapagliflozin + 
Glucophage vs 
phentermine + 
topiramate 
24 
weeks 
No T1D, 
no T2D 
Women, 
age 18-45 
years, 
PCOS, 
BMI 
>30<45 
kg/m2 
135 2020/09 
 
NCT indicates Clinicaltrials.gov registration number. * indicates primary outcome.  
 
Abbreviations: BIA, bioelectrical impedance analysis; BID, bis in die (Latin: twice a day); BMI, body mass index; DEXA, dual energy X-ray absorptiometry; GLP-1RA, glucagon-like peptide-1 receptor agonist; MRI, 
magnetic resonance imaging; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PCOS, polycystic ovarian syndrome; T1D, type 1 diabetes; T2D, type 2 diabetes.  
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Supplemental Table 2i: Ongoing GLP-1RA mechanistic randomized placebo-controlled trials (neurological)  
PATIENTS WITH DIABETES 
Outcome 
(Neurological) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
Comparator 
Duration Glycemic Status Population N Date 
Complete 
Cerebral perfusion ASL NCT03361098 
(DECREASE) 
(*neuronal 
activity) 
Combined Effects of SGLT2 Inhibition and GLP-1 
Receptor Agonism on Food Intake, Body Weight and 
Central Satiety and Reward Circuits in Obese T2DM 
Patients 
Exenatide + 
dapagliflozin 
vs exenatide 
+ placebo vs 
dapagliflozin 
+ placebo vs 
double 
placebo 
16 
weeks 
T2D Obesity (BMI 30-
40 kg/m2) 
64 2020/01 
Neuronal activity in 
central reward & 
satiety circuits 
fMRI BOLD 10 days 
& 16 
weeks 
Peripheral 
autonomic function 
Sudorimetry (Sudoscan) NCT03426085 
(*) 
The Effects of Liraglutide on Sudomotor Function 
and Inflammation in T2D 
Liraglutide 
vs placebo 
1 year T2D Age 18-80 years 44 2020/08 
Cognition EEG and cognitive 
performances 
NCT02092896 
(T1DMLIRA) 
(*) 
Treatment With Liraglutide as add-on to Insulin in 
T1D Patients. Effects on Glycemic Control and 
Counterregulation and Cognitive Performance 
During Hypoglycaemia 
Liraglutide + 
insulin vs 
placebo + 
insulin 
12 
weeks 
T1D No residual β-
cell function 
(glucagon test 
with c-peptide < 
60 pM) 
40 2014/10 
(awaited) 
PATIENTS WITHOUT DIABETES 
Outcome 
(Neurological) 
Technique Trial 
Registration 
Full Official Title GLP-1RA vs 
Comparator 
Duration Glycemic Status Population N Date 
Complete 
Brain protection Cerebral Performance 
Category, modified 
Rankin Scale 
NCT02673931 
(GLORIOUS) 
Efficacy of GLP-1 Agonists and Restrictive vs. 
Liberal FiO2 in Patients Undergoing CABG or AVR - 
a 2-by-2 Factorial Designed, Randomized Clinical 
Study 
Exenatide vs 
placebo & 
restrictive vs 
liberal 
oxygenation 
24 
months 
Not stated Ischemic heart 
disease 
requiring CABG 
and/or aortic 
valve disease 
scheduled for 
AVR 
108
0 
2020/01 
Cerebral glucose 
metabolic rate 
(not stated) NCT01843075 
(ELAD) 
(*cerebral 
glucose 
metabolic rate) 
Evaluating the Effects of the Novel GLP-1 Analogue, 
Liraglutide, in Patients With Mild Alzheimer's 
Disease 
Liraglutide 
vs placebo 
12 
months 
Not stated 
(exclude if on 
treatment for 
diabetes) 
Mild Alzheimer’s 
disease 
204 2019/12 
z-scores for ADAS 
Exec, MRI changes, 
microglial activation, 
CSF markers 
(not stated) 
Microglial activation TSPO PET 
Tau deposition, 
cortical amyloid load 
(not stated) 
Parkinson’s disease 
symptoms 
MDS-UPDRS III motor NCT03439943 
(LixiPark) (*) 
Multicenter, Randomised, Placebo-controlled, 
Double Blinded, Parallel Arm Proof-of-concept Trial 
of Lixisenatide in Patients With Early Parkinson's 
Disease 
Lixisenatide 
vs placebo 
12 
months 
No T1D, no T2D Early-stage 
Parkinson’s 
disease 
158 2021/12 
Heavy drinking days Timeline-Follow-Back 
method 
NCT03232112 
(EXALT) (*) 
Does GLP-1RA Stimulation Reduce Alcohol Intake 
in Patients With Alcohol Dependence? 
Exenatide vs 
placebo 
(saline) 
30 days 
prior to 
26 
weeks 
No T1D, no T2D Alcohol 
dependence 
152 2020/12 
Motor function MDS-UPDRS part 3 in 
OFF medication state 
NCT03659682 
(GIPD) (*) 
Effect of GLP-1R Stimulation on Neuroprotection 
and Inflammation in Parkinson's Disease 
Semaglutide 
vs placebo 
48 
months 
No T2D Newly 
diagnosed 
Parkinson’s 
disease 
120 2024/12 
Brain activation 
during cigarette, 
alcohol & food 
fMRI BOLD signal NCT02690987 
(GHADD) (*) 
Do Appetitive Gut Hormones Reduce Addictive and 
Eating Behaviours in Obesity, and Nicotine and 
Alcohol Dependence? 
Crossover: 
Exenatide vs 
desacyl 
4 years No T1D, no T2D Ex-smoker or 
ex-alcohol 
dependent or 
95 2020/08 
43 
picture evaluation 
task 
ghrelin vs 
placebo 
(saline) 
overweight/obes
e (BMI 28-50 
kg/m2) 
Schizophrenia 
negative symptoms 
SANS NCT02417142 
(*) 
Exenatide Weekly Injections as an Adjunctive 
Treatment in Patients with Schizophrenia 
Exenatide vs 
placebo 
24 
weeks 
Not stated (No 
uncontrolled 
diabetes, no SU) 
Schizophrenia or 
schizoaffective 
disorder 
70 2020/01 
Neuronal activity, 
reward system 
fMRI BOLD signal (%) NCT03347890 
(LIRAOB) (*) 
Central Nervous System Effects of Liraglutide® 3.0 
mg on Reward Mechanisms in Obese Patients 
Without Diabetes, in Relation to Food Addiction. A 
Randomized, Single-centre, Double-blind, Placebo 
Controlled Clinical Trial 
Liraglutide 
vs placebo 
16 
weeks 
No T1D, no T2D Obese (BMI ≥30 
& <40 kg/m2) 
70 2020/05 
Pre-prandial and 
post-prandial fMRI-
FCR 
fMRI NCT03795701 
(*) 
To Predict Weight Loss Response to Liraglutide 
(Saxenda®), From fMRI-based Determination of 
Food Cue Reactivity 
Liraglutide 
vs placebo 
4 & 16 
weeks 
No T1D, no T2D BMI 30-50 kg/m2 64 2020/06 
Motor function MDS-UPDRS NCT02953665 
(*all 3 
measures) 
A Phase II, Randomized, Double-blinded, Placebo-
controlled Trial of Liraglutide in Parkinson's Disease 
Liraglutide 
vs placebo 
54 
weeks 
No diabetes Idiopathic 
Parkinson’s 
disease 
57 2020/12 
Non-motor function NMSS score 
Cognitive function MADRS-2 
Cognitive outcomes (multiple) NCT02140983 
(LGT) (*) 
Effects of Liraglutide on Hippocampal Structure and 
Function in Aging Adults With Prediabetes 
Liraglutide 
vs placebo 
3 
months 
Prediabetes (no 
T1D, no T2D) 
Age 50-70 
years, BMI 27-
37 kg/m2 
41 2017/02 
(awaited) 
Cognitive function ADAS-cog score NCT02847403 
(DRINN) (*) 
Long-acting Exenatide: a Tool to Stop Cognitive 
Decline in Dysglycemic Patients With Mild Cognitive 
Impairment? 
Exenatide vs 
placebo 
16 & 32 
weeks 
Dysglycemia/predi
abetes (no 
diabetes) 
Mild cognitive 
impairment 
40 2019/10 
(awaited) 
Smoking abstinence Biochemically verified 
CO reading (Vitalograph 
Breath CO Analyzer) 
NCT03712098 
(DAL) (*) 
GLP-1RAs as Novel Pharmacotherapies for Nicotine 
Dependence 
Liraglutide + 
smoking 
cessation 
counseling 
vs placebo + 
smoking 
cessation 
counseling 
18 & 32 
weeks 
No T1D, no T2D Overweight/obes
e cigarette 
smokers 
interested in 
quitting smoking 
40 2021/05 
 
NCT indicates Clinicaltrials.gov registration number. * indicates primary outcome.  
 
Abbreviations: ADAS(-cog), Alzheimer’s Disease Assessment Scale(-cognitive subscale); ASL, arterial spin labelling; AVR, aortic valve replacement; BMI, body mass index; BOLD, blood-oxygen-level-dependent; 
CABG, coronary artery bypass grafting; CO, carbon monoxide; CSF, cerebrospinal fluid; EEG, electroencephalography; FCR, food cue reactivity; FiO2, fraction of inspired oxygen; fMRI, functional magnetic resonance 
imaging; GLP-1(RA), glucagon-like peptide-1 (receptor agonist); MADRS-2, Mattis Dementia Rating Scale; MDS-UPDRS, Movement Disorder Society-Unified Parkinson's Disease Rating Scale; MRI, magnetic 
resonance imaging; NMSS, Non-Motor Symptoms Scale; PET, positron emission tomography; SANS, Scale for the Assessment of Negative Symptoms; SGLT2, sodium-glucose co-transporter 2; SU, sulphonylurea; 
T1D, type 1 diabetes; T2D(M), type 2 diabetes (mellitus); TSPO, translocator protein-18 kDa.  
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Supplemental Table 2j: Ongoing GLP-1RA mechanistic randomized non-placebo-controlled trials (neurological)  
PATIENTS WITH DIABETES 
Outcome (Neurological) Technique Trial Registration Full Official Title GLP-1RA vs 
Comparator 
Duration Glycemic Status Population N Date 
Complete 
Olfactory brain activation fMRI NCT03961659 
(*olfactory brain 
activation) 
A Prospective, Randomized, Open Label, 
Parallel, 16-week Study to Explore and 
Evaluate the Therapeutic Effects of 
Liraglutide, Dapagliflozin and Acarbose on 
the Cognitive Function, Olfactory Function, 
and Odor-induced Brain Activation in 
Overweight/Obese Patients With T2DM 
Inadequately Controlled With Metformin 
Monotherapy 
Liraglutide vs 
dapagliflozin vs 
acarbose 
16 
weeks 
T2D MMSE >24, 
right 
handed, age 
40-75 years, 
BMI ≥25 
kg/m2 
87 2021/02 
Cognitive function MoCA 
Diabetic neuropathic pain Numerical pain scale NCT04137328 (*) Clinical Study on the Improvement of 
Diabetic Neuropathic Pain by Liraglutide 
Liraglutide vs 
control (insulin) 
3 
months 
T2D Diabetic 
neuropathic 
pain 
60 2022/11 
Brain insulin sensitivity fMRI: change in rCBF 
from before to 30 
minutes after nasal 
insulin spray 
NCT03881995 
(Lixibrain01) 
(*brain insulin 
sensitivity) 
Effect of Insulin Glargine and Lixisenatide 
Versus Insulin Glargine on Brain Insulin 
Sensitivity in Patients With T2D 
Lixisenatide + 
insulin glargine vs 
insulin glargine 
12 
weeks 
T2D BMI 25-45 
kg/m2 
40 2021/03 
Cognitive function (multiple) 
PATIENTS WITHOUT DIABETES 
Outcome (Neurological) Technique Trial Registration Full Official Title GLP-1RA vs 
Comparator 
Duration Glycemic Status Population N Date 
Complete 
Neurological outcome NIHSS NCT03287076 
(TEXAIS) 
(*NIHSS) 
A Multicentre, Randomised Controlled 
Trial of Exenatide Versus Standard Care in 
Acute Ischemic Stroke 
Exenatide vs 
standard care 
7 (*) & 
90 days 
Not stated (include 
if blood glucose 
level on admission 
≥4 mmol/L) 
Acute 
ischemic 
stroke 
528 2021/12 
Modified Rankin Scale 90 days 
Brain response to acute 
consumption of sugar 
sweetened drinks 
fMRI NCT03500484 
(*fMRI) 
Effect of Liraglutide on Neural Responses 
to High Fructose Corn Syrup in Individuals 
With Obesity 
Liraglutide in 
obese vs no 
intervention in 
lean 
1 & 12 
weeks 
15 control & 30 obese (± 
prediabetes) adolescents/young 
adults 
45 2020/04 
Neural responses (not stated) 
 
NCT indicates Clinicaltrials.gov registration number. * indicates primary outcome.  
 
Abbreviations: BMI, body mass index; fMRI, functional magnetic resonance imaging; GLP-1RA, glucagon-like peptide-1 receptor agonist; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; 
NIHSS, National Institutes of Health Stroke Scale; rCBF, regional cerebral blood flow; T2D(M), type 2 diabetes (mellitus).  
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